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Abstract 	
Many cancers rely on glycolysis rather than mitochondrial metabolism as their primary source of 
ATP. As such, altering this balance through forced mitochondrial activation has yielded 
promising results as anticancer therapies for specific cancers. In previous studies, stimulated 
mitochondrial activation through exposure to palmitoylcarnitine, a mitochondrial fatty-acid 
substrate, resulted in colon and prostate cancer-specific cell death, however, mitochondrial fatty-
acid oxidation led to increased cervical cancer growth. The primary mechanism for promoting 
antineoplastic effects in response to palmitoylcarnitine is through oxidative stress, namely 
through production of superoxide and subsequently hydrogen peroxide (H2O2). However, H2O2 
can be hormetic in nature, whereby elevated H2O2 can result in deleterious effects, yet modest 
H2O2 can promote growth. Therefore, the ability of the cell to regulate H2O2 is of apparent 
importance, highlighting glutathione, the most abundant intracellular antioxidant, as a potential 
determinant of cancer survival following palmitoylcarnitine. The purpose of this dissertation was 
to first determine the response of glutathione to palmitoylcarnitine within relation to cell 
survival. Following palmitoylcarnitine, glutathione responses seemingly dictated cell fate, 
whereby HT29 colorectal carcinoma cells displayed decreased cell survival, increased H2O2 and 
decreased glutathione. CCD 841 normal colon cells were insensitive to palmitoylcarnitine 
despite increased H2O2, yet maintained glutathione. HepG2 hepatocarcinoma cells, cells 
associated with fatty-acid stimulated disease progression, increased cell growth with coordinated 
increases in glutathione following palmitoylcarnitine. This dissertation considered recent 
evidence that suggests combined inhibition of glutathione and thioredoxin, another intracellular 
antioxidant, is required for anticancer effects in established tumours. Auranofin is a putative 
inhibitor of the thioredoxin system. HCT 116 p53-/- cells were resistant to auranofin at doses that 
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HCT 116 p53+/+ cells were sensitive to, however concurrent exposure of auranofin and 
glutathione depletion through serine and glycine starvation sensitized HCT 116 p53-/- cells to 
decreased cell survival. This observation was repeated in a p53mutant cell line, HT29. Taken 
together, this thesis identifies glutathione as an important regulator in determining cell fate in 
response to palmitoylcarnitine, the dual role of glutathione and thioredoxin in influencing cell 
fate in relation to p53, and highlights the potential of redox-buffering systems as therapeutic 
targets for selective antineoplastic growth. 
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Chapter 1 General introduction 	
Cancer is a disease of uncontrollable cell proliferation, and it is characterized by the 
development many possible mutations resulting in selective advantages allowing a cell to divide 
despite restraints on cell growth (Figure 1.1) [1].  
  	
Figure 1 1 Tumour formation as a result of uncontrollable cell growth. Tumour growth is a 
result of a variety of mutations conferring pro-growth properties towards a cell, resulting in an 
increase in cellular division and/or avoidance in cell death pathways.  Adapted from Alberts et 
al. [2].  
 
This unrestrained cell growth allows for cancer cells to invade foreign tissues and reside and 
grow in areas reserved for other cells [2]. At our current abilities of cancer prognosis and 
therapies, roughly one in five people will die as a result of cancer [2]. The development of cancer 
is genetic in nature, however given that essentially an infinite variation of mutations may lead to 
cancer development, the search for both genetic and phenotypic-based therapies are warranted 
Normal cell division
Normal cell death
Homeostasis
Normal cell death
Normal cell division
Increased cell division
Decreased cell death
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Cancer
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[1]. Mitochondrion, although historically thought of as the primary source of ATP production 
throughout the cell, is a complex multifaceted organelle capable of influencing a variety of 
cellular functions and pathways such as cell growth and cell death. As such, altered 
mitochondrial and redox metabolism are key components in oncogenic behavior driving cancer 
growth and cell death avoidance, and presents an opportunity for selective cancer targeting for 
novel anticancer therapies. The dynamic relationship between mitochondrial metabolism and 
oxidative stress implicates glutathione, the most abundant intracellular antioxidant, as a potential 
pivotal agent in determining the success of mitochondrial targeted therapies as potential novel 
anticancer avenues. 
 
Mitochondria 	
Mitochondria produce ATP through a process known as oxidative phosphorylation 
(OXPHOS), whereby the generation of an electrochemical gradient, or mitochondrial membrane 
potential, is harnessed to drive the production of ATP [3]. As mitochondrial membrane potential 
increases, reactive oxygen species (ROS) can be generated from the electron transport chain [4]. 
ROS production is a natural byproduct of OXPHOS and is linked to altered levels of 
mitochondrial ATP production and cell growth, where low levels of ROS can act as critical cell 
signaling molecules promoting growth, however high levels of ROS can be deleterious to the cell 
resulting in cell death. Given that cancer is ultimately a disease of sustained accelerated cell 
growth, cancer cells have developed different strategies to maintain high levels of ATP 
production while minimizing the deleterious effects of ROS.  
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Targeting mitochondria in cancer 	
 Altered cancer mitochondrial metabolism was first observed almost 100 years ago when 
Otto Warburg noted that cancer cells produced excessive lactate despite the presence of oxygen 
[5, 6]. This was coined as ‘aerobic glycolysis’, and is directly observed through the high rates of 
glucose consumption in cancers and is currently exploited as a cancer diagnostic tool, whereby 
excessive 18F-2-deoxyglucose (FGD) accumulation in cancer cells is detected by positron 
emission tomography [7, 8]. It appears that many cancers (although not all) rely on aerobic 
glycolysis as their primary source of ATP, concurrent with a decrease in reliance on 
mitochondrial OXPHOS [9]. These metabolic alterations vary greatly from normal cells and 
allow for several key adaptations ultimately resulting in a pro-growth cellular environment. The 
complete oxidation of glucose is a more efficient way to produce ATP compared to the 
fermentation of glucose; however, aerobic glycolysis is a less efficient yet faster source of ATP 
production [10]. The higher rate of glucose import in many cancers is able to offset lower 
mitochondrial ATP production, as well as the increased carbon flux through glycolysis allows for 
an increase in the production of biosynthetic precursors [9]. As such, countering the Warburg 
effect is thought to be a potential strategy to slow cancer progression resulting in cancer cell 
death. In this regard, it has been suggested that activating mitochondrial OXPHOS may redirect 
metabolic control away from glycolysis and stimulate mitochondrial ROS production in a 
manner that would be selectively toxic to highly glycolytic cancers but less toxic to non-
transformed cells. The redirection of the end product of glycolysis, pyruvate, away from lactate 
and towards OXPHOS resulted in an increase in ROS and decreased cell growth in both lung and 
tongue cancer cells [11]. Whereas directly promoting fat oxidation has led to decreasing cell 
survival in several different cancer cell lines [12-15], however analogous normal cells were 
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resistant [14, 15]. This suggests that stimulating mitochondrial bioenergetics may serve as a 
therapeutic approach to selectively target cancer cells. Some cancer cells have however 
demonstrated a resistance to mitochondrial activation while others have increased cell growth 
rates when promoting OXPHOS [16, 17].  
 
The role of glutathione in mediating cell survival 	
The influence of the mitochondria on determining cell fate is seemingly dichotomous: the 
provision of ATP promotes cell growth, whereas excessive ROS generation promotes cell death. 
Therefore, the ability of the cell to tolerate and respond to excess ROS may dictate the cell’s 
response to mitochondrial-activation therapies. To combat high intracellular levels of ROS, cells 
produce antioxidant molecules capable of oxidant buffering. Glutathione is the most abundant 
intracellular antioxidant throughout the body [18]. Glutathione is critical in regulating the 
cellular redox environment by donating an electron at times of oxidative stress to an oxidized 
intracellular target [19]. The conversion of H2O2 to H2O is catalyzed by glutathione peroxidase, 
whereby reduced glutathione (GSH) can donate an electron to H2O2 sacrificially self-oxidizing 
itself resulting in oxidized glutathione (GSSG). GSSG can be re-reduced by glutathione 
reductase using NADPH as an electron donor. Consequently, the redox state of glutathione is 
critical in determining the amount of oxidative stress the cell experiences, and the relative ratio 
of GSH/GSSG can be indicative of cellular oxidative stress. Therefore, an intriguing possibility 
is that heterogeneity in the glutathione response to mitochondrial challenges across cancers may 
dictate their susceptibility to cell death in response to mitochondrial ROS generated during 
oxidative phosphorylation.  
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Purpose 	
The purpose of this thesis is twofold: 1) Does the glutathione response to increasing 
mitochondrial substrates dictate cell fate? and 2) Can manipulating glutathione alter cell-fate and 
sensitize cancer cells to mitochondrial-influenced cell death?   
 	 6 
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Chapter 2 Literature review 
Cancer is a disease that is caused by a variety genetic mutations resulting in a state of 
rapid cell growth and resistance to cell death programming. In order to sustain accelerations in 
cell growth, cancers display highly adapted metabolic profiles resulting in altered ATP 
production, increased cyto-protective ability against ROS and apoptosis and an increased ability 
to produce biosynthetic precursors required for cell growth. The mitochondria is the main site for 
ATP production, yet it is involved in many other cellular processes such as ROS and apoptotic 
regulation, calcium handling and involved in DNA, fatty acid and protein synthesis. Therefore, 
understanding the role and regulation of the mitochondria is critically important in understanding 
bioenergetic regulation of cancer.  
 
2.1 The mitochondrion 	
Over 1 billion years ago, protobacterial mitochondria and eukaryotes merged resulting in 
precursors to modern day cells [1]. Due to the ancient nature of the mitochondria within 
eukaryotic cells, mitochondria are involved in many cellular systems, however they are primarily 
responsible as the main source of ATP production accounting for ~95% of the ATP produced in 
the cell [2]. The mitochondria are double membrane structures consisting of an outer 
mitochondrial membrane (OMM), an intermembrane space and an inner mitochondrial 
membrane (IMM). As the mitochondria originated from a separate protobacterial origin, it has its 
own mitochondrial DNA (mtDNA) [3] which encodes essential components required for 
functional electron transport through the electron transport chain (ETC). The ETC comprises of 
five protein complexes (I through V) along with two electron carriers, coenzyme Q and 
cytochrome C. The ETC results in the production of ATP through an electrochemical gradient; a 
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concept that was first proposed by Peter Mitchell in 1961 [4], when, among several reasons, he 
failed to reconcile why ATP production was closely related to membranous structures within the 
cell. Originally, ATP synthesis was attributed to the release of high-energy bonds allowing for 
ADP and inorganic phosphate (Pi) to produce ATP [4]. Mitchell’s chemiosmotic theory of 
oxidative phosphorylation explains the movement of ions generated in a series of redox reactions 
down an electrochemical gradient to produce ATP. The pumping of protons from the negative 
mitochondrial matrix into the positive intermembrane space produces a proton motive force 
capable of driving ATP synthase (complex V) to produce ATP from ADP and Pi through the 
protons flowing back through ATP synthase into the mitochondrial matrix [2]. The protons 
required for OXPHOS are generated through the reducing equivalents NADH and FADH2 
(Figure 2.1), and the generation of reducing equivalents is through the catabolism of fuel 
sources, primarily glucose and fat, through glycolysis and β-oxidation respectively.  
		  
Figure 2 1 Schematic of mitochondrial ATP production through oxidative phosphorylation. 
There are five protein complexes and two electron carriers embedded within the inner 
mitochondrial membrane. These components are responsible for catalyzing redox-reactions 
transferring electrons to the eventual release of free energy, upon which protons are pumped into 
the intermembrane space from the mitochondrial matrix to create an electrochemical gradient 
which is harnessed by complex V resulting in the phosphorylation of ADP into ATP, the energy 
currency of the cell.  
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2.1.1 Glycolysis 	
Glycolysis is the phosphorylation dependent breakdown of glucose to pyruvate (Figure 
2.2). Gustav Embden first proposed our current understanding of glycolysis in 1933 [5] and it 
was further elucidated following Embden’s death by Otto Meyerhof and Jakub Parnas 
(glycolysis is also referred to as the Embden-Meyerhof-Parnas pathway) [6].  Glucose enters the 
cell through glucose transporters where it undergoes a series of catabolic processes resulting in 
the formation of two pyruvate molecules. Glycolysis alone produces two net ATP molecules and 
two NADH molecules. Pyruvate ultimately has two distinct fates, fermentation or oxidation. 
Pyruvate can be converted to lactate through lactate dehydrogenase (LDH), or it can enter the 
mitochondria and be enzymatically converted into acetyl-CoA by pyruvate dehydrogenase 
(PDH) to stimulate mitochondrial OXPHOS.  
 
Figure 2 2 Schematic depicting the major components of glycolysis and β-oxidation ending 
in acetyl-CoA production. Glucose enters the cell through glucose transporters where it is 
immediately catalyzed by hexokinase (HK) into glucose-6-phosphate (G6P). Through a series of 
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enzymatic reactions, G6P gets converted to fructose-6-phosphate (F6P), where 
phosphofructokinase (PFK) converts F6P into fructose 1,6 bisphosphate (F1,6P). Over a series of 
reactions, F1,6P results in the production of two molecules of phosphoenolpyruvate (PEP) and 
eventual conversion by pyruvate kinase (PK) into 2 pyruvate molecules. Pyruvate is imported 
into the mitochondria, whereby it gets converted into acetyl-CoA by pyruvate dehydrogenase 
(PDH). Although fatty acids enter the mitochondria through different mechanisms, they result in 
a similar fate to glucose. Fatty acids are imported into the cell through fatty acid transporters. 
Once reaching the mitochondria, fatty acids get converted into acetylcarnitines by carnitine 
palmitoyltransferase 1 (CPT1), where they freely bypass the outer mitochondrial membrane. 
Once in the intermembrane space, acetylcarnitines are imported into the mitochondrial matrix 
and the carnitine group is removed by carnitine palmitoyltransferase 2 (CPT2). Fatty acids 
undergo beta-oxidation resulting in the production of reducing equivalents, NADH and FADH2, 
as well as acetyl-CoA production. Acetyl-CoA, either from glucose or fatty acid sources, enters 
the TCA cycle where it undergoes cyclic degradation to produce further reducing equivalents, 
which stimulate oxidative phosphorylation and eventual ATP production. 
 
2.1.2 β-oxidation 	
While fat enters the cell through different mechanisms than glucose, the catabolism of fat 
results in acetyl-CoA production through a process known as β-oxidation (Figure 2.2). Georg 
Knoop first discovered β-oxidation in 1904 where in which he theorized that the breakdown of 
fatty acids was through the successive removal of two carbon pairs starting at the β carbon [7]. β-
oxidation is the cyclic removal of two carbon pairs resulting in the production of acetyl-CoA, 
NADH and FADH2, as well as a fatty acyl-CoA (two carbons shorter than the original starting 
molecule) that is further continually degraded. Given that 1 molecule of each acetyl-CoA, 
NADH and FADH2 are produced from a two carbon pair from the fatty acyl chain; β-oxidation 
yields more ATP in contrast to glycolysis. Palmitate, a 16-carbon long chain fatty acid, produces 
129 ATP molecules compared to 36 ATP molecules from the oxidation of a glucose molecule 
[8]. Ultimately, both glycolysis and β-oxidation are able to stimulate mitochondrial OXPHOS 
through acetyl-CoA production entering the tricarboxylic acid (TCA) cycle.  
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2.1.3 The TCA cycle 	
Hans Adolf Krebs first proposed the TCA cycle (also known as the Krebs cycle) in 1937 
[9]. The TCA cycle refers to the multi-step oxidation of acetyl-CoA in the mitochondrial matrix. 
The first step of the TCA cycle is the production of citrate from acetyl-CoA and oxaloacetate 
catalyzed by citrate synthase [10]. The subsequent production of reducing equivalents (NADH 
and FADH2) from the serial catabolism of acetyl-CoA is able to stimulate OXPHOS to produce 
ATP (Figure 2.2). While our primary understanding of the TCA cycle is through the role of ATP 
production, the TCA cycle is crucial in supplying many biosynthetic molecules required for 
growth. Cataplerosis is the process by which TCA cycle intermediates are removed from the 
TCA cycle to be used in other cellular processes, while anapleurosis describes the replenishing 
of TCA cycle intermediates to account for molecules that were lost during cataplerosis [11]. As 
an avenue for fatty acid synthesis, citrate can be exported into the cytosol to produce cytosolic 
acetyl-CoA catalyzed by ATP citrate lyase (ACL). While mitochondrial acetyl-CoA stimulates 
the TCA cycle with the potential for ATP production, cytosolic acetyl-CoA is able to simulate 
fatty acid synthesis, which is a key component to drive cell growth. As such, inhibition of ACL 
has demonstrated some antineoplastic properties [12], suggesting that mitochondrial cataplerosis 
is crucial in promoting cell growth in cancers.  
 
2.1.4 Mitochondrial-mediated cell death 	
Along with the promotion of cell growth through generation of ATP and biosynthetic 
molecules, the mitochondria are key regulators in promoting cell death [13]. Mitochondrial-
mediated cell death is triggered upon exposure of a death stimulus, where pro-apoptotic Bcl-2 
proteins Bax and Bad on the OMM form dimers resulting in pore formation and mitochondrial 
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outer membrane permeabilization (MOMP) leading to cytochrome c release into the cytosol and 
mitochondrial dysfunction [14]. The release of cytochrome c results in the cleavage of a group of 
cysteine proteases, called caspases, which upon cleavage from their pro-caspase form, cleave and 
degrade intracellular substrates and cellular components. Under normal physiological conditions, 
anti-apoptotic proteins such as Bcl-XL and Bcl-2 bind to and inhibit Bax and Bad. As a potential 
mechanism for resistance to cell death, many cancers typically display decreased levels of pro-
apoptotic related genes and an increase in anti-apoptotic related genes such as breast cancer [15], 
colorectal cancer [16], ovarian cancer [17] and acute myeloid leukemia [18]. Along with MOMP, 
cell death can be initiated through formation of the mitochondrial permeability transition pore 
(mPTP) located on the IMM. While typically the IMM is fairly impermeable, following the 
promotion of cell death conditions (such as calcium overload or excessive oxidative stress) 
however, formation of the mPTP results in rapid mitochondrial swelling leading to the rupture of 
the OMM and a loss of mitochondrial ATP production. While the components and regulation of 
the mPTP are highly debated, it is clear that many solid tumours display drastic suppression of 
mPTP formation resulting in cell death avoidance [19].  
 
2.2 Reactive oxygen species 	
Increased cell growth is linked to increased mitochondrial OXPHOS and increased 
mitochondrial OXPHOS can lead to an accumulation of oxidative damage. Interestingly, 
increased oxidative damage associated through mitochondrial OXPHOS is witnessed in many 
different organisms along with humans such as zebra finches [20], yellow-legged gulls [21] and 
coal tits [22]. The role of mitochondrial ROS in promoting cell growth and maturation is not 
entirely defined, however, in an attempt to determine whether mitochondrial ROS can regulate 
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cell growth in yellow-legged gulls, Velando et al. [23] administered the mitochondrial-targeted 
antioxidant, mitoQ (mitoubiquinone), to chicks and observed an increased growth rate. Lowering 
mitochondrial ROS and promoting growth suggests that while ATP is critical in promoting cell 
growth and maturation, mitochondrial ROS production can function to suppress growth. This 
highlights the link between mitochondrial ATP production and mitochondrial ROS emission.  
Mitochondrial ROS is a natural byproduct of mitochondrial OXPHOS, and both 
mitochondrial ATP and ROS production are generated by electron transfer reactions [8]. During 
OXPHOS, electrons are transferred through the ETC to form H2O at complex IV, however 
electrons are able to slip out of the ETC prior to complex IV. When electrons slip, they form a 
single electron reduction of O2 resulting in the radical superoxide (O2●-). While O2●- is reactive, it 
does not cross lipid membranes easily. O2●- is degraded by superoxide dismutase (SOD) 
enzymes, manganese SOD (mnSOD) in the mitochondrial matrix, and copper/zinc SOD 
(CuZnSOD) throughout the rest of the cell [24]. The dismutation of O2●- by SOD results in the 
production of O2 and hydrogen peroxide (H2O2) (Figure 2.3) [25]. H2O2 can bypass lipid 
membranes either through lipid solubility or through aquaporins, where it can elicit global 
cellular effects [26-28]. H2O2 in low levels can act as a critical signaling messenger throughout 
the cell, primarily through its ability to oxidize thiols on target proteins [25].		
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Figure 2 3 Schematic depicting mitochondrial reactive oxygen species production from 
electron slip off of complex I and III. Currently, 11 sites within the mitochondria have been 
identified as sites for electron slip and subsequent ROS production. As an electron slips out of 
the electron transport chain, it forces the semi-reduction of oxygen resulting in superoxide (O2 ●-) 
formation. O2 ●- is quickly dismutated to hydrogen peroxide (H2O2) by superoxide dismutase 
(SOD), whereby H2O2 can leave the mitochondria resulting in global cellular effects.  
 
As a response to oxidative stress, the Keap1-Nrf2 axis is a primary example of H2O2 
signaling properties. Keap1 (Kelch-like ECH-associated protein 1) binds to and prevents the 
stabilization of Nrf2 (Nuclear factor erythroid-derived 2-like 2 protein) through Nrf2 
ubiquitination and subsequent proteasomal degradation. H2O2 is able to stimulate an increase in 
Nrf2 stabilization and nuclear accumulation in HeLa cells through oxidation of two exposed 
cysteines found on Keap1 resulting in a disulfide bond preventing Keap1-targeted degradation of 
Nrf2 [29]. Furthermore, H2O2 is able to directly stabilize and prevent degradation of HIF-1α 
(hypoxia inducible factor 1-α) in murine embryonic cells, thereby regulating the O2-sensing 
ability of the cell [30]. In addition, H2O2 is able to act as a second messenger in a variety of 
signaling pathways unrelated to cell protection against oxidative stress, such as angiogenesis, 
immune responses and cell proliferation [31]. However, in high enough levels, H2O2 can elicit 
deleterious effects throughout the cell. These harmful effects range from uncontrolled 
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oxidization of proteins, DNA damage, or the production of hydroxyl radicals (OH●) through 
Fenton chemistry reactions (Figure 2.4) [24]. OH● have a strong oxidizing potential, are lipid 
insoluble and have a very short half-life. They are recognized as molecules that are capable of 
doing irreversible oxidative damage to any macromolecular structure.  
 
Figure 2 4 Schematic depicting reactive oxygen species production leading to cellular 
damage. Superoxide (O2 ●-) is produced as a byproduct of mitochondrial oxidative 
phosphorylation where it is converted by superoxide dismutase into hydrogen peroxide (H2O2). 
H2O2 can freely diffuse out of the mitochondria, where upon expose to iron, can result in the 
production of hydroxyl radicals (OH●). O2 ●-, H2O2 and OH● in high enough concentrations can 
lead to the oxidation of DNA, proteins and lipids result in cellular damage and eventual cell 
death. 
 
Currently, there are 11 identified sites of O2●- production within the mitochondria [8]. This list 
includes isocitrate dehydrogenase (IDH), 2-oxoglutrate dehydrogenase (ODH), pyruvate 
dehydrogenase (PDH) [32], as well as two sites on complex I, one known site on each of 
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complex II and complex III among others [8]. NADPH oxidases (NOX) are further sources of 
O2●- generation throughout the cell, however NOX are commonly associated as critical signaling 
enzymes through an oxidative burst, or a transient production of O2●- [33]. The role of NOX 
varies based on cell type and subcellular distribution, however NOX has been implicated in a 
variety of non-pathological systems. NOX generation of O2●- contributes to a variety of signaling 
such as regulating blood pressure [34], renal function [35], smooth muscle contraction [36] and 
others [33]. NOX production of O2●- is not thought to be a primary contributor to the deleterious 
effects of ROS, therefore the role of mitochondrial ROS production appears to be critical for 
both cell signaling and oxidative stress. 
 
2.2.1 Oxidative stress 	
In excess, accumulated ROS can lead to macromolecular damage, and disruption of key 
redox sensitive circuitry, this is termed as oxidative stress [37]. Common forms of 
macromolecular damage attributed to oxidative stress are lipid peroxidation, DNA and protein 
oxidation (Figure 2.4). O2●- is highly reactive, and a single oxidizing event has the potential to 
initiate chain oxidative reactions, whereby up to 200 to 400 lipid molecules can be oxidatively 
damaged upon a single O2●- initiating molecule [37]. O2●- is a 1-electron free radical, however 
O2●- is rapidly dismutated to H2O2, a 2-electron oxidant, therefore this thesis focuses on H2O2 
and H2O2-specific antioxidant mechanisms. Between 1-4% of all O2 consumed results in the 
formation of H2O2 [37]. H2O2 signaling is primarily through the reversible modification of 
protein function through the oxidation of thiols found on exposed cysteine residues [38]. While 
H2O2 production can lead to deleterious cellular effects such as single and double strand DNA 
breaks [39], the additional depletion of glutathione, the most abundant intracellular antioxidant 
 	 17 
[40], through the use of buthionine sulfoxomine (BSO) was able to lower the amount of H2O2 
required to induce DNA strand breaks [39]. This suggests that while H2O2 can elicit cellular 
damages, the buffering and removal of H2O2 by glutathione is also of critical importance in 
determining cell fate when cells undergo oxidative stress.  
 
2.3 Mechanisms for regulating oxidative stress 	
Many physiological and pathological conditions can increase the rate of O2●- production, 
resulting in an increase in H2O2 emission.  The prevention of efficient ATP production through 
mitochondrial OXPHOS can result in an increase in the likelihood of electron slip, conditions 
such as elevated mitochondrial membrane potential, blockage of ETC components downstream 
of electron entry, high NADH/NAD+ ratio or simply low levels of ADP can all result in a build-
up of electrons within the ETC allowing for O2●- and subsequent H2O2 production [41]. Without 
sufficient levels of ADP present within the mitochondria, complex V is unable to complete the 
final step of phosphorylating ADP into ATP. This results in a potential back-flow of electrons 
resulting in an increase in membrane pressure, resulting in elevated electron slip leading to the 
production of O2●- and H2O2. Lowering mitochondrial H2O2 levels can be done through the 
degradation of H2O2 by antioxidant buffering systems, or through lowering the production 
mitochondrial H2O2 itself.  
 
2.3.1 Decreasing mitochondrial ROS production 	
Mitochondrial ATP production is not perfectly coupled to mitochondrial OXPHOS, 
whereby proton-leak is able to dissipate mitochondrial membrane potential decreasing the 
pressure driving electron slip and O2●- and subsequent H2O2 emission. One of the most prevalent 
 	 18 
mechanisms of decreasing mitochondrial O2●- and H2O2 emission is through mitochondrial 
uncoupling. 
 
Mitochondrial uncoupling 	
A protein embedded in the IMM in brown adipose tissue was discovered in the early 
1980s to be able to dissipate mitochondrial membrane potential [42] and elicit what is now 
termed as non-shivering thermogenesis [43]. This protein was called uncoupling protein-1 
(UCP1). Since then, 5 different uncoupling proteins have been discovered throughout 
mammalian cells (UCP1-5). While the primary role of UCP1 appears to be the generation of 
heat, the role of the other uncoupling proteins appears to be that of attenuation of mitochondrial 
ROS production [44]. The tissue distribution and function of the various UCPs is still highly 
debated, however it appears that through various mechanisms, UCPs are able to dissipate 
mitochondrial membrane potential resulting in decreasing mitochondrial ROS production [44].  
 
2.3.2 Promoting ROS degradation 	
In order to tightly control H2O2 levels, cells have evolved many antioxidant pathways 
designed to regulate intracellular H2O2 concentrations. It was originally believed that all 
enzymes had the power to catalytically degrade H2O2. However, upon further exploration, it was 
determined that enzymes such as emulsion, pepsin and trypsin did not catalyze H2O2 degradation, 
it was therefore concluded that a specific enzyme functioned to degrade H2O2, this enzyme was 
termed catalase [45]. Catalase is ubiquitously expressed in aerobic organisms and present in most 
mammalian cells [46]. Catalase functions through the enzymatic conversion of 2 H2O2 molecules 
into 2 H2O and O2, however this function is primarily in the peroxisome [47], and catalase has 
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little function outside of peroxisome [48]. Many intracellular molecules are thought to contribute 
to the overall protection and regulation of oxidative stress, such as lactate [49], pyruvate [50, 51], 
certain vitamins [52] and free cysteine [53]. While many compounds can contribute to situational 
antioxidant defenses, there are two major antioxidant systems within mammalian cells: The 
glutathione and thioredoxin systems.   
 
Glutathione 	
Glutathione was first discovered in 1888 when it was noted that yeast cells and yeast 
extract contained the property to reduce sulfur [54]. It wasn’t until 1921 when the basic structure 
and function of glutathione was understood when Hopkins [55] concluded that glutathione was a 
dipeptide of cysteine and glutamate. It is now understood that glutathione (γ-glutamyl-cysteinyl-
glycine) is non-nuclear encoded tri-peptide containing glutamate, cysteine and glycine [40]. 
Glutathione is the most abundant non-protein thiol and is present in all mammalian tissues in 
concentrations between 1-10mM with the highest concentrations being noted in the liver [56]. 
Glutathione has many critical functions beyond an antioxidant, such as promoting cell growth 
[57] through nuclear recruitment [58, 59], acting as a substrate for protein post-translational 
modifications [60], xenobiotic functions [61] and as a critical cysteine reservoir in the cell [62]. 
However, given that the mitochondria are the major source of ROS production, the role of 
glutathione in buffering and degrading H2O2 is of primary focus. 
 
Glutathione as an antioxidant 	
H2O2 is enzymatically converted to H2O by glutathione peroxidase (GPx) with reduced 
glutathione (GSH) as the electron donor. Glutathione is also able to function as the electron 
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donor to reduce lipid peroxides. The sacrificial oxidation of GSH results in a disulfide bond 
forming between two oxidized glutathione molecules creating the oxidized form of glutathione – 
GSSG. The redox cycle is completed by the re-reduction of GSSG to GSH catalyzed by 
glutathione reductase (GR) using NADPH as a master electron donor (Figure 2.5). The redox 
potential of the cell is largely determined by the amount of free GSH and the ratio of GSH to 
GSSG (GSH/GSSG), therefore the cell is able to tightly regulate levels of both GSH and GSSG 
[63]. If GSSG levels rise to a point to threaten the GSH/GSSG ratio, the cell has several possible 
mechanisms to lower GSSG. Along with the re-reduction of GSSG to GSH, the cell is able to 
export GSSG into the extracellular space, or GSSG can also react with proteins creating protein-
glutathione adducts through a disulfide bond.  
 
Figure 2 5 Schematic depicting NADPH as the ‘master reducer’ of the cell. Upon production 
of H2O2, reduced glutathione (GSH) is able to act as a direct electron donor allowing for 
glutathione peroxidase (GPx) mediated reduction of H2O2 to H2O, leading to the oxidation of 
GSH into oxidized glutathione (GSSG). GSSG can be re-reduced to GSH by glutathione 
reductase (GR) using NADPH as the ‘master’ electron donor. Thioredoxin is able to act as an 
indirect electron donor for the reduction of H2O2 to H2O, whereby it donates an electron to 
reduced peroxiredoxin system. This leads to he oxidation of reduced thioredoxin (TRx-SH2) to 
oxidized thioredoxin (TRx-S2). TRx-S2 can be re-reduced by thioredoxin reductase (TRxR) using 
NADPH as the ‘master’ electron donor. 
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Given the unique structure of glutathione, the only known enzyme capable of degrading 
glutathione is γ-glutamyltranspeptidase (γGT). γGT is only present on the external surface of cell 
membranes resulting in glutathione degradation occurring externally to cells that express γGT 
[56]. Excess GSSG production can result in the cellular depletion of GSH through decreasing 
GSSG by cellular export and subsequent degradation by γGT [56]. While catalase is able to 
enzymatically degrade H2O2 in the peroxisome, glutathione is a critical regulator of H2O2 in the 
cytosol, nucleus and the mitochondria. Excess mitochondrial H2O2 production can result in an 
increase in GSSG formation, however the mitochondria are unable to export elevated GSSG 
levels [64], and the re-reduction of GSSG to GSH by GR is critically important. Therefore, 
elevated levels of GSSG molecules can result in severe mitochondrial dysfunction through 
protein-glutathione adducts resulting in loss or change of function in critical mitochondrial 
proteins [65]. ROS generation by complex I within the mitochondria can result in certain 
subunits of complex I forming a disulfide bond with glutathione resulting in novel adduct 
formation [66]. Upon glutathionylation, complex I O2●- and subsequent H2O2 production are 
increased, and upon reduction by glutathione, O2●- and H2O2 return to steady-state levels. 
Interestingly, oxidation of the mitochondrial glutathione pool alone was able to increase complex 
I glutathionylation resulting in increased ROS emission, stressing the importance of the 
GSH/GSSG ratio in maintaining cellular redox balance [66]. Cellular glutathione depletion is a 
hallmark during apoptosis and cell death, however it is not simply a byproduct of cell death 
associated oxidative stress, rather a critical stimuli committing the cell to its fate [67]. The 
prevention of glutathione efflux upon an apoptotic stimuli was able to protect U937 and HepG2 
 	 22 
cells [68] as well as Jurkat cells [69] from apoptosis. While glutathione depletion is able to 
promote cell death, glutathione synthesis is a critical regulator in cell protection and cell growth.  
 
Glutathione synthesis 	
Glutathione synthesis occurs entirely in the cytosol. While there are several pathways 
involved in the production of the individual constituent parts of glutathione (glutamate, cysteine 
and glycine), glutathione synthesis is ultimately regulated by two enzymes; glutamate-cysteine 
ligase (GCL – formerly known as γ-glutamylcysteine synthetase) and glutathione synthetase 
(GS) (Figure 2.6) [56]. Glutathione synthesis is an energy consuming process, as both GCL and 
GS require ATP for catalytic function. The rate-limiting step in glutathione synthesis is the 
formation of γ-glutamylcysteine through the enzymatic joining of glutamate and cysteine by 
GCL. GCL activity, therefore glutathione synthesis, is influenced by the availability of cysteine 
[70] and feedback from intracellular glutathione levels [71]. The final step in glutathione 
synthesis is the addition of glycine to γ-glutamylcysteine by an ATP consuming process 
catalyzed by GS. GS is not subject to regulation by GSH levels, and overexpression of GS alone 
did not significantly increase GSH production [72]. Many factors are able to influence 
glutathione synthesis, such as glutathione and cysteine levels, cellular oxidative stress and 
nutrient availability. While both serine and glycine are non-essential amino acids, starvation of 
serine and glycine resulted in marked glutathione depletion in HCT 116 cells [73]. While 
glutathione itself is synthesized in the cytosol, many key enzymes involved in glutathione 
synthesis are transcriptionally regulated by Nrf2. Nrf2 is a redox sensor, whereby nuclear 
accumulation of Nrf2 through disassociation of Nrf2 from its negative regulator, Keap1, allows 
for a significant increase in many glutathione associated enzymes [56, 74, 75]. This results in 
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tight control on glutathione synthesis through both transcriptional and non-transcriptional 
regulation. 
 
Figure 2 6 Schematic of glutathione synthesis. Glutathione comprises of glutamate, cysteine 
and glycine, and is enzymatically produced in a two-stage process. The rate-limiting enzyme, 
glutamate-cysteine ligase (GCL) produces y-glutamylcysteine through the conversion of cysteine 
and glutamate. Glutathione synthetase (GS) produces glutathione through the additional joining 
to glycine. The rate of glutathione synthesis is controlled, in part, by the availability of cysteine, 
glutamate and glycine.  
 
Thioredoxin 	
Along with the glutathione system, the other major intracellular antioxidant system is the 
thioredoxin (Trx) system. Unlike glutathione, Trx is unable to directly degrade H2O2; rather it 
supplies electrons for peroxiredoxin (Prx)-dependent removal of H2O2 [76]. Through successive 
crude fractionation of E. Coli samples, Trx was first identified and isolated in 1964 [77]. It is 
currently understood that mammalian cells contain two Trx systems, cytosolic (Trx1) and 
mitochondrial (Trx2). The function of Trx is through sacrificially donating electrons to 
Homocysteine
Cystathionine
Cysteine
γ -Glutamylcysteine
Glutathione
Serine
Glutamate
Glycine
Tr
an
ss
ul
fu
ra
tio
n
pa
th
w
ay
G
S
G
CL
ATP
ATP
 	 24 
downstream donors going from a reduced form (Trx-SH2) to an oxidized form (Trx-S2). These 
downstream donors consist of several different redox sensitive compounds such as Prx for redox 
detoxification, or to certain transcription factors with redox-sensitive cysteine’s [76]. The Trx-
Prx system is able to degrade H2O2 as well as reduce oxidized protein targets and other forms of 
ROS such as peroxynitrite through NADPH-dependent electron regulation (Figure 2.5) [76].  
The re-reduction of Trx-S2 is enzymatically carried out by Trx-reductase (TrxR), however 
physiological levels of glutathione, NADPH and glutathione reductase have all been 
demonstrated to be able to re-reduce Trx-S2 back to Trx-SH2 in HeLa cells through the catalytic 
function of glutaredoxin (Grx – the enzyme responsible for regulating glutathione in protein-
redox detoxification) [78]. This stresses that while the Trx and glutathione systems are typically 
viewed as separate antioxidant pathways, there does appear to be some degree of redundancy 
between the two. Trx is also involved in the regulation of cell death pathways. Upon response to 
oxidative stress, the Trx interacting protein (TXNIP) can leave the nucleus and enter the cytosol 
or mitochondria where it binds to and oxidizes Trx-SH2. Under normal conditions, there is a pool 
of Trx-SH2 bound to ASK1, preventing ASK1-initiated cell death pathways, however, upon 
binding of TXNIP, Trx dissociates from ASK1 promoting ASK1-initiated cell death [79, 80]. 
TXNIP is therefore viewed as an inhibitor of Trx resulting in Trx degradation, and the loss of 
TXNIP (and the subsequent removal of Trx inhibition) can lead to increases in cell proliferative 
rates, and is highly implicated in a variety of cancers [81, 82]. Furthermore, the inhibition of Trx 
resulted in a marked increase in Nrf2 activity [29], likely through increasing cellular oxidative 
stress, promoting the dissociation of Nrf2 and Keap1, and similar to the glutathione system, 
many key Trx-associated proteins are transcriptionally regulated by Nrf2 [76, 83]. Additionally, 
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both glutathione and Trx redox-systems function through NADPH-dependent mechanisms, 
implicating NADPH as the ‘master reducer’ of the cell. 
 
NADPH 	
Nicotinamide adenine dinucleotide phosphate comes in an oxidized form (NADP+) or a 
reduced form (NADPH). NADPH serves as the master electron donor for the glutathione and Trx 
systems [84]. NADPH can be made through several metabolic pathways, such as malic enzyme 
(ME), isocitrate dehydrogenase (IDH), folate dehydrogenase (FDH), with the most prominent 
source of NADPH production stemming from the pentose phosphate pathway (PPP) [84]. The 
most crucial enzyme responsible for NADPH synthesis in the PPP is glucose-6-phosphate 
dehydrogenase (G6PD), where overexpression of G6PD led to increased NADPH and a more 
reduced GSH:GSSG ratio, resulting in an increased resistance to oxidative challenges and a 
prolonged lifespan in drosophila melanogaster [85]. Pyruvate Kinase M2 (PKM2) is a glycolytic 
enzyme (Figure 2.3) commonly overexpressed in cancers, and is associated with conferring 
much of the ‘aerobic glycolysis’ phenotype [86]. Upon mild oxidative stress, there was an 
increase PKM2 phosphorylation in HeLa cells resulting in an increase in carbon redirection into 
the PPP and subsequent NADPH production [87]. The metabolic implication of glycolytic and 
mitochondrial derived NADPH production conveys that key metabolic pathways are responsible 
for not only regulating ROS production, but also ROS buffering and degradation.  
 
2.4 The mitochondria and cancer 	
Altered cancer metabolism was first observed almost 100 years ago, when Otto Warburg 
noted that cancers produce high levels of lactate, despite the presence of oxygen [88, 89]. 
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Interestingly, Warburg proposed that aerobic glycolysis observed in cancers was a result of 
mitochondrial defects driving the increase in glycolysis. However, it has since been proven that 
while mitochondrial metabolism is often altered in cancers, the mitochondria in cancers are able 
to influence a variety of steps throughout oncogenesis [90]. There are many potential drivers of 
the Warburg effect, these factors have been defined as both direct mutations within metabolic 
genes, or through secondary influences of mutations upstream of glycolytic and mitochondrial 
pathways. Mutations in the p53 gene for example, are associated with conferring the ‘Warburg 
phenotype’, where mutant-p53 was able to increase glucose transporter 1 (GLUT1) expression in 
H1299 lung cancer cells and promote the Warburg effect and knockdown of wildtype-p53 in 
MCF7 breast, H460 and A549 lung cancers promoted increased glucose uptake and lactate 
production [91]. Kras-mediated tumourgenicity requires high levels of glucose consumption, 
mitochondrial derived ROS and TCA catapleurosis to promote elevated cancer cell proliferation 
[92]. The PI3K/Akt/mTOR pathway is highly implicated in promoting tumourgenisis, the 
Warburg effect and altered mitochondrial function [93]. Activation of Akt signaling via upstream 
influence of PIP3 (phosphatidylinositol (3, 4, 5)-trisphosphate) promotes increased cell growth 
with suppression in cell death signaling [94]. The inhibition of PIP3 therefore decreases Akt 
signaling. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) functions as the 
lipid phosphatase that dephosphorylates and inhibits PIP3 [95]. Interestingly, PTEN has two 
exposed cysteines within its active site, and oxidation of cys124 by H2O2 resulted in inhibition of 
PTEN activity through cysteine disulfide bond formation [96, 97]. Functionally, this inhibition is 
reversible through the reductive properties of Trx. While the role of PTEN is diverse, it is the 
most common deregulated phosphatase in cancers. PTEN may be additionally involved in 
mitochondrial apoptotic signaling, whereby upon staurosporine-induced apoptosis, PTEN can 
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translocate to the mitochondria where it may interact with Bax, promoting apoptosis, and 
knockdown of PTEN resulted in cell protection from apoptosis [98]. Additionally, Akt 
stimulation resulted in the promotion of glucose uptake and lactate production beyond the 
requirements needed to sustain cell growth, yet had no influence over mitochondrial oxygen 
consumption [99]. Additional to the PI3K/Akt/mTOR pathway stimulating aerobic glycolysis, 
oncogenic activation of PI3K/Akt was able to stimulate an increase in GSH (and presumably 
Trx) through the activation of Nrf2 [100].  
 Given that mitochondrial assembly is reliant on both mitochondrial and nuclear DNA, 
mutations in both have been implicated in altering cancer metabolism [101]. Mutations in the 
subunits of succinate dehydrogenase (SDH - complex II of the ETC) in humans have been 
implicated in increased risk of renal cell carcinoma development resulting in aggressive cancer 
growth [102], while mutations in isocitrate dehydrogenase (IDH) are common in acute myeloid 
leukemia’s and glioma’s [103]. Both SDH and IDH mutations can result in drastically altered 
mitochondrial function, along with altered rates of lipid synthesis and ROS production. Despite 
the root cause of altered mitochondrial metabolism in cancers, the mitochondria play an 
important role in all facets of cancer progression. In murine 4T1 breast cancer cells, chronic 
exposure of low-dose ethidium bromide resulted in mitochondrial ablation (mitochondrial-null 
cells were referred to as 4T1p0 cells) and subsequently blunted tumour formation of 4T1p0 cells 
following murine injection relative to the parental 4T1 cell line [104]. Unlike the findings of 
mitochondrial ablation decreasing tumourigenesis, Guo et al. [105] demonstrated that depletion 
of mtDNA was able to promote tumourigenesis and chemoresistance in certain colorectal 
carcinomas. While separately, increasing mtDNA in other colorectal carcinoma lines was able to 
increase cell proliferation and inhibit cell death [106]. It appears that the role of the mitochondria 
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in cancer is not as universally defined relative to what Warburg first proposed almost 100 years 
ago, in contrast to his initial argument, it appears that the mitochondria are involved in tumour 
formation and growth, although how the mitochondria is involved appears to be vary greatly 
between cancers. Inserting point mutations in mtDNA in HeLa cells coding for a subunit of ATP 
synthase resulted in conferring an advantage in tumour growth when these cells were 
xenographically implanted into nude mice. This was attributed to a significant decrease in 
apoptosis occurring in the mutant compared to the wild-type HeLa cell transplants [107]. 
Nutrient starvation resulted in decreased glucose uptake and lower ATP production in CT26 
colorectal carcinoma cells, however this apparent decrease in glycolysis was accompanied by an 
increase in O2 consumption and oxidative stress, which concurrently amplified the cytotoxic 
effects of the chemotherapy oxaliplatin [108]. In Rat-1 fibroblasts, human MCF7 breast and 
HepG2 hepatocellular carcinoma cell lines, inhibiting mitochondrial OXPHOS decreased 
mitochondrial apoptotic signaling brought upon by a variety of pro-apoptotic external stimuli 
[109]. This highlights the notion that normal mitochondrial function is required for proper 
regulation of apoptotic stimuli, and that aerobic glycolysis may confer a potential advantage to 
cancers through apoptotic evasion [110]. However, there is a misconception that cancers display 
intense apoptotic resistance. Many cancers display an increased sensitivity to a variety of 
external apoptotic stimuli (such as a variety of chemotherapies), and overcome this heightened 
sensitivity by constant and rapid cell division [111].  
 
2.4.1 Cancer metabolism confers a pro-neoplastic environment 	
Mitochondria are linked to a variety of pro-growth events throughout the cell. 
Dihydroorotate dehydrogenase (DHODH) is an enzyme found on the outer leaflet of the IMM 
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and is critical for de novo pyrimidine biosynthesis [112]. In epithelial carcinoma cells, 
decreasing mitochondrial flux through the ETC resulted in a decrease in de novo pyrimidine 
biosynthesis through decreasing DHODH activity [113], suggesting that while cancers may elicit 
decreased mitochondrial flux through the ETC, some tonal level is required for de novo 
pyrimidine biosynthesis resulting in steady-state mitochondrial ROS production. Mitochondrial 
ROS emission is associated with an increase in HIF-1α, and overexpression of HIF-1α is linked 
to increased tumour aggression and growth [114]. Once increased, HIF-1α can increase the 
transcription of many pro-glycolytic genes including GLUT1 and GLUT3 [115], pyruvate 
dehydrogenase kinase (PDK) [116], hexokinase II (HKII) and phosphofructokinase (PFK) [117]. 
Knocking down HIF-1α resulted in decreased glycolytic metabolism [118] and increased the 
sensitivity of multiple myeloma cells to melphalan-induced cell death [119]. HIF-1α is not the 
only driver of aerobic glycolysis, however it is certainly well characterized, regardless, the 
promotion of aerobic glycolysis can confer many pro-growth benefits to cancers. Overexpression 
of B7-H3, an immunoregulatory protein, resulted in the increase in glucose consumption, lactate 
production and HKII activity in colon cancer cells [120]. This increase in aerobic glycolysis 
conferred chemo resistant properties, and the inhibition of HKII prevented the increase in aerobic 
glycolysis and restored chemo sensitivity [120]. While understanding the role of B7-H3 in 
cancers is still in its infancy, the promotion of aerobic glycolysis is able to drive many pro-
neoplastic adaptations. These adaptations are likely a result of both aerobic glycolysis and 
mitochondrial metabolism, as aerobic glycolysis can produce ATP and biosynthetic molecules, 
and through anapleurosis and catapleurosis, the mitochondria can supply the cell with other 
required molecules for growth and replenish TCA cycle intermediates through various alternate 
pathways.  
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Glycolytic intermediates promote a pro-neoplastic environment 	
Malignant tumour development is a process of micro-evolutionary events resulting in the 
cancer phenotype. Aerobic glycolysis likely stems from the micro-evolutionary adaptations to 
hypoxia during early stages of tumourigenesis [121].  During this initial hypoxic event, there is 
an increase in lactate production that is fatal to most cells, therefore the surviving cancer 
population typically display protective mechanisms against acidosis and a marked growth 
advantage associated with aerobic glycolysis [121]. Hypoxia, along with mitochondrial ROS, 
increases HIF-1α which increases lactate dehydrogenase (LDH) expression [122]. LDH catalyzes 
the production lactate from pyruvate at the cost of the oxidation of NADH producing NAD+ in 
the process. Increased intratumoural lactate, which in itself is associated with increased aerobic 
glycolysis, is associated with an increased likelihood for metastasis in head and neck cancers 
[123] and cervical cancers [124]. In order to sustain elevated rates of aerobic glycolysis, a 
constant supply of NAD+ must be available. Therefore, one of the benefits of high rates of lactate 
production is through the restoration of the NAD+ pool through the oxidation of NADH [125]. 
Inhibition LDH by oxamate resulted in an increase in G2/M cell cycle arrest and an increase in 
apoptosis in two nasopharyngeal carcinoma cell lines, which was accompanied by an increase in 
mitochondrial ROS production, and N-acetylcysteine (NAC, an exogenous antioxidant) was able 
to partially blunt the effects [126]. However, the role of LDH in cancer progression is still 
debated, as LDH silencing led to the surprising increase in HIF-1α in HT29 cells, yet HIF-1α 
was unable to function properly as it was no longer able to promote expression of its regular 
targets [127]. Regardless, excess cancer lactate itself is a prominent pro-oncogenic signal, as it 
promotes vascularization through VEGF production in endothelial cells [125], inhibits T-cell 
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function through the prevention of T-cell lactic acid transport (disrupting T-cell metabolism) 
[128] and promotes cancer metastasis and migration [123, 124].  
Along with excess lactate production, aerobic glycolysis also affords an increase in 
glycolytic-derived carbon flux through the pentose phosphate pathway (PPP). The PPP branches 
off of glycolysis following the first committed step of glucose. The PPP fulfills two main 
requirements of the cell, as it is required for the biosynthesis of ribonucleotides, and is a site of 
NADPH production [129].  Cancers display relatively high levels of glucose-6-phosphate 
dehydrogenase (G6PDH - the rate-limiting enzyme for initiating the PPP) protein content [130] 
and high levels of G6PDH enzymatic activity [131]. Dehydroepiandreosterone (DHEA) is an 
endogenous circulating steroid shown to display inhibitory properties towards G6PDH [132], and 
DHEA abrogated cell survival in several cancer cells. The inhibition of G6PDH rendered cells 
more susceptible to H2O2-induced decreasing cell survival, while overexpression G6PDH 
increased cellular proliferation [132]. This data highlights the importance of the PPP in 
regulating cancer growth, where the production of ribonucleotides is critical for constantly 
dividing cells, as is the production of NADPH for redox regulation and for other components of 
cell growth such as the requirement of NADPH to drive de novo lipid synthesis [129]. The in 
vivo efficacy of direct PPP inhibition is currently not well understood, however the PPP is the 
only known source of NADPH production in red blood cells, and G6PDH inhibition resulted in 
drastic red blood cell sensitization to ROS-induced cell damage [129], likely suggesting that 
G6PDH-inhibition through our current understanding may not be a viable therapeutic target 
given the potential for harmful deleterious off target effects. 
 
TCA cycle intermediates are required for neoplastic growth 	
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Alterations in IDH, SDH and fumarate hydratase (FH) have all been implicated in 
altering cancer metabolism and conferring pro-neoplastic properties [133]. Wild type IDH 
converts isocitrate to α-ketoglutarate, however mutant IDH gains the function to convert α-
ketoglutarate to 2-hydroxyglutarate (2-HG) [134]. While the presence of 2-HG can serve as a 
potential biomarker for IDH-bearing mutant cancers to potentially guide therapies [135], mutated 
IDH and increased 2-HG resulted in the elevation of free amino acids and increased lipid 
precursors in human oligodendroglioma cells [136]. Activation of HIF-1α is able to promote 
aerobic glycolysis through the increase in pyruvate shunting towards lactate instead of the 
mitochondria; the regulation of HIF-1α can be manipulated by many of the TCA cycle 
intermediates [133]. Elevated levels of fumarate and succinate can stabilize and promote HIF-1α 
activity [137], which in turn increases glutamate import into the mitochondria for anapleurotic 
replenishment of TCA cycle intermediates, while silencing FH resulted in an increase in HIF-1α 
and a subsequent increase in aerobic glycolysis [133, 138]. FH-deficient human fibroblasts 
displayed altered metabolism through an increase in HKII, and a reduced redox state through a 
decrease in ROS and an increase in GSH [139]. Increased glycolysis corresponding to alterations 
in cellular redox conditions is common in cancer pathology, linking metabolism and redox 
regulation as properties involved in conferring a pro-neoplastic cellular environment.  
 
2.5 Cancer and antioxidant regulation 	
ROS accumulation within cancers has long been associated as a mitogenic signal 
promoting tumourigenesis. Elevated ROS in cancers has been attributed to a variety of neoplastic 
functions such as altered metabolic activity, further oncogene activation and pseuo-hypoxic 
signaling [140]. At higher levels however, rather than promoting cell proliferation, mitochondrial 
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ROS can promote cell death if not countered by antioxidant defense systems [140]. Exogenous 
exposure of MCF7 cells to varying concentrations of H2O2 resulted in both an increase and 
decrease in cell proliferation compared to no H2O2 [141]. Chronic 25µM H2O2 exposure resulted 
in a drastic increase in MCF7 cell proliferation, however 250µM H2O2 resulted in a significant 
decrease in MCF7 cell proliferation. Given that low levels of H2O2 were able to stimulate growth 
yet high levels resulted in blunted proliferation, it is likely that the ability of the cell to buffer 
changes in ROS is an important factor in dictating cell fate upon exposure to potential oxidative 
stress. It has been previously reported in lung cancer patients (non-smoking population) that 
there was a significant increase in complex I associated mtDNA mutations [142], and given that 
complex I is a primary site for ROS generation in the mitochondria, it is a fair assumption that 
mutations in complex I may have resulted in abnormal mitochondrial ROS production. 
Furthermore, overexpression of the oncogene Ras promoted hyper proliferation in normal human 
fibroblasts despite increased DNA damage, which was accompanied by elevations in ROS [143]. 
However, the exogenous antioxidant NAC was able to prevent hyper proliferation induced by 
Ras overexpression restoring normal growth patterns in the Ras overexpressed cells. It is 
therefore apparent that the role of ROS in cancers is through promotion of both cell growth and 
cell death, and it is likely that if a cell can properly buffer elevations in ROS, ROS can 
potentially result in a pro-growth environment, yet if a cell is unable to buffer these elevations in 
ROS, the cell will undergo oxidative stress and cell death. As are many components associated 
with metabolism and redox signaling, the two main intracellular antioxidants, glutathione and 
Trx, are highly implicated in many cancers. 
 
2.5.1 Glutathione and thioredoxin are highly implicated in cancers 	
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Following the conversion of mitochondrial O2●- to H2O2, the reduction of H2O2 to H2O 
prevents the formation of hydroxyl radicals (OH●) through Fenton chemistry [8]. The peroxidase 
systems responsible for the reduction of H2O2 are the glutathione and Trx systems. Interestingly, 
both the Trx and glutathione system are highly implicated in cancer regulation.  
 
2.5.2 Cancer and glutathione 	
Glutathione is often increased in many cancers [144], however the role of glutathione in 
cancer progression remains not entirely defined. Glutathione has many roles in regulating the 
progression of cancer other than redox regulation, as excess GSH can promote tumour growth 
and eventual metastases [145]. Elevated tumoural glutathione levels at the onset of diagnosis 
seemingly conferred with a worse prognosis in colorectal carcinoma patients [146]. While 
glutathione is implicated in a variety of cellular systems, it is highly implicated in promoting 
cancer growth and chemoresistance. 
 
Glutathione regulating cancer growth  	
One of the main associative causes of death with cancer is through metastatic growth. 
Upon relocation of cancer cells to a new environment, metastatic cancer cells are exposed to a 
transient hypoxic environment resulting in the rapid production of ROS. Therefore, the ability of 
the cell to combat these elevations in ROS in part dictates cell survival during metastasis. Such 
that NB4 leukemia cells cultured in hypoxic conditions displayed an acute burst of ROS, 
resulting in marked cell death, however not cell extinction. Following 7 days of hypoxia, the 
surviving fraction of NB4 cells displayed significantly greater GSH levels to protect from excess 
ROS generation [147]. Cancer cell dormancy during metastasis allows for cancer cells to remain 
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in circulation for years, and despite the absence of cell proliferation in these cells, they can 
eventually lead to latent metastatic tumour formation. Havard et al. [148] demonstrated that 
elevated levels of GSH and citrate were able to re-animate previously dormant LNCaP prostate 
cells. While it currently remains undetermined, the combined role of increasing a mitochondrial 
substrate (citrate) and glutathione unifies cancer mitochondria and glutathione as critical 
regulators for cancer progression. In B16-F10 melanoma-bearing mice, elevated circulating GSH 
resulted in increased intratumoural GSH levels resulting in an increase in metastatic growth 
[149]. B16-F10 melanoma cells secreted interleukin-6 (IL-6), which resulted in increased 
hepatocyte release of GSH into the circulation, allowing for more GSH uptake by B16-F10 cells 
in a feedback loop. This is evidence that cancers are able to alter their redox environment 
through endocrine signaling. Following an increase in systemic glutathione, circulating 
glutathione is broken down at the target cell by cell membrane-bound γGT, allowing for the 
import of the constituent ingredients required for intracellular glutathione reassembly. This 
pathway for glutathione synthesis is separate from de novo glutathione synthesis and is called the 
γ-glutamyl cycle. Interestingly, γGT expression increases following oxidative stress and is 
commonly up-regulated in a variety of cancers. Additionally, in B16-F10 melanoma-bearing 
mice, the circulation of exogenously added GSH-ester promoted further metastasis, however the 
inhibition of γGT by acivicin prevented GSH-ester induced cell metastasis [150]. Furthermore, 
inhibition of γGT by acivicin resulted in increased tumour cytotoxicity to glutathione depletion 
[151]. As evidence that glutathione can directly promote cell division, glutathione has been 
previously demonstrated to co-localize with the nucleus as cells undergo proliferation. Nuclear 
translocation of glutathione serves to protect the nucleus during nuclear disintegration, as well as 
serve as a regulator of redox-dependent proteins involved in initiating and regulating cell cycle 
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[58, 59, 152]. While the role of glutathione directly regulating cell cycle progression has yet to 
be determined in cancers, it is fairly safe to assume that associative increases of glutathione in 
cancers is also likely involved in further progressing cell proliferation.  
 
Glutathione in chemoresistance 	
Fujimori et al. [153] noted a relationship between cisplatin sensitivity and expression of 
GCL (the rate-limiting enzyme in de novo glutathione synthesis, Figure 2.6), whereby 
overexpression of the GCL subunits correlated with cisplatin resistance in human non-small-cell 
lung carcinoma (NSCLC) xenografts in vivo. While de novo glutathione synthesis is one 
mechanism for increasing GSH levels, another mechanism is through the breakdown and 
subsequent import of extracellular glutathione. Interestingly, when human ovarian tumour 
samples acquired chemoresistance, there was a corresponding ~10-fold increase in intratumoural 
GSH [154]. The notion of elevated GSH conferring chemoresistance has been confirmed in a 
variety of cancers to several different therapeutic compounds [145]. The role of glutathione in 
chemoresistance is primarily responsible for buffering chemotherapy-induced ROS and direct 
binding to xenobiotic compounds allowing for the export of anticancer compounds out of the 
cell. Many current cancer therapies elicit anticancer properties through either the generation of 
ROS or the depletion of antioxidant defenses [155].  To that point, Diehn et al. [156] reasoned 
that ionizing radiation kills cells through the rapid generation of ROS, and that radiation-resistant 
cancer could be sensitized to radiation through combined radiation and glutathione depletion by 
BSO. Indeed, they discovered that radiation-resistant tumours had higher levels of glutathione 
and contained cancer cells that were spared to ionizing radiation compared to non-transformed 
cells, yet glutathione depletion through BSO resulted in complete sensitization of the tumour to 
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radiation [156]. Additionally, many cancer cells have been demonstrated to be highly reliant on 
glutamine uptake to sustain elevated cell proliferation, where glutamine gets converted within 
the cell to glutamate by glutaminase. Upon enzymatic conversion, glutamate can function as a 
precursor to glutathione synthesis. Using radiolabeled glutamine, it was demonstrated that H460 
and A549 lung cancer cells rapidly synthesize glutathione from cytosolic glutamine, and both 
glutaminase inhibition and glutamine starvation sensitized the cells to radiation-induced death 
[157]. Along with glutamine import, cancers typically have up-regulated xCT membrane 
expression. xCT is a cysteine-glutamate antiporter, and is critical in the development of many 
cancers such as colorectal, kidney, brain and breast cancer cells [145, 158]. While cysteine is 
typically viewed as a non-essential amino acid because it can be synthesized from methionine in 
many tissues, many cancers have demonstrated an inability to synthesize cysteine from 
methionine, and therefore rely on cysteine uptake. Likely stemming from the inability to 
synthesize de novo cysteine, many cancers have demonstrated an increase in both light and 
heavy chain subunits of the xCT antiporter, and this increase in xCT is seen as a primary 
mechanism for cysteine import for cell growth and glutathione synthesis to aid in 
chemoresistance. Interestingly, cysteine starvation or xCT inhibition has lead to drastic 
glutathione depletion and cancer cell death [158]. The role of glutathione as an antioxidant 
during chemoresistance is fairly well defined, as certain therapies aim to increase intratumoural 
ROS to elicit anticancer effects, cancers combat this through elevations in GSH to prevent the 
deleterious effects of ROS. The other primary mechanism for glutathione-induced 
chemoresistance is mediated primarily through the family of enzymes known as glutathione s-
transferases (GSTs). 
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Glutathione S-transferase 	
B16-F10 melanoma cells have high levels of GSH and display hyper proliferative 
qualities relative to B16-F1 low glutathione cells [150, 151], which is consistent with previous 
literature demonstrating high glutathione confers pro-growth properties. However, B16-F10 cells 
display inhibition towards glutathione efflux resulting in metastatic cell resistance to oxidative 
stress, while knocking out multidrug resistance protein-1 (MRP-1) resulted in the full prevention 
of glutathione efflux, suggesting that glutathione efflux is channeled through MRP-1 [151]. The 
regulation of glutathione efflux is critical in cancers not only to regulate extracellular glutathione 
levels, but also through the functioning role of glutathione as a xenobiotic regulator. MRP-1 is a 
member of a class of pumps called GS-X pumps, which serve to export glutathione conjugates 
out of the cell. Once a glutathione conjugate is formed through enzymatic regulation by GSTs, 
the glutathione conjugate is exported out of the cell for extracellular degradation and 
detoxification [159]. GSTs have been identified as commonly up-regulated in variety of cancers, 
and GST activity has been demonstrated to be elevated in a variety of breast cancers [160]. 
Interestingly, GST-null mutations lead to increased risk of cancer development as a consequence 
of cells losing the ability to remove carcinogenic compounds [161]. Furthermore, GST-null 
mutations result in a significantly worse prognosis and expected response to chemotherapies in 
breast cancer patients [162]. Contrary to this however, lower GST activity is associated with 
better survival in ovarian cancer patients, and there was a slight increase in survival advantage 
with GST-null mutations [163]. This demonstrates the complicated nature of GSTs in cancer, 
where the systemic lack of GSTs can result in an increase in cancer development due to 
increased cellular exposure to carcinogens; lower GST can result in either better or worse 
survival. Although speculative, it appears that the loss of GST on survival may be involved in the 
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systemic response to chemotherapies. Where lower survival with a GST-null mutation may result 
in systemic sensitization to chemotherapies resulting in negative systemic effects, however 
depending on the cancer itself, it may render the cancer more susceptible to therapy over 
surrounding tissue. Furthermore, high levels of GST expression have also been correlated to 
chemoresistance in ovarian cancer [164]. Future research will further elucidate the role of GSTs 
in cancers, currently however, therapeutic targeting of GSTs remain controversial given the 
contradictory nature of GSTs in determining survival.  
 
2.5.3 Cancer and thioredoxin 	
Along with glutathione, Trx is commonly up-regulated in many cancers [165], and Trx 
expression is associated with aggressiveness of the tumours themselves, whereby the more 
aggressive tumours have greater levels of Trx [166]. Along with its antioxidant function, reduced 
thioredoxin is bound to ASK1, preventing ASK1 from initiating downstream apoptotic signaling. 
Trx disassociates from ASK1 upon oxidation, allowing for ASK1 to initiate apoptotic signaling 
[167]. Given the important role of Trx in redox and apoptotic signaling, emerging evidence 
highlights the importance of Trx in clinical cancer populations. In human primary gastric 
carcinoma samples, there was a positive correlation of Trx levels with cancer cell proliferation, 
and a negative correlation with DNA damage, suggesting that Trx is associated with both the 
promotion cancer cell growth and resistance to DNA damage [168]. Similar to glutathione, Trx is 
important in regulating both cancer growth and promoting chemoresistance. 
 
Thioredoxin regulating cancer growth 	
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Trx has been implicated through various pathways to promote both normal cell growth 
and cancer growth. Trx is a known inhibitor of PTEN, whereby an exposed cysteine on Trx can 
bind to an exposed cysteine on PTEN inhibiting PTEN inhibition on Akt [169]. Therefore, 
overexpression of Trx functions to increase the PI3K/Akt/mTOR pathway through inhibition of 
PTEN. While several different Akt inhibitors were able to decrease cancer cell viability, the 
coordinated exposure of cells to Akt inhibitors plus Trx rescued the original effect of the Akt 
inhibitors. Interestingly, Trx alone was able to promote an increase of cells in S and G2/M phase 
and decrease cells in G0/G1, suggesting that Trx is able to promote an increase in cell cycle 
progression [170]. Furthermore, overexpression of Trx in HeLa, HT29, MCF7 and EMT6 cells 
all resulted in an increase in HIF-1α activity [171]. Beyond Trx itself, mitochondrial thioredoxin 
reductase (TrxR2) is up-regulated in NSCLC tumour samples. Knocking down TrxR2 in A549 
and NCI-H1299 cells resulted in suppression of cell growth, induced apoptosis and decreased 
cell invasion, whereas overexpression of TrxR2 resulted in the opposite effects [172]. This 
suggests that TrxR2 can also promote cancer cell aggression. Interestingly, ribonucleotide 
reductase (RR) functions as the rate-limiting enzyme in DNA synthesis, however following the 
enzymatic reduction of a ribonucleotide to a deoxyribonucelotide by RR, cysteine residues on 
RR need to be re-reduced. RR physically interacts with Trx, and ectopically increased Trx 
expression increases RR expression (along with DNA synthesis, cell proliferation and 
migration). In human colorectal carcinoma tumours, Trx (but not glutaredoxin) and RR were 
coordinately up-regulated, and the expression of both Trx and RR were correlated with tumour 
aggression [173]. Beyond activation of Trx in cancers, the inhibition of Trx is also altered in 
many cancers. Thioredoxin interacting protein (TXNIP) is typically viewed as an inhibitor of 
Trx, resulting in decreasing Trx function. TXNIP expression is decreased in many cancers, and 
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lower TXNIP results in altered lipid metabolism [174], which in itself is a common phenotype in 
many cancers. The Trx system is a complex system in both normal and cancer cells. It is critical 
in regulating cell growth through normal cell development, and alterations in the Trx system 
further promote cancer progression. 
 
Thioredoxin in chemoresistance 	
Similar to glutathione, Trx is highly implicated in cell protection from oxidative stress, 
this holds true in both normal cells as well as in cancer cells. Interestingly, Trx levels correlate to 
cisplatin resistance in human ovarian cancers [175]. Beyond simple correlation, the creation of 
cisplatin resistant HT29 and St-4 cell lines resulted in a ~2-2.5X increase in Trx relative to their 
parental lines. In line with resistance to cisplatin, levels of Trx prior to the exposure of docetaxel 
predicted chemoresistance, however there was no witnessed relationship between the levels of 
Trx after docetaxel exposure to the sensitivity of the cell to docetaxel-induced cell death [176]. 
This suggests that the adaption of Trx to anticancer therapies is less important than the starting 
levels of Trx. However, contrary to the notion of elevated Trx being able to confer 
chemoresistance, breast cancers that are resistant to anti-estrogen therapy are sensitized when 
mitochondrial thioredoxin (Trx2) is overexpressed. Anti-estrogen elicits an increase in 
intracellular H2O2 production; and modest increases in H2O2 may promote neoplastic growth. 
The overexpression of Trx2 may prevent the accumulation of modest levels of H2O2 allowing for 
non-ROS inducing cell death mechanisms to kill the cell [177]. While the role of Trx in 
promoting chemoresistance appears to be diverse, evidence suggests that alterations in Trx is 
highly involved in cell protection [178]. Androgen deprivation therapy (ADT) is the standard-of-
care for prostate cancers when surgical or radiation options fail. While ADT initially results in 
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tumour regression, prostate cancer relapse typically occurs between ~1-3 years later. The 
relapsed prostate cancer is considered incurable and is termed castration-resistant prostate 
cancer. Samaranayake et al. [178] demonstrated that Trx is significantly increased in castration-
resistant prostate cancer cells and shRNA knockdown of Trx impedes cell growth and promotes 
cell death, and early Trx knockdown in castration-resistant prostate cancer prevented tumour 
formation [178]. Additionally, diffuse Large B cell lymphomas have a fairly high initial therapy 
success rate, however similar to ADT treated prostate cancers, diffuse Large B cell lymphomas 
have a high rate of relapse and a low patient survival rate following cancer return. This is largely 
attributed to diffuse Large B cell lymphoma chemoresistance. Interestingly, in both derived and 
primary lines, diffuse Large B cell lymphoma cells have higher levels of cytosolic thioredoxin 
(Trx1), and Trx1 expression is associated with decreased patient survival. Further inhibition of 
Trx1 by siRNA or a specific Trx1 inhibitor (PX-12) resulted in the blunting of diffuse Large B 
cell lymphoma cell growth and sensitized diffuse Large B cell lymphoma cells to doxorubicin-
induced cell death in vitro [179]. In doxorubicin-resistant McA diffuse Large B cell lymphoma 
cells, it was noted that Trx1 was significantly higher compared to the parental cell line that was 
not generated to be resistant to doxorubicin, yet the doxorubicin-resistant cells were more 
sensitive to Trx1-inhibition induced decreasing cell survival compared to the parental 
doxorubicin-sensitive line. This is particularly interesting because it suggests a form of Trx 
addiction in cancers, where the heightened levels of Trx likely means cancers have a heightened 
reliance on cyto-protective Trx properties.  Beyond Trx itself, the regulators of Trx also appear 
to be important to promote chemoresistance. To this point, selenite is used as an anticancer 
therapy that functions through the induction of cellular oxidative stress. Interestingly, selenite 
seems to be more potent in cancer cells relative to non-transformed cells. Preventing the 
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reduction of Trx-S2 by decreasing cytosolic thioredoxin reductase (TrxR1) resulted in increased 
sensitivity to selenite, despite TrxR1 knockdown resulting in a compensatory increase in 
glutathione (which in turn elicited marginal cyto-protective effects) [180]. The role of Trx in 
promoting cancer growth and chemoresistance is still not entirely defined. However, it appears 
that elevated levels of Trx and Trx-related proteins are able to alter cell growth and cell death 
dynamics, and manipulations in both glutathione and Trx offer potential potent therapeutic 
options given the heightened reliance of cancers both for ROS production to promote cell 
growth, but also Trx and glutathione to regulate and manage ROS levels. 
 
2.5.4 Antioxidant targeting for cancer therapy 	
Much work has been conducted on examining the potential of exogenous antioxidant 
supplementation as an adjunct anti-caner therapy. Exposure of HT1080 fibroscarcoma and RD 
rhabdomyoscarcoma cells in vitro to the mitochondrial-targeted antioxidant, SkQ1, resulted in 
drastic tumour growth suppression [181]. However, several different clinical trials have 
demonstrated that dietary antioxidant supplementation were able to mitigate treatment-related 
off-target effects [182-187]. Interestingly, several reports have suggested that exogenous 
antioxidant supplementation may not only confer protective benefits to normal tissues, but also 
to cancer tissues rendering anticancer therapies less potent [188-190]. Bairati et al. [186] 
administered oral α-tocopherol and β-carotene in a clinical trial with patients with head and neck 
cancers. While β-carotene administration was ceased during the trial, α-tocopherol was 
administered during treatment and up to three years after. Interestingly, α-tocopherol 
administration resulted in an increase in cancer-specific mortality compared to placebo; resulting 
in the conclusion that high-dose α-tocopherol could be harmful to cancer survival [186]. 
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However, given the role of glutathione and Trx in promoting both cancer progression and 
chemoresistance, and the potential addiction of cancers to endogenous antioxidant systems, 
rather than the administration of exogenous antioxidants to patients with cancer, selective 
targeting of glutathione and Trx has gained more recognition in recent years as a potential for 
anticancer therapies. 
 
Glutathione inhibition for cancer therapy 	
Many studies have demonstrated that genetic manipulation of glutathione can alter cancer 
survival (see section 2.5.2 Cancer and Glutathione). The use of glutathione-specific depleting 
agents or inhibitors has demonstrated potentially beneficial results towards anticancer growth, 
and warrants further exploration.  
 
Buthionine sulfoximine (BSO) 	
BSO is an inhibitor of glutamate cysteine ligase (GCL – Figure 2.6), resulting in the 
inhibition of glutathione synthesis leading to a rapid decrease in intracellular glutathione levels 
[191]. BSO-induced glutathione depletion can result in decreasing cancer growth and survival, as 
well as act in combination with a variety of other anticancer therapies to provide beneficial 
effects [192]. Using Auger electron emitting thymidine (I-125-ITdU) as a cancer specific 
radiotherapy (I-125-ITdU incorporates into the DNA of target cells, but radiation of the Auger 
electron has the capacity of only nanometers, therefore it only degrades DNA of the host cell, 
with minimal side effects, this is called nanosurgery), GSH depletion by BSO was able to 
markedly sensitize triple-negative breast cancer stem cells to DNA damage and death from I-
125-ITdU, suggesting a potential avenue for concurrent glutathione depletion in novel anticancer 
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therapies [193]. However, while phase I clinical trials demonstrated that BSO was safe, it did not 
however result in marked decreases in intracellular glutathione levels [194]. This was likely due 
to rapid elimination of BSO from plasma resulting in a short half-life minimizing the effects of 
BSO on glutathione depletion [195]. While BSO remains an important compound to test the 
influence of glutathione depletion in cancer, it is unlikely that BSO is a viable option for an 
anticancer therapy; therefore other mechanisms to induce glutathione depletion are required. 
 
Serine and glycine starvation 	
Serine and glycine are integral for glutathione synthesis (Figure 2.6). During serine 
starvation, glycolysis is redirected towards the one-carbon cycle for de novo serine synthesis, and 
typically a compensatory increase in mitochondrial activity is observed to counteract decreasing 
glycolytic ATP supply. To that point, serine and glycine starvation resulted in glutathione 
depletion in HCT 116 colorectal cancer cells [73]. Upon serine and glycine starvation and 
glutathione depletion, HCT 116 p53+/+ cells were able to promote a cell cycle arrest, resulting in 
the decreased demand for serine and glycine for pro-growth synthesis, allowing for de novo 
serine synthesis through one-carbon metabolism and the restoration of glutathione levels. 
However, in HCT 116 p53-/- cells, there was no witnessed cell cycle arrest, therefore serine and 
glycine were required to sustain growth rather than being redirected towards glutathione 
replenishment, resulting in a further decrease in glutathione levels [73]. Interestingly, Kras-
driven mouse models of both pancreatic and intestinal cancers were less sensitive to serine and 
glycine starvation due to increased expression of enzymes involved in serine synthesis [196]. 
The therapeutic potential for serine and glycine starvation in anticancer therapies is incredibly 
high, as serine and glycine are non-essential amino acids, and serine and glycine starvation is 
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likely systemically well tolerated. However, given that some cancers are able to modulate serine 
synthesis related enzymes, adjunct therapy is required to increase the sensitivity of serine and 
glycine starvation in order to promote glutathione depletion. 
 
Other novel glutathione-depleting compounds 	
There are many compounds known to alter or deplete intracellular glutathione systems. 
Compounds such as telcyta (an inhibitor of GSTs), disulfiram (causes an increase in GSSG 
relative to GSH) and NOV-002 (GSSG conjugated to cisplatin) have been met with various 
successes as anticancer therapies [192]. Flavonoids have been demonstrated to induce 
glutathione depletion in A549 lung cancer cells, HL-60 myeloid cancer cells and PC3 prostate 
cancer cells resulting in decreasing cell survival [197]. However, the role of flavonoids on 
glutathione depletion in vivo remains unknown. One such novel compound to undergo clinical 
trials is imexon. Imexon incubations resulted in cytotoxic effects in 8226 myeloma cells at 
varying concentrations with long duration, low-concentrations of imexon eliciting the most 
potent effects [198]. Imexon elicited oxidative stress through cellular depletion of glutathione, 
and NAC partially blunted imexon-induced cytotoxicity, whereas concurrent BSO and Imexon 
incubations increased cytotoxic effects on 8226 myeloma cells [198]. Phase I trials demonstrated 
a relatively safe dosage with encouraging anticancer properties in patients with advanced 
pancreatic cancer [199], however, phase II trials with imexon and gemcitabine resulted in no 
observable improved outcome in patients with advanced pancreatic cancer [200]. Interestingly, 
in a phase II trial of imexon in patients with B-cell non-Hodgkin lymphoma, patient success with 
imexon was correlated with baseline levels of redox-related genes such as SOD1 and glutathione 
peroxidase, such that patients with cancers that a higher ‘redox-score’ were more likely to be 
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sensitive to imexon-induced partial responses compared to patients with cancers with a lower 
‘redox-score’ [201]. Which is in alignment with the notion of antioxidant addiction, where 
cancer cells with higher antioxidant function are more sensitive to antioxidant inhibition. 
 
Thioredoxin inhibition for cancer therapy 	
Many studies have demonstrated that genetic manipulation of Trx can alter cancer 
survival (see section 2.5.3 Cancer and Thioredoxin). The use of Trx-specific depleting agents or 
inhibitors has demonstrated potentially beneficial results towards anticancer growth, and 
warrants further exploration.  
 
Auranofin 	
Auranofin is a gold compound originally deployed for the treatment of rheumatoid 
arthritis [202]. Auranofin displays potent inhibition on thioredoxin reductase (TrxR) through the 
putative inhibition of the active site selenocysteine on TrxR [203]. Given that auranofin has a 
recognized toxicity profile and is considered safe for human consumption, auranofin is now 
being repurposed towards anticancer therapies [204]. There are currently 6 clinical trials 
involving auranofin and cancer according to the NCI database, to date however there are 
currently no reports on the efficacy of auranofin in humans towards anticancer therapies.  
 
PX-12 	
Unlike auranofin, which binds with TrxR, PX-12 inhibits Trx through binding to an 
exposed cysteine residue on Trx itself [192]. In A549 lung cancer cells, PX-12 resulted in an 
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increase in ROS generation leading to apoptosis, while NAC was able to partially blunt the 
cytotoxic effects of PX-12 [205]. A phase I clinical trial demonstrated that PX-12 is safe for 
administration and resulted in a stable disease state for ~18% of patients for up to a year [206]. 
However, PX-12 displayed a lack of anticancer activity in a phase II clinical trial in patients with 
advanced pancreatic cancer likely due to these patients having low baseline Trx levels [207]. 
 
Brilliant green 	
Brilliant green (BG) functions through the targeted inhibition of mitochondrial 
thioredoxin (Trx2) resulting in cell death at nanomolar concentrations. In HeLa cells, BG 
resulted in selective cancer cell death because fibroblasts appeared resistant to BG [208]. 
Furthermore, knocking down Trx2 increased sensitivity to BG-induced cell death in HeLa cells, 
however knocking down Trx2 had no effect in altering BG sensitivity in fibroblasts.  
 
Dual targeting of glutathione and thioredoxin for cancer therapy 	
Glutathione and Trx are often viewed in part as redundant systems. Transformed mouse 
embryonic fibroblasts (MEFs) taken from TrxR knockout mice displayed no difference in 
tumourigenic potential relative to MEFs isolated from control mice [209]. However, TrxR 
knockout MEFs were significantly more sensitive to BSO induced cell death relative to control 
MEFs [209]. This highlights the redundancy between systems given that TrxR knockout MEFs 
were solely reliant on glutathione for antioxidant defense purposes. To that end, Harris et al. 
[210] demonstrated in mice that generated spontaneous mammary tumours that while glutathione 
depletion with BSO was able to prevent tumour formation, only combined BSO + auranofin 
resulted in cancer death following established tumour formation. Separately, disulfiram has 
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demonstrated potent anticancer effects in PCa prostate cancer cells through the induction of 
mIR-17 that in turn suppresses expression of both glutathione peroxidase-2 and mitochondrial 
TrxR (TrxR2) [211]. Dual targeting of glutathione and Trx systems may lead to potent anticancer 
therapies, however, given the importance of both glutathione and Trx in normal cell 
development, potential cancer specific targeting of glutathione and/or Trx may be required to 
minimize deleterious off-target effects.   
 
2.6 Mitochondrial targeted therapies 	
Mitochondria are attractive therapeutic targets for a number of reasons, in particular 
because it is highly debated whether cancers display metabolic flexibility [212]. Given the hyper-
reliance of cancers on ATP production along with other growth requirements, it is still unknown 
whether cancers are able to adapt and alter these pathways. Interestingly, it appears that ATP is 
not rate-limiting for cancer growth, rather the carbon distribution to glycolytic biosynthetic 
pathways (see section 2.4.1 Cancer metabolism confers a pro-neoplastic environment) appears to 
be crucial. In line with the importance of carbon sparing, one theory as to why pyruvate is not 
fully oxidized in many cancers is to prevent carbon loss through the oxidation product of CO2 
[212]. Some cancer metabolic adaptations are due to direct irreversible genetic mutations [101]; 
it appears that most alterations in cancer metabolism are due to upstream adaptive phenotypes, 
such as the overexpression of PKM2 which results in slower carbon flux through glycolysis 
allowing for greater carbon redirection to glycolytic biosynthetic pathways such as the PPP. 
While these adaptive phenotypes may be theoretically reversible, the reversion of these 
metabolic phenotypes would come at a significant cost towards neoplastic growth. The impact of 
mitochondrial targeted anticancer therapies are based on the principle that alterations in cancer 
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metabolism are in fact irreversible, or indeed would be too costly to the cancer and arrest further 
cell division. However, there is a wide variety of mitochondrial-targeted therapies, some are 
designed to inhibit mitochondrial activity, while some therapies are targeted towards 
mitochondrial activation. What remains unclear is why some cancers are sensitive to 
mitochondrial inhibition, whereas some cancers are sensitive to mitochondrial activation. 
Increasing mitochondrial OXPHOS through forced overexpression of frataxin in MIP101, DLD2 
and HT29 colorectal cancer cells resulted in decreased growth rates, inhibited colony formation 
and decreased tumourigenic properties when xenographically implanted into nude mice [213]. 
Contrary to the findings of increasing mitochondrial metabolism to slow cancer growth, 
decreasing mitochondrial metabolism through the formation of mitochondrial-null B16 mouse 
melanoma cells (B16po) resulted in impaired tumourigenesis when xenographically implanted 
and significantly impaired the population doubling time under normoxic conditions [214]. 
However, under hypoxic conditions, there was no major difference between doubling time of 
B16po cells relative to the parental B16 cell line largely due to impaired population doubling of 
the parental B16 cell line. Further to this complication, elevated mitochondrial transcription 
factor A (TFAM), which promotes expression of mtDNA, is correlated to both increased cancer 
aggression and decreasing cancer progression. In 336 human breast cancer samples, patients with 
elevated levels of TFAM in cancer tissues correlated to poorer clinical outcomes and survival 
[215], whereas lower TFAM expression was correlated to a greater cell invasion in melanoma 
cell lines and human metastatic melanoma samples [216]. The efficacy of mitochondrial 
activation or inhibition appears to vary greatly between cancers. While debated, it appears that 
cancers may be susceptible to therapies designed at altering their metabolic profile whereas 
normal cells are able to display metabolic flexibility and are more resistant to mitochondrial 
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targeted therapies. Through detailed genetic manipulation, it can be ascertained that 
mitochondrial manipulation may provide a novel therapeutic target area selective for cancers, 
and many compounds have been examined to elicit desired effects. 
 
2.6.1 Mitochondrial activation as an anticancer therapy 	
Dichloroacetate (DCA) is perhaps the most commonly studied compound for 
mitochondrial activating therapies. In 2007, Bonnet et al. discovered that DCA displayed potent 
anticancer properties through the forced oxidation of pyruvate in A549 NSCLC cells, M059K 
glioblastoma cells and MCF7 breast cancer cells, despite resulting in no witnessed negative 
effects to non-cancerous cells [217]. DCA functions through the inhibition of PDH kinase 
(PDK), resulting in the conversion of pyruvate to acetyl-CoA by PDH whereby acetyl-CoA 
stimulates mitochondrial OXPHOS. While many trials have demonstrated selective potent 
anticancer effects of DCA, Feuerecker et al. [218] demonstrated that DCA stimulated cancer 
growth in Neuro-2a neuroblastoma xenografts in vivo, while stimulating increased cell growth in 
Neuro-2A and SkBr3 breast carcinoma cells in vitro, but had no effect on cell growth in the 
neuroblastoma cell lines Kelly and SK-N-SH in vitro. Additionally, DCA has been associated 
with peripheral nerve and hepatocellular toxicity [219]. The possibility of forced pyruvate 
oxidation is still currently under examination as phenyl butyrate has also demonstrated inhibitory 
properties towards PDK [219]. However, another avenue for forcing mitochondrial OXPHOS is 
through the supply of mitochondrial substrates. One intriguing example is through the provision 
of free carnitine and palmitoylcarnitine, a mitochondrial fatty-acid substrate able to bypass 
inhibition of carnitine palmitoyltransferase-1 (CPT-1, Figure 2.7), which has demonstrated 
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selective anticancer properties in HT29 colorectal cancer cells [220], as well as PC3 prostate 
cancer cells [221], while leaving normal cells healthy.  
 
Figure 2 7 Schematic depiction of palmitoylcarnitine entry into the mitochondria. 
Palmitoyl-CoA and L-carnitine get converted to palmitoylcarnitine by carnitine 
palmitoyltransferase 1 (CPT1), whereby palmitoylcarnitine can freely diffuse into the 
intermembrane space, where it is imported into the mitochondrial matrix by carnitine 
acetyltransferase (CAT) through the antiporter function of palmitoylcarnitine against L-carnitine. 
Once in the mitochondrial matrix, palmitoylcarnitine gets broken down into palmitoyl-CoA and 
L-carnitine by carnitine palmitoyltransferase 2 (CPT2), allowing for L-carnitine cycling back out 
of the mitochondria. 
 
When mice were treated with 1,2-dimethylhydrazine (DMH) to induce colon carcinogenesis, the 
addition of orally administered acetylcarnitine was able to significantly reduce the formation of 
DMH-induced colorectal neoplastic lesions, with no deleterious side effects reported [222]. 
Additionally, following 4-weeks of azoxymethane injections used to elicit carcinogen-induced 
colon cancer, a diet high in butterfat resulted in an increase in aberrant crypt foci (ACF), 
however when butterfat was combined with free carnitine, it appears that there was a significant 
CPT1
Palmitoyl-CoA
L-CarnitinePalmitoycarnitine
Palmitoycarnitine
CAT
Palmitoycarnitine
Palmitoyl-CoA
L-Carnitine
CPT2
OMM IMM
 	 53 
decrease in ACF formation compared to control [223]. As an alternative to both pyruvate 
oxidation and oversupply of mitochondrial substrates, Maddocks et al. [73] demonstrated that 
serine and glycine starvation resulted in the increase in mitochondrial reliance due to glycolytic 
redirection away from pyruvate and towards de novo serine synthesis. This redirection of 
glycolysis likely resulted in a decrease in ATP production, stimulating mitochondrial OXPHOS 
to generate ATP. Interestingly, serine is an allosteric regulator for PKM2, and serine starvation 
resulted in inhibition of PKM2 causing carbon backflow into de novo serine synthesis [224].  
 
2.6.2 Mitochondrial inhibition as an anticancer therapy 	
Work by Nieman et al. [225] demonstrated that primary human ovarian cancer cells and 
SKOV3ip1 human ovarian cancer cells utilize neighboring fatty acids from the omentum to 
stimulate fatty acid oxidation and drive metastasis, potentially through the up-regulation of fatty 
acid binding protein 4 (FABP4). In line with the theory of cancer metabolic inflexibility, the 
inhibition of mitochondrial fatty acid import by etomoxir resulted in complete ablation of 
SKOV3ip1 cell growth with or without the presence of omental adipocytes [225]. Furthermore, 
inhibition of mitochondrial fatty acid oxidation by avocatin B selectively killed human primary 
acute myeloid leukemia cells without harming normal cells, and functioning mitochondria are 
critical for avocation B-induced cell death in Jurkat T cells as well as TEX leukemia cells [226]. 
Further research has demonstrated that mitochondrial inhibition can selectively kill cancers in a 
mitochondrial dependent fashion using the compound ONC201 in many cancer lines [227] as 
well phenethyl isothiocyanate in LNCaP and PC3 prostate cancer cells [228]. Interestingly, in 
both cell models of brain cancer and acute myeloid leukemia cells, a novel clinical grade small 
molecule, IACS-010759, directly inhibited complex I, resulting in a decrease in mitochondrial 
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ATP and nucleotide biosynthesis leading to cell death, and was further validated in a murine 
tumour model where IACS-010759 inhibited tumour growth in vivo [229]. These findings are 
consistent with previous research demonstrating that direct complex I inhibition in MCF7 breast 
cancer cells with rotenone (a putative complex I inhibitor resulting in elevated H2O2 emission) 
elicited potent apoptotic signaling responses resulting in decreasing MCF7 cell survival [230]. 
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Chapter 3 Objectives and hypothesis 	
Cancers display irreversible or costly alterations in bioenergetics geared towards 
sustained accelerated growth. While previous research has extensively examined the response of 
many cancers to forced mitochondrial activation as a possible route for anticancer therapy, it 
currently remains unknown why some cancers are able to tolerate mitochondrial activation, 
whereas others are not. Increased mitochondrial ROS is a well-established byproduct of 
increasing mitochondrial OXPHOS, therefore, perhaps the ability of the cell to tolerate 
alterations in mitochondrial-derived ROS can in part dictate cell survival during forced 
mitochondrial activation.  
3.1 Overview of thesis 	
The overall purpose of this thesis is to determine the response of glutathione following 
metabolic alterations, and whether experimental manipulation of glutathione can alter cell 
survival. The specific objectives and hypothesis for each study are outlined below.  
3.2 Objectives and hypothesis for study 1 (Chapter 4) 	
Palmitoylcarnitine has previously been demonstrated to selectively decrease cell survival 
in HT29 colorectal carcinoma cells and prostate cancer cells, but not in analogous normal cells. 
It has been demonstrated that palmitoylcarnitine (with the addition of L-carnitine) enters the 
mitochondria where it stimulates ROS production leading to caspase activity and HT29 specific 
cell death, but not in NCOL-1 normal epithelial cells. The purpose of Chapter 4 was to evaluate 
the degree to which palmitoylcarnitine abrogates cell survival in HT29 colorectal cancer cells vs. 
non-transformed cells as previously demonstrated, and to determine whether cell-specific 
susceptibilities to palmitoylcarnitine are due to intrinsic differences in the glutathione response. 
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Hypothesis 	
1) Following palmitoylcarnitine incubations, HT29 cells will display decreased glutathione 
levels corresponding to decreasing cell survival, whereas CCD 841 cells will maintain 
glutathione levels resulting in no change in cell survival. 
2) Concurrent glutathione depletion will sensitize CCD 841 cells to palmitoylcarnitine-
induced decreasing cell survival and further sensitize HT29 cells.  
3) Palmitoylcarnitine will have no effect on glutathione levels and cell survival in MCF7 
cells, which have been previously demonstrated to be reliant on mitochondrial activity for 
survival. 
3.3 Objectives and hypothesis for study 2 (Chapter 5) 	
Obesity and high-fat diets are associated with increased risk of developing hepatocellular 
carcinoma (HCC), and high-fat diets during HCC result in a more aggressive cancer phenotype. 
While systemic inflammatory effects of high-fat diets and obesity are often cited as key 
regulators promoting HCC growth, several studies have identified direct effects of fatty acids on 
promoting HepG2 (a HCC cell line) cell growth. Interestingly, HepG2 cells require glutathione 
to grow and depletion of glutathione stagnates HepG2 cell growth, while increasing glutathione 
in HepG2 cells is able to promote cell growth. Based on the findings of Chapter 4, the 
mitochondrial substrate palmitoylcarnitine resulted in drastic decreases in cell survival in HT29 
and HCT 116 colon cancer cells, whereas MCF7 breast cancer and CCD 841 colon epithelial 
cells were insensitive to palmitoylcarnitine. The purpose of this study is to examine the early 
effects of a mitochondrial fatty acid challenge on HepG2 cells, and to better understand the 
underlying mechanisms associated with HepG2 cell resistance to palmitoylcarnitine, and whether 
glutathione is implicated in mediating this insensitivity. 
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Hypothesis 	
1) Palmitoylcarnitine will promote a unique HepG2 cell growth response while causing 
varying degrees of decreasing cell growth in other cancer cell lines.  
2) Palmitoylcarnitine will cause an adaptive increase in mitochondrial reliance in HepG2 
cells. 
3) Glutathione levels will increase in HepG2 cells following palmitoylcarnitine, and 
glutathione depletion will prevent palmitoylcarnitine-induced HepG2 cell growth. 
3.4 Objectives and hypothesis for study 3 (Chapter 6) 	
The response of glutathione to a metabolic challenge seemingly dictates cell fate. 
Building upon the results of Chapters 4 and 5, whereby palmitoylcarnitine resulted in a 
corresponding decrease in both cell survival and glutathione in HT29 cells, yet a corresponding 
increase in cell growth and glutathione in HepG2 cells. Glutathione depletion in HT29 cells 
resulted in further palmitoylcarnitine-induced decreasing cell survival and abrogated 
palmitoylcarnitine-induced cell growth in HepG2 cells. Recent evidence has suggested that the 
abolishment of both glutathione and thioredoxin is required to elicit anticancer effects in 
established tumours. In this regard, the repurposing of auranofin towards anticancer therapy has 
gained popularity. Auranofin functions through inhibition of thioredoxin reductase, ultimately 
inhibiting the thioredoxin system. Auranofin is an established drug historically used to target 
rheumatoid arthritis. While thioredoxin inhibition is effectively achieved through auranofin 
administration, there is currently a lack of a concrete method for glutathione inhibition/depletion. 
While buthionine sulfoxomine (BSO) is a potent glutathione-depleting agent in vitro, it appears 
that it has limited functionality in vivo. To that end, serine and glycine starvation appears to be a 
novel approach for glutathione depletion, with heightened sensitivity in p53-null cells. 
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Interestingly, p53-null cells are more likely to be chemo resistant, as p53 is a common cell cycle 
inhibitor and apoptosis inducer. Therefore, the purpose of this study was twofold: 1) Are p53-
null cells resistant to auranofin-induced anticancer effects? and 2) Can concurrent serine and 
glycine starvation along with auranofin sensitize p53-null cells to auranofin? 
Hypothesis 	
1) It stands to reason that inhibiting thioredoxin within a cell sensitizes that cell to ROS. As 
p53 responds to excessive ROS to trigger cell cycle arrest or apoptosis, the loss of p53 
may allow a cell to withstand higher levels of ROS, allowing instead of compensatory 
increases in antioxidant pathways mediated by the ROS-sensitive Nrf2. Therefore, HCT 
116 p53-/- will be more insensitive to auranofin relative to HCT 116 p53+/+ cells. 
2) While auranofin will result in ROS mediated-decreasing cell survival in HCT 116 p53+/+ 
cells, auranofin will cause a compensatory increase in glutathione allowing for 
continuation of cell survival in HCT 116 p53-/- cells, and depletion of glutathione through 
serine and glycine starvation will sensitive HCT 116 p53-/- cells to auranofin. 
 
3.5 Additional contributions 	
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that are not included in my dissertation. 
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Chapter 4 The fatty acid derivative palmitoylcarnitine abrogates colorectal cancer cell 
survival by depleting glutathione 
 
This chapter is an original published article. It is presented in its published form.  
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Abstract 	
Previous evidence suggests that palmitoylcarnitine incubations trigger mitochondrial-mediated 
apoptosis in HT29 colorectal adenocarcinoma cells, yet non-transformed cells appear insensitive. 
The mechanism by which palmitoylcarnitine induces cancer cell death is unclear. The purpose of 
this investigation was to examine the relationship between mitochondrial kinetics and 
glutathione buffering in determining the effect of palmitoylcarnitine on cell survival. HT29 and 
HCT 116 colorectal adenocarcinoma cells, CCD 841 non-transformed colon cells and MCF7 
breast adenocarcinoma cells were exposed to 0µM, 50µM and 100µM palmitoylcarnitine for 24-
48 hours. HCT 116 and HT29 cells showed decreased cell survival following palmitoylcarnitine 
compared to CCD 841 cells. Palmitoylcarnitine stimulated H2O2 emission in HT29 and CCD 841 
cells but increased it to a greater level in HT29 cells due largely to a higher basal H2O2 emission. 
This greater H2O2 emission was associated with lower glutathione buffering capacity and 
caspase-3 activation in HT29 cells. The glutathione depleting agent, buthionine sulfoximine, 
sensitized CCD 841 cells and further sensitized HT29 cells to palmitoylcarnitine-induced 
decreases in cell survival. MCF7 cells did not produce H2O2 when exposed to palmitoylcarnitine 
and were able to maintain glutathione levels. Furthermore, HT29 cells demonstrated the lowest 
mitochondrial oxidative kinetics vs CCD 841 and MCF7 cells. The results demonstrate that 
colorectal cancer is sensitive to palmitoylcarnitine due in part to an inability to prevent oxidative 
stress through glutathione-redox coupling thereby rendering the cells sensitive to elevations in 
H2O2. These findings suggest that the relationship between inherent metabolic capacities and 
redox regulation is altered early in response to palmitoylcarnitine. 
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Introduction 	
It is believed that cancer cell proliferation can be influenced by the interaction between 
cellular metabolism and redox conditions (reviewed in (14, 35)). As mitochondria generate 
reactive oxygen species during oxidative phosphorylation, it follows that the balance between 
glycolysis and oxidative metabolism may influence the cellular redox environment by altering 
the demands placed on the glutathione redox couple. This highly regulated antioxidant system is 
essential for both cancer cell growth and protection from cell death in response to a variety of 
cellular stressors, including certain chemotherapeutic compounds (reviewed in (6, 31)). As such, 
the effectiveness of targeting cancer metabolism to attenuate cancer survival may depend on the 
efficiency of glutathione buffering mechanisms in response to changes in metabolically derived 
reactive oxygen species generation. 
As many cancers are inherently glycolytic (25, 36, 37), numerous studies have attempted 
to promote the generation of mitochondrial reactive oxygen species by activating oxidative 
phosphorylation in various models. For example, redirecting pyruvate away from lactate and 
towards oxidative phosphorylation through the activation of pyruvate dehydrogenase increases 
reactive oxygen species production and reduces cell proliferation in lung and tongue cancer cell 
lines (4). Likewise, resveratrol promotes fat oxidation and triggers reactive oxygen species-
induced death in SW620 colon cancer cells, (7) and orally administered acetylcarnitine reduces 
the formation of colorectal neoplastic lesions in a mouse model with no apparent deleterious side 
effects (32). Additionally, a diet high in butterfat causes an increase in aberrant crypt foci in 
another mouse model of colon cancer, which is partially prevented by the addition of free 
carnitine in the diet (10). While it is not fully clear how targeting mitochondrial oxidative 
phosphorylation decreased survival in these cancer models, several different groups have also 
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demonstrated that the fatty acid-derived mitochondrial substrate, palmitoylcarnitine, selectively 
decreased cell survival in colorectal (38) and prostate cancer cells (1). Specifically, Wenzel et al. 
(38) reported augmented superoxide production during palmitoylcarnitine oxidation that was 
lethal to colorectal HT29 cancer cells yet tolerated by preneoplastic NCOL-1 epithelial cells. 
This approach is intriguing in that palmitoylcarnitine oxidation may be less toxic to healthy cells 
given it is a natural metabolite oxidized by mitochondria. Collectively, these findings suggest 
approaches that stimulate mitochondrial bioenergetics may serve as a therapeutic avenue to 
selectively target cancer cells, but the mechanism for why non-transformed cells may be 
insensitive remains unclear. It seems possible that heterogeneous effects of palmitoylcarnitine on 
cell survival could be linked to inherent differences in glutathione redox buffering responses.  
The purpose of this investigation was to evaluate the early time course by which 
palmitoylcarnitine abrogates cell survival in HT29 colorectal cancer cells vs non-transformed 
cells as reported by Wenzel et al. (38), and to determine whether cell-specific susceptibilities to 
palmitoylcarnitine are due to intrinsic differences in the glutathione response. We also 
determined whether differences in mitochondrial oxidative characteristics are related to the redox 
response to palmitoylcarnitine. Palmitoylcarnitine elicited HT29 specific decreases in cell 
survival, concurrent with a decrease in glutathione levels, despite no effect on non-transformed 
CCD 841 cell survival or glutathione. However, both HT29 and CCD 841 cells increased H2O2 in 
response to palmitoylcarnitine, despite HT29 cells having ~2-fold greater baseline steady-state 
H2O2. By pharmacologically depleting glutathione concurrently with palmitoylcarnitine 
incubations, we rendered CCD 841 cells sensitive to palmitoylcarnitine and further sensitized 
HT29 cells to the deleterious effects of palmitoylcarnitine. This data supports the notion that 
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glutathione is a critical regulator in determining cell survival in HT29 and CCD 841 cells when 
exposed to palmitoylcarnitine. 
 
Experimental procedures 		
Cell lines 
CCD 841 Con primary colon epithelial cells were purchased from the American Type 
Culture Collection (ATCC, Manassas,VA, USA). HT29 and HCT 116 colorectal 
adenocarcinoma cells and MCF7 breast adenocarcinoma cells were a generous gift from Dr. 
Samuel Benchimol (York University, Toronto, Canada). CCD 841 cells were grown in EMEM 
(Wisent Inc, Saint-Jean-Baptiste, QC, Canada), HT29 and HCT 116 cells were grown in DMEM 
(Wisent Inc) and MCF7 cells were grown in AMEM (Wisent Inc). All media was supplemented 
with 10% fetal bovine serum (Wisent Inc) and 1% penicillin/streptomycin (Wisent Inc) and 
grown at 37oC in 5% CO2.  
 
Palmitoylcarnitine incubations 
For palmitoylcarnitine treatments, cells were treated with 2mM L-carnitine (Sigma-
Aldrich) and increasing palmitoyl-L-carnitine (palmitoylcarnitine, 0µM, 50µM and 100µM, 
Toronto Research Chemicals) for 24 hours or 48 hours in phenol-red free versions of their 
respective growth media (Wisent Inc). 
 
Relative Cell Survival Assay 
The crystal violet assay was used to determine relative cell survival (13). Following 24 
hours or 48 hours of palmitoylcarnitine incubations, with or without and 50µM L-buthionine-
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sulfoximine (BSO, Sigma-Aldrich), cells plated in 96-well optical bottom black walled plates 
(ThermoFisher Scientific) were incubated in 10% formalin (Sigma-Aldrich) for 10 minutes. 
Formalin was removed and a 0.5% Crystal Violet (Sigma-Aldrich) solution in 25% MeOH was 
added for 10 minutes. Following crystal violet staining, wells were rinsed clean with water and 
allowed to dry overnight. Visualization of crystal violet as a marker for relative cell survival was 
conducted using the LiCor odyssey scanner (Licor Biosciences, Lincoln, NE, USA) and 
fluorescent density analyses was conducted using LiCor software. 
 
XTT as a measure of NAD(P)H 
XTT is a negatively charged tetrazolium salt that changes colour and becomes soluble 
following reduction, particularly in response to NADH (12, 19). Therefore, XTT serves as an 
indirect measure of either NADH or NAD(P)H concentration which are collectively referred to 
as NAD(P)H. In this study, it is assumed that a change in XTT signal in response to 
palmitoylcarnitine reflects a change in NADH. To perform the assay, cells were treated with 
increasing amounts of palmitoylcarnitine for 24 hours or 48 hours in 96-well plates. In the final 4 
hours of each treatment, 50µl of XTT solution comprising of 1mg/ml XTT (BioShop Canada 
Inc.) dissolved in media with 25µM phenazine methosulfate (Sigma-Aldrich,) was added directly 
into each well. Cells were incubated for 4 hours at 37oC at 5% CO2 and then absorbance at 
450nm was read using the VICTOR3 1420 Multilabel Counter plate reader (PerkinElmer, 
Waltham, MA, USA). NAD(P)H absorbance was made relative to 0µM palmitoylcarnitine. In 
order to account for variations in cell number, cells were then digested in-well using 10% RIPA 
(Sigma-Aldrich,) while protein was assessed with BCA (ThermoFisher Scientific) according to 
kit instructions.  
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Live-cell H2O2 measurements 
Cells were seeded in a 96-well optical bottom black-walled plate (ThermoFisher 
Scientific). For H2O2 determination, cells were treated with palmitoylcarnitine for 24 hours and 
48 hours. Cells were then incubated with 10µM Amplex® UltraRed and 1 U/ml horseradish 
peroxidase for 20 minutes and then fluorescent intensity (EX568/EM581) was taken using the 
BioTek Cytation 3 fluorescent plate reader (BioTek, Winooski, VT, USA). A single read after 
these timepoints reflected the net accumulated fluorescent resorufin product of oxidized Amplex 
Ultrared and therefore represents the ‘net emission’ or ‘net pressure’ of H2O2 that cells 
experienced throughout this time period. This measurement was then made relative to a H2O2 
standard curve. To account for variations in cell number, cells were then digested in-well using 
10% RIPA (Sigma-Aldrich) while protein was assessed with BCA (ThermoFisher Scientific) 
according to kit instructions.  
 
Glutathione analysis 
Glutathione was measured as previously published (17, 18, 27). Both reduced (GSH) and 
oxidized (GSSG) glutathione were measured using an Agilent HPLC 1100 (Agilent 
Technologies, Mississauga, ON, Canada) and separation was achieved using a Zorbax C18 
column (Agilent Technologies). Cells were trypsin lifted, washed with PBS then re-suspended in 
50mM TRIS buffer with 20mM boric acid (Sigma-Aldrich), 2mM L-serine (Sigma-Aldrich), 
20µM acivicin (Enzo Life Sciences) and 5mM N-ethylmaleimide (Sigma-Aldrich), pH at 8.0 
with HCl. Glutathione concentrations were calculated using standard concentration curves for 
GSH and GSSG (Sigma-Aldrich) and normalized to total protein. 
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GSH: This method was adapted from Giustriani et al. (15). Cells were deproteinated in 
10µl trichloroacetic acid with 100µl cells in TRIS buffer suspension. GSH samples were run 
under isocratic conditions using a 0.25% glacial acetic acid mobile phase with 6% acetonitrile 
with a flow rate of 1.25ml/min. GSH was detected using a using a modular variable wavelength 
detector (Agilent Technologies) at 265nm wavelength. 
GSSG: This method was adapted from Kand’ar et al. (21). Cells were deproteinated in 
equal parts 15% perchloric acid to sample volume. 100µl of deproteinated sample was added to 
500µl of 0.5M NaOH. 37.5µl of 0.1% o-pthalymide (Sigma-Aldrich) in methanol was added to 
the 600µl sample volume and incubated for 15 minutes rocking in the dark creating a GS-OPA 
conjugate. Following incubation, samples were transferred to an HPLC autosampler vial for 
column separation. GSSG mobile phase was 25mM Na2HPO4 in HPLC grade water with 15% 
methanol at a flow rate of 0.5ml/min. Following column separation, the eluent flowed through a 
Firefly Sci 8830 flow-through cuvette (Firefly Sci Inc, NY, USA) and GSSG peak was detected 
using a QuantaMaster 40 spectrafluoromoter (Horiba, Edison, NJ, USA). GS-OPA was excited at 
350nm and emission was detected at 420nm. 
 
Caspase activity assay 
Enzymatic activity of caspase-3 was determined using the substrate Ac-DEVD-AMC 
(Enzo Life Sciences), as previously described (8, 9). Following palmitoylcarnitine incubations, 
cells were isolated using lysis buffer containing (mM): 20 mM HEPES, 10 mM NaCl, 1.5 mM 
MgCl, 1 mM DTT, 20% glycerol, and 0.1% Triton-X100, pH 7.4, without addition of protease 
inhibitors and were sonicated for 3x3 seconds. Cells were incubated in 96-well plates with Ac-
DEVD-AMC at 37°C. Fluorescence was measured with excitation and emission wavelengths of 
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360 nm and 440 nm respectively. Caspase-3 activity was normalized to total protein content and 
expressed as fluorescence intensity in arbitrary units (AU) per milligram protein. 
 
Intracellular lactate determination 
Following palmitoylcarnitine incubations, adherent cells were trypsin harvested, washed 
twice in PBS and re-suspended in 0.5M perchloric acid, vortexed and free-thawed in liquid 
nitrogen three times. Following centrifugation, 2.2M KHCO3 was added and centrifuged at 4oC 
for 15 minutes at 7,000 rpm and the supernatant was collected. 20µl of supernatant was added to 
258µl lactate buffer (1M glycine, 500mM hydrazine sulphate (Sigma-Aldrich), 5mM EDTA pH 
9.5) and 20µl NAD (Sigma-Aldrich) and 2µl of heart lactate dehydrogenase (LDH, Sigma-
Aldrich). Each sample was rocked briefly, and 300µl was inserted into a 96-well plate, in 
triplicate, and compared to a non-LDH added mirroring sample. Absorption of NADH was 
measured at 340nm on a BioTek Cytation 3 plate reader and made relative to total protein.  
 
Cell permeabilization and high-resolution respirometry 
Cells were seeded in 10 cm dishes for 48 hours, trypsin harvested, washed in PBS and re-
suspended in mitochondrial respiration media (MIRO5, in mM): 0.5 EGTA, 10 KH2PO4, 3 
MgCl2·6 H2O, 60 K-lactobionate, 20 Hepes, 20 Taurine, 110 sucrose and 1 mg/ml fatty acid free 
BSA (pH 7.1) supplemented with 20mM creatine. Cells were then permeabilized with 10µg/ml 
digitonin (Sigma-Aldrich) for 30 minutes rocking at room temperature. Following centrifugation 
for 5 minutes at 2,000 RPM, cells were re-suspended in 105µl MIRO5, with 5µl subsequently 
removed to determine protein content, while the remaining 100µl was used for high-resolution 
respirometry. 
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Cells were loaded into the Oroboros Oxygraph-2k (Oroboros Instruments, Corp., 
Innsbruck, Austria) system. Total volume was 2 ml, with spinning at 750 rpm and temperature at 
37oC. To determine ADP-stimulated respiration, 5mM pyruvate and 2mM malate were added as 
complex I substrates (NADH), followed by ADP titrations of 25µM, 500µM and 5mM ADP. 
Polarographic oxygen measurements were acquired in 2 s intervals with the rate of respiration 
derived from 40 data points and expressed as pmol/s/mg protein.  
 
Statistics 
All results are expressed as means ± SEM. Significance was determined as p<0.05 for all 
measures. Each ‘N’ signifies an individual experiment, with each experiment conducted in 
triplicate where appropriate. For the comparison of only two groups, unpaired t-tests were used. 
For the comparison of more than two groups, ANOVA’s were conducted. Following significance 
with a one-way ANOVA, a Dunnett’s post-hoc analysis was performed, and following a 
significant two-way ANOVA a Fisher’s LSD post-hoc was performed. All statistics were 
performed using GraphPad Prism 7 (San Diego, CA, USA). 
 
Results 		
HT29 cells are sensitive to palmitoylcarnitine induced cell death 
In order to determine the influence of palmitoylcarnitine on relative cell survival, HT29 
and HCT 116 cells and non-transformed colon epithelial CCD 841 cells were incubated for 24 
hours (Figure 4.1A) and 48 hours (Figure 4.1B) with 0µM, 50µM and 100µM palmitoylcarnitine, 
similar to concentrations used in previous literature (1, 38). While CCD 841 cells had a modest 
~10% decrease in relative cell survival with 100µM, HT29 and HCT 116 cells had more robust 
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decreases in relative cell survival at 50µM (~20%) and 100µM (~90%) palmitoylcarnitine 
(p<0.05), with HT29 and HCT 116 cells showing decreased relative cell survival compared to 
CCD 841 cells at each palmitoylcarnitine concentration (p<0.05) (Figure 4.1A and 4.1B).  
 
Figure 4 1 Palmitoylcarnitine toxicity is greater in colorectal cancer HT29 and HCT 116 
cells than normal CCD 841 cells. Relative cell survival was measured in non-transformed CCD 
841 cells (N=11) as well as HT29 (N=8) and HCT 116 cells (N=3) for A 24 hours and B 48 
hours. Data are reported as means ±SEM with  ‘*’ representing a significant difference relative 
to 0µM palmitoylcarnitine within the same cell type, and ‘#’ representing a significant difference 
of the same palmitoylcarnitine concentration relative to CCD 841, P < 0.05. 
 
We next determined whether colorectal cancer displayed altered mitochondrial oxidative 
capacities and metabolic flexibilities in order to explain their sensitivity to palmitoylcarnitine. 
HT29 cells had significantly lower coupled oxidative kinetics (ADP-stimulation of ATP 
synthesis) relative CCD 841 cells (p<0.05) (Figure 4.2A and 4.2B). CCD 841 cells demonstrated 
increased net lactate levels in response to 24 hours of palmitoylcarnitine (p<0.05), which is in 
line with the expected redirection of glucose-derived pyruvate away from the mitochondria when 
excess fatty acids are present (Figure 4.2C). At 48 hours, there was no difference in intracellular 
lactate levels. While difficult to explain, this may suggest that CCD 841 cells had exhausted the 
exogenously added palmitoylcarnitine supply. This metabolic flexibility was not observed in 
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HT29 cells given no change in net lactate concentrations were observed in response to 
palmitoylcarnitine (Figure 4.2D).  
 
Figure 4 2 Lower mitochondrial respiratory kinetics and impaired metabolic flexibility in 
HT29 cells compared to CCD 841 cells. Mitochondrial respiratory kinetics and the cell lactate 
concentrations were assessed in response to palmitoylcarnitine in CCD 841 and HT29 cells. A a 
representative high resolution respirometric trace showing oxygen consumption (red line) that is 
calculated by the change in slope of oxygen concentration in the respiratory chamber (blue line; 
top, CCD 841 cells; bottom, HT29 cells). The blue line represents in-chamber oxygen 
concentration that is used to calculate the rate of oxygen consumption (red line). B 
Mitochondrial respiratory kinetics of CCD 841 cells compared to HT29 cells across a range of 
ADP concentrations reflecting low and high metabolic demands. ‘*’ represents a significant 
difference between HT29 and CCD 841 cells of a given substrate, P < 0.05. ‘Φ’ represents a 
main effect of cell type. P < 0.05. (N=5). Net intracellular lactate was determined in C CCD 841 
cells (N=8-9) and D HT29 cells (N=5) for 24 and 48 hours. ‘*’ represents a significant difference 
relative to 0µM palmitoylcarnitine of the same time point, P < 0.05. Data are reported as means 
±SEM. 
 
Excessive NADH generation relative to low rates of oxidative phosphorylation can lead 
to H2O2 production, which can trigger deleterious cellular effects such as caspase-3 activation 
0µ
M
50
µM
10
0µ
M
0µ
M
50
µM
10
0µ
M
0
1000
2000
3000
4000
5000
Palmitoylcarnitine
La
ct
at
e 
(µ
m
ol
/L
 *
m
g 
pr
ot
ei
n)
HT29
24 Hour 48 Hour
0µ
M
50
µM
10
0µ
M
0µ
M
50
µM
10
0µ
M
0
1000
2000
3000
4000
5000
Palmitoylcarnitine
La
ct
at
e 
(µ
m
ol
/L
 *
m
g 
pr
ot
ei
n)
CCD 841
24 Hour 48 Hour
*
p=0.0924
0µM
50µM
100µM
A
C DB
0
50
100
150
200
JO
2 
(p
m
ol
⋅se
c-
1 ⋅
m
g-
1 
pr
ot
ei
n)
P/M 25µM
ADP
500µM
ADP
5000µM
ADP
CCD 841
HT29
φ
* *
Time
 	 86 
(Figure 4.3A) (29). Given the lower oxidative capacities shown in Figure 4.2, we next tested the 
hypothesis that NADH generation from palmitoylcarnitine remained intact in HT29 cells such 
that excess NADH provision to the electron transport chain would increase H2O2 emission 
(Figure 4.3A). Indeed, palmitoylcarnitine resulted in greater accumulations in NAD(P)H in 
HT29 cells at both 24 and 48 hours (100µM: +~35%), with only a modest increase in NAD(P)H 
observed at 48 hours in CCD 841 (50µM: +~20%) as detected by XTT (p<0.05) (Figure 4.3B 
and 4.3C). This was associated with greater H2O2 emission (p<0.05) (Figure 4.3D and 4.3E) and 
induction of caspase-3 activity (p<0.05) (Figure 4.3F and 4.3G) in HT29 cells at 24 hours, yet 
there was no observable change in capase-3 activity at 48 hours, suggesting an early activation of 
caspase-3 resulting in cell death leading to the cessation of caspase-3 activity. This relationship 
of NAD(P)H to H2O2 emission was not observed in all conditions, such as 50µM at 24 hours 
(Figure 4.3B and 4.3D), but may be related to the difficulty in capturing the precise temporal 
relationship between NADH and H2O2 kinetics. 
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Figure 4 3 Elevated NAD(P)H production leads to increased H2O2 emission and caspase-3 
induction in low oxidative capacity HT29 cells but not high oxidative capacity CCD 841 
cells. A Proposed schematic of how palmitoylcarnitine may result in elevated caspase-3 activity 
through H2O2 generation in a state of low oxidative capacity. NAD(P)H levels were measured in 
CCD 841 (N=9) and HT29 (N=9) cells for B 24 hours and C 48 hours. Total H2O2 emission was 
measured in CCD 841 (N=6) and HT29 (N=6) cells after D 24 hours and E 48 hours. P < 0.05. 
Caspase-3 activity was measured in CCD 841 (N=4-5) and HT29 (N=8) cells for F 24 hours and 
G 48 hours. Data are reported as means ±SEM with ‘*’ representing a significant difference 
relative to 0µM palmitoylcarnitine of the same time point and ‘#’ representing a significant 
difference relative to CCD 841 of the same palmitoylcarnitine concentration, P < 0.05.  
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Elevated H2O2 emission in relation to decreased cell survival in HT29 cells suggested 
that glutathione redox buffering might be insufficient to protect HT29 cells from 
palmitoylcarnitine-induced stress. In HT29 cells, 24 hours of palmitoylcarnitine lowered the 
reduced/oxidized glutathione ratio (p<0.05) (Figure 4.4A and 4.4B), reduced (p<0.05) (Figure 
4.4C and 4.4D) and total glutathione (p<0.05) (Figure 4.4G and 4.4H) without changing total 
oxidized glutathione (Figure 4.4E and 4.4F), suggesting a net attenuation of glutathione redox 
buffering dynamics, despite no changes in CCD 841 cell glutathione response to 
palmitoylcarnitine.  
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Figure 4 4 Palmitoylcarnitine lowers glutathione redox buffering capacity in HT29 cells but 
not CCD 841 cells. The following parameters of glutathione redox buffering were assessed after 
24 and 48 hours of palmitoylcarnitine respectively: ratio of reduced to oxidized glutathione 
(GSH/GSSG) (A, B), reduced glutathione (GSH) (C, D), oxidized glutathione (GSSG) (E, F), 
and total glutathione (tGS) (G, H) (n=5). Data are reported as means ±SEM with ‘*’ representing 
a significant difference relative to 0µM palmitoylcarnitine of the same cell type, P < 0.05. 
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Based on these associations, we then determined whether glutathione redox buffering directly 
determined cell survival in response to palmitoylcarnitine. The glutathione synthesis inhibitor 
buthionine sulfoxomine (BSO) (Figure 4.5A) nearly eliminated reduced glutathione in CCD 841 
and HT29 cells (p<0.05) (Figure 4.5B) and sensitized CCD 841 cells to palmitoylcarnitine-
induced decreasing cell survival (p<0.05) (Figure 4.5C and 4.5D) while further sensitizing HT29 
cells to decreasing cell survival (p<0.05) (Figure 4.5E and 4.5F). 
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Figure 4 5 Glutathione depletion sensitizes CCD 841 and HT29 cells to palmitoylcarnitine-
induced decreasing cell survival. A Schematic depicting the influence of buthionine 
sulfoxomine (BSO, inhibitor of glutathione synthesis) on glutathione levels. ETC – electron 
transport chain, GSH – reduced glutathione, GSSG – oxidized glutathione. B Reduced 
glutathione was measured in CCD 841 and HT29 cells following 24 hours with 0µM or 50µM 
BSO, ‘*’ representing a significant difference relative to 0µM BSO. Following 
palmitoylcarnitine incubations concurrent with BSO, relative cell survival was measured in CCD 
841 cells for 24 and 48 hours respectively (C, D) and in HT29 cells (E, F) (N=3). Data are 
reported as means ±SEM with  ‘*’ representing a significant difference relative to 0µM 
palmitoylcarnitine, with ‘#’ representing a significant difference between vehicle and 50µM 
BSO of the same palmitoylcarnitine concentration. P < 0.05.  
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We then explored whether the susceptibility of HT29 cells to palmitoylcarnitine was 
observed in a cancer line previously shown to be reliant on mitochondrial function (2), the MCF7 
breast cancer cell line. In so doing, the role of metabolic and redox flexibility in determining the 
degree of (in)sensitivity to palmitoylcarnitine could be compared between cell lines.  
Palmitoylcarnitine had a small effect on cell survival in MCF7 cells after 24 hours (p<0.05) but 
not 48 hours (Figure 4.6A), indicating that MCF7 cells are more insensitive to palmitoylcarnitine 
than HT29 cells. In order to validate whether MCF7 cells displayed greater mitochondrial 
respiratory kinetics compared to HT29 cells (consistent with the notion that MCF7 cells are 
reliant on mitochondrial metabolism), mitochondrial respiration was compared across HT29, 
MCF7 and CCD 841 cells. MCF7 cell mitochondrial respiration was greater than HT29 cells at 
physiological 25µM ADP, yet not statistically different than CCD 841 cells at 25µM and 500 
µM ADP (Figure 4.6B). However, no changes in intracellular lactate were observed in response 
to palmitoylcarnitine (Figure 4.6C) suggesting MCF7 cells lack metabolic flexibility in response 
to fatty acid challenges. Indeed, an increase in NAD(P)H was observed at 48 hours (Figure 4.6D) 
similar to that seen previously with HT29 cells suggesting the generated NADH is not oxidized 
by the attenuated rates of oxidative phosphorylation. However, this NADH generation was not 
sufficient to stimulate H2O2 emission (Figure 4.6E), which was consistent with no increases in 
caspase-3 activity (Figure 4.6F) and no changes in glutathione redox buffering responses 
(Figures 4.6G-4.6J).  
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Figure 4 6 MCF7 cells are insensitive to palmitoylcarnitine. A MCF7 cells were incubated 
with palmitoylcarnitine for 24 and 48 hours and assessed for relative cell survival (N=11). B 
Mitochondrial respiratory kinetics in MCF7 cells was compared to CCD 841 and HT29 cells 
(from Fig 2A) (N=5). MCF7 cells were incubated with palmitoylcarnitine for 24 and 48 hours 
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and assessed for C net intracellular lactate (N=5) D NAD(P)H (N=9) E H2O2 (N=6) F caspase-3 
activity (N=4) G GSH/GSSG (N=5) H reduced glutathione (N=5) I oxidized glutathione (N=5) J 
total glutathione (N=5). Data are reported as means ±SEM with  ‘*’ representing a significant 
difference relative to 0µM palmitoylcarnitine of the same time point, P <0.05.  
 
Overall, these results indicate that the susceptibilities of HT29 cells to palmitoylcarnitine 
are linked to insufficient redox buffering that is not observed in MCF7 breast cancer cells or non-
transformed CCD 841 cells. 
 
Discussion 	
Palmitoylcarnitine caused marked reductions in cell survival in HT29 and HCT 116 
colorectal cancer cells with minor reductions in non-transformed CCD 841 colon cells and 
MCF7 breast cancer cells. The degree of response was related to oxidative kinetics, H2O2 
emission and the ability to maintain glutathione redox buffering (Figure 4.7). Specifically, the 
greatest H2O2 emission occurred in HT29 cells in association with a collapse in glutathione redox 
buffering capacity and attenuated cell survival. These results suggest cancer-specific 
mitochondrial oxidative kinetics and glutathione may influence cell-specific responses to 
palmitoylcarnitine-induced oxidative stress. 
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Figure 4 7 Palmitoylcarnitine induced decreases in cell survival are dictated by baseline 
mitochondrial reactive oxygen species and glutathione response. Upon exposure to 
palmitoylcarnitine, there is an increase in reactive oxygen species production, however this 
increase in reactive oxygen species is sufficiently buffered by glutathione resulting in 
maintaining CCD 841 cell survival. HT29 cells however have significantly higher baseline 
reactive oxygen species production; therefore upon exposure to palmitoylcarnitine, the additional 
increase in reactive oxygen species production leads to decreases in glutathione and subsequent 
caspase-3 activation and cell death. 
 
Oxidative kinetics and redox flexibility determines susceptibility to palmitoylcarnitine 
In the present study, we considered classic bioenergetic principles which posit that an 
over-supply of reducing equivalents (NADH, FADH2) from excess fat oxidation relative to the 
metabolic demands for oxidative phosphorylation leads to increased membrane potential and 
concurrent electron slip onto oxygen to generate superoxide and subsequently H2O2 (29). With 
these bioenergetic principles in mind, cells with low dependencies on mitochondrial oxidative 
phosphorylation may generate higher rates of H2O2 emission when provided with excess 
substrate. Bypassing CPT-1 in HT29 cells with palmitoylcarnitine increased NADH steady state 
levels possibly because the lower reliance on oxidative phosphorylation in this cell line caused 
Response to palmitoylcarnitine induced H2O2
CCD 841 primary epithelial cells HT29 colorectal carcinoma cells
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NADH production to exceed its oxidation in the electron transport chain, thereby stimulating 
H2O2 emission. In contrast, highly oxidative CCD 841 non-transformed epithelial cells may have 
been able to oxidize the NADH that was generated in response to palmitoylcarnitine, although 
this is speculative. As CCD 841 cells demonstrated lower baseline H2O2 emission kinetics, the 
subsequent increase in H2O2 emission with palmitoylcarnitine reached a lower absolute rate than 
seen in HT29 cells. The data suggests that this lower H2O2 was effectively buffered by the 
glutathione redox couple and resulted in no caspase-3 induction and markedly less effects on 
overall cell survival.  Conversely, the higher rates of H2O2 emission generated in HT29 cells 
were related to a concurrent collapse in glutathione buffering capacity which further reveals an 
inferior redox buffering response in this cancer. This is in line with previous literature 
demonstrating that cells with higher baseline or steady-state reactive oxygen species production 
are more susceptible to further elevations in reactive oxygen species through glucose starvation, 
likely resulting in an increased reliance on mitochondrial metabolism (3).   
However, several observations are not entirely in agreement with our previous 
conclusions. For example, while palmitoylcarnitine resulted in an increase in NAD(P)H in MCF7 
cells, there was no associated increase in H2O2 emission, perhaps due to glutathione levels 
successfully buffering changes in palmitoylcarnitine-induced H2O2 preventing any associated 
change in fluorescent signal. Furthermore, there was no statistical increase in NAD(P)H levels at 
24 hours following 50µM palmitoylcarnitine in HT29 cells despite an associated increase in 
H2O2 emission and a corresponding decrease in cell survival. While difficult to explain, this 
perhaps could be attributed to the temporal nature of bioenergetics, such that an earlier increase 
in NAD(P)H may have preceded the increase in H2O2 emission. The highly dynamic turnover of 
NAD(P)H, H2O2 and glutathione particularly during oxidative phosphorylation poses a challenge 
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in capturing the precise temporal relationship at any given palmitoylcarnitine challenge and time 
point. Nevertheless, as noted above, the responses following 100µM palmitoylcarnitine suggest 
that the lower cell survival in HT29 cells were related to insufficient glutathione homeostasis. 
While palmitoylcarnitine is naturally produced within the cell, exogenous 
palmitoylcarnitine has been demonstrated to increase intracellular palmitoylcarnitine levels in 
neuroblastoma NB-2a cells (28), and has previously been demonstrated to cause an adaptive 
increase in oxidative capacity in mouse embryonic fibroblasts (26). Elevating mitochondrial 
oxidative phosphorylation has also been mimicked in experiments designed to force pyruvate 
shuttling towards mitochondria either through inhibiting lactate production (23) or by activating 
pyruvate dehydrogenase (4). It is therefore possible that similar relative increases in 
mitochondrial reactive oxygen species production between cancerous and non-transformed cells 
result in different fates, whereby increasing reactive oxygen species in cells with higher baseline 
levels would cause great attenuations in glutathione resulting in cell death, whereas cells with 
lower baseline levels would be able to combat similar relative elevations in reactive oxygen 
species production through glutathione buffering. 
A key finding in this study is that glutathione depletion by BSO amplified the reduction 
in cell survival following palmitoylcarnitine incubations in HT29 cells and sensitized non-
transformed CCD 841 cells. BSO is a selective inhibitor of glutamate cysteine ligase (previously 
known as γ-glutamylcysteine synthethase), resulting in a rapid decrease in intracellular 
glutathione levels by preventing its synthesis (11, 16), which was effective at inhibiting growth 
of a mammary adenocarcinoma cell line in vivo (34). The decreased cell survival in HT29 cells 
in the present study reveals an insufficient ability of this cancer to maintain glutathione-based 
redox buffering capacity that is otherwise intact in CCD 841 cells. This suggests that 
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assessments of glutathione redox buffering capacity may serve as a biomarker to predict cancer-
specific sensitivity to palmitoylcarnitine as a therapy. 
Intriguingly, selective leukemia cell death in acute myeloid leukemia (AML) cells was 
achieved by inhibiting mitochondrial fat oxidation with Avocatin B (24), mitochondrial complex 
I with mubritinib (5), amino acid mitochondrial oxidation (20) and BCL-2 dependent 
mitochondrial metabolism (22). These findings seem to be opposite to the present data whereby 
the provision of excess mitochondrial substrates resulted in colorectal cancer cell death. While 
we cannot fully explain the heterogeneity in cancer cell responses toward mitochondrial-targeted 
therapies, the response of glutathione to metabolic-targeting therapies may provide insight into 
determining cell fate. Many current chemotherapies elevate intracellular levels of reactive 
oxygen species or target redox-homeostasis to elicit anticancer effects (39). However, given that 
we are currently unable to detect in vivo kinetics of reactive oxygen species production in cancer 
patients, the present results may serve as a foundation to explore the possibility that unique 
glutathione redox buffering capacities within tumours may yield predictive value for guiding 
future therapies which trigger mitochondrial reactive oxygen species by targeting mitochondrial 
metabolism. 
We note two limitations of the present work. First, the respiratory kinetics observed in the 
present study may be under-estimations given the respirometric protocols were performed with 
cells in suspension rather than in an adherent environment as they are accustomed to given their 
epithelial origin. While palmitoylcarnitine-supported respiration was not detected in any cell 
lines likely due to this reason (data not shown), the increased ADP-stimulated respiration 
nonetheless demonstrates a robust difference in mitochondrial oxidative phosphorylation 
between cell lines. Second, the lactate concentrations reflect intracellular lactate rather than 
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efflux, which would otherwise require assessments of acidification rates of local media in 
combination with lactate efflux assessments. However, changes in intracellular lactate 
concentrations serve as an index of altered glycolytic flux and support the present interpretation. 
 
Perspectives and Conclusions 
Collectively, HT29 cells demonstrate greater reductions in cell survival in response to 
palmitoylcarnitine in association with lower oxidative kinetics, higher baseline H2O2 and inferior 
glutathione redox flexibility. These relationships were observed in less than 48 hours suggesting 
metabolic and redox processes occur early in response to palmitoylcarnitine challenges. Previous 
literature demonstrates a paradoxical role of mitochondrial activation in cancer survival, whereby 
some cancers rely on mitochondrial metabolism to drive cell growth, such as MCF7 cells (2), 
ovarian cancers (30) and leukemia cells (24), whereas other cancers demonstrate decreased 
survival if forced to rely on mitochondrial oxidative phosphorylation (3, 23, 33, 38). A striking 
corollary is the potential for non-transformed cells to tolerate changes in metabolism, as was 
observed in CCD 841 cells. In contrast, it may be that certain cancers lack such metabolic 
flexibility by developing a stronger reliance on dedicated metabolic pathways through a myriad 
of micro-evolutionary adaptations in order to maximize growth rates. The metabolic flexibilities 
of cancers are likely heterogeneous, as seen in the present study whereby HCT 116 and HT29 
cell deleterious responses to palmitoylcarnitine were not seen in MCF7 breast cancer cells which 
otherwise maintained cell proliferation rates without an increase in H2O2 emission. These 
findings also guide new directions into the role of H2O2 and glutathione-based redox signaling of 
specific pathways that regulate cell fate. Finally, MCF7 cells also demonstrated greater oxidative 
kinetics at physiological levels of ADP relative to HT29 cells, and maintained glutathione-
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buffering capacities throughout palmitoylcarnitine incubations. This finding highlights the 
possibility that heterogeneous responses of cancers to metabolic therapies may be linked to a 
dynamic relationship between their inherent metabolic capacities and redox regulation. This 
discovery guides additional research to determine whether a combination of lower mitochondrial 
oxidative kinetics and inferior redox buffering couples may represent a biomarker that predicts 
whether a cancer will be uniquely susceptible to palmitoylcarnitine-mediated reductions in 
survival.  
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Chapter 5 Synergistic activation of mitochondrial metabolism and the glutathione 
redox couple protects HepG2 hepatocarcinoma cells from palmitoylcarnitine-
induced stress 
 
This chapter is formatted for publication in the American Journal of Physiology – Cell 
physiology, rapid reports.  
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Abstract 	
Fatty acid stress can have divergent effects in various cancers. We explored how 
metabolic and redox flexibility in HepG2 hepatocarcinoma cells mediate protection from 
palmitoylcarnitine. HepG2 cells, along with HCT 116 and HT29 colorectal cancer cells 
were incubated with 100µM palmitoylcarnitine for up to 48 hours.  Mitochondrial H2O2 
emission, glutathione and cell survival were assessed in HT29 and HepG2 cells. 100µM 
palmitoylcarnitine promoted early growth in HepG2 cells by ~8% after 48 hours vs 
decreased cell survival observed in HT29 and HCT 116 cells. Palmitoylcarnitine 
increased mitochondrial respiration at physiological and maximal concentrations of ADP 
while lowering cellular lactate content in HepG2 cells, suggesting a switch to 
mitochondrial metabolism. HepG2 cell growth was associated with an early increase in 
H2O2 emission by 10 minutes followed by a decrease in H2O2 at 24 hours that 
corresponded with increased glutathione content, suggesting a redox-based compensatory 
mechanism. In contrast, abrogation of HT29 cell proliferation was related to decreased 
mitochondrial respiration (likely due to cell death) and decreased glutathione. Concurrent 
glutathione depletion with BSO prevented palmitoylcarnitine-induced growth in HepG2 
cells indicating that glutathione was critical for promoting growth following 
palmitoylcarnitine. Inhibiting UCP2 with genipin sensitized HepG2 cells to 
palmitoylcarnitine, suggesting that activation of UCP2 may be a 2nd redox-based 
mechanism conferring protection. These findings suggest that HepG2 cells possess 
inherent metabolic and redox flexibility that confers protection from palmitoylcarnitine-
induced stress via adaptive increases in mitochondrial respiratory control, glutathione 
buffering and induction of UCP2.  
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Introduction 	
Fatty acid challenges have been shown to induce cell death in some cancers, such 
as HT29 colorectal (20) and PC3 prostate carcinoma cells (1), while other cells appear 
resistant to this stress. In fact, excess hepatic fat accumulation is associated with 
increased risk of hepatocellular carcinoma (HCC) development (18). Likewise, a high-fat 
diet induced HCC in rodents, and reversal back to a low-fat diet prevented HCC 
development (9). Vendel Nielsen et al. (19) also observed that the unsaturated fatty acid, 
oleic acid, increased growth in HepG2 HCC cells. However, the mechanisms that confer 
resistance to fatty-acid stress in HCC remain unresolved. 
One possibility is the influence of fatty acid metabolism on the cellular redox 
environment through mitochondrial H2O2 emission – a natural byproduct of oxidative 
phosphorylation (OXPHOS). This concept is intriguing given cellular redox conditions 
can dictate cell fate, whereby an excess of H2O2 can invoke deleterious effects on cell 
function and fate, (reviewed by (13)), yet low levels of H2O2 can act as a hormetic signal 
that drives cancer cell growth (8). This suggests that the influence of metabolically 
derived H2O2 on cell fate will depend on the ability of the cell to maintain cellular redox 
conditions. In this regard, the main cellular antioxidant glutathione is essential in 
maintaining cell survival. Indeed, pharmacological increases in glutathione stimulated 
HepG2 cell growth, whereas glutathione depletion prevented HepG2 cell proliferation 
(10).  
 Evidence also suggests that uncoupling protein-2 (UCP2) attenuates 
mitochondrial H2O2 emission potentially by dissipating membrane potential and 
preventing increases in superoxide production (the precursor to mitochondrial H2O2 
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emission) from fatty acid oxidation (review by (2, 4, 14)). While there is controversy 
over the specific mechanistic function of UCP2 (3, 5, 15), it appears that UCP2 is able to 
dissipate H2O2 emission. However, it remains to be determined whether UCP2 mediates a 
redox-dependent compensation in response to fatty acid challenges that ultimately 
prevents oxidative stress and creates a pro-growth reduced environment in HCC. Indeed, 
palmitic acid increased superoxide production in HepG2 cells, which was amplified by 
genipin, a selective UCP2 inhibitor (12). Likewise, transgenic overexpression of UCP2 in 
HepG2 cells prevented oxidative modifications of membranes and proteins, which is 
indicative of attenuated reactive oxygen species production (6).  
The degree to which UCP2 determines cell fate in response to fatty acid stress 
remains uncertain, as does the potential synergistic responses of the glutathione redox 
couple. Such dynamic relationships make it difficult to predict whether HepG2 cells 
would fail or succeed at invoking sufficient metabolic and redox adaptations to survive 
fatty acid stress. In this study, we determined the response of HepG2 cells to 
palmitoylcarnitine-induced stress and explored potential metabolic and redox-based 
mechanisms. The results demonstrate that palmitoylcarnitine stimulates early growth in 
HepG2 cells that contrasted with decreased cell survival in HT29 and HCT 116 cells. 
This protection from palmitoylcarnitine stress in HepG2 cells was dependent on 
glutathione and UCP2, and was related to rapid changes in mitochondrial bioenergetics. 
These findings reveal a dynamic metabolic and redox response system that ultimately 
confers protection against palmitoylcarnitine stress in HepG2 cells. 
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Experimental procedures 		
Cell culture conditions 
HepG2 hepatocarcinoma cells were gifted by Dr. Paul Spagnuolo (University of 
Guelph, Guelph, Canada). HT29 and HCT 116 colorectal carcinoma cells were gifted by 
Dr. Samuel Benchimol (York University, Toronto, Canada). HepG2 cells were grown in 
EMEM, whereas both HT29 and HCT 116 cells were grown in DMEM. All media was 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Wisent Inc, 
Saint-Jean-Baptiste, Canada). 
 
Palmitoylcarnitine incubations 
Cells were cultured with 2mM L-carnitine (Sigma-Aldrich) and 0µM or 100µM 
palmitoylcarnitine (Toronto Research Chemicals, Toronto, Canada).  
 
Relative Cell Survival Assay 
Following 24 or 48 hours of palmitoylcarnitine incubations, with or without 
buthionine-sulfoximine (BSO) and genipin (Sigma-Aldrich), cells plated in 96-well 
optical bottom black walled plates were fixed using 10% formalin and then stained using 
0.5% Crystal Violet (Sigma-Aldrich) in 25% MeOH. Visualization and fluorescent 
analyses of Crystal Violet as a measure of relative cell survival was conducted using the 
LiCor odyssey scanner (LiCor Biosciences, Lincoln, NE, USA). 
 
NAD(P)H 
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The reduction of XTT can serve as an indirect measure of NADH and NADPH, 
collectively referred to as NAD(P)H (7). During the final 4 hours of palmitoylcarnitine 
incubations, 50µl of XTT solution (1mg/ml XTT, 25µM phenazine methosulfate; 
BioShop Canada Inc.) was added into each well and incubated at 37oC with 5% CO2. 
Absorbance was read at 450nm using the VICTOR3 1420 Multilabel Counter plate reader 
(PerkinElmer, Waltham, MA, USA). Cells were digested in-well using 10% RIPA 
(Sigma-Aldrich) and protein was assessed with BCA (ThermoFisher) to normalize 
NAD(P)H signal. 
 
Live-cell H2O2 measurements 
HepG2 cells were seeded in a 96-well optical bottom black-walled plate 
(ThermoFisher Scientific). Following palmitoylcarnitine incubations, 10µM Amplex® 
UltraRed and 1 U/ml horseradish peroxidase was added to each well for 10 minutes and 
fluorescence (EX568/EM581) was measured using the BioTek Cytation 3 fluorescent 
platereader (BioTek, Winooski, VT, USA). A single read after these time points reflected 
the net accumulated fluorescent resorufin product of oxidized Amplex Ultrared and 
therefore represents the ‘net emission’ of H2O2 that cells accumulated which was made 
relative to a H2O2 standard curve. Cells were then normalized to protein by BCA as 
described above. 
 
Glutathione analysis 
Analysis was performed as previously demonstrated (11) with alterations for cell 
culture. Following palmitoylcarnitine incubations, cells were trypsin-lifted, washed with 
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PBS and re-suspended in final buffer (50mM TRIS, 20mM boric acid, 2mM L-serine, 
20µM acivicin, 5mM N-ethylmaleimide) for reduced (GSH) and oxidized (GSSG) 
glutathione determination.   
 
Intracellular lactate determination 
Cells were trypsin-harvested, washed with PBS and re-suspended in 0.5M 
perchloric acid, vortexed and freeze-thawed in liquid nitrogen. Supernatant was collected, 
centrifuged (4oC, 5 minutes, 5,700rcf), treated with 2.2M KHCO3, and subsequently 
centrifuged with new supernatant collected. Supernatant was added in triplicate in a 96-
well plate and incubated for 1hr with lactate buffer (1M glycine, 500mM hydrazine 
sulphate, 5mM EDTA, pH 9.5), NAD+ and LDH (Sigma-Aldrich). Absorption of NADH 
was measured at 340nm on a BioTek Cytation 3 fluorescent plate reader (BioTek, 
Winooski, VT, USA). Signal was normalized to pre-perchloric acid protein determination 
as described above. 
 
Mitochondrial Bioenergetic Assessments 
Following palmitoylcarnitine incubations, cells were trypsin-harvested from 10cm 
dishes, washed in PBS and re-suspended in mitochondrial respiration media (11) 
supplemented with 20mM creatine. Cells were permeabilized with 10µg/ml digitonin 
(Sigma-Aldrich) for 30 minutes rocking at room temperature. Following centrifugation (5 
minutes, 500rcf), cells were re-suspended for high-resolution respirometry as previously 
described (11) with an aliquot removed to determine protein concentration for 
normalization as outlined above.  
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Western Blotting 
SDS-PAGE was performed as previously described (11) with alterations for cell 
culture. Cells were trypsin harvested, PBS washed, and re-suspended in lysis buffer 
(0.5% IGEPAL, 50mM TRIS, 10% glycerol, 0.1mM EDTA, 150mM NaCl, 1mM DTT) 
with protease and phosphatase inhibitors (Sigma-Aldrich). Monoclonal anti-UCP2 
antibody produced in rabbit (1:1000 dilution, D105V, Cell Signaling Technology) was 
used to determine UCP2 protein content, polyclonal anti-TXNRD2 produced in rabbit 
(1:200, HPA003323, Sigma-Aldrich) was used to determine thioredoxin reductase-2 
protein content. 
 
Statistics 
All results are expressed as means ± SEM. Significance was determined as 
p<0.05 for all measures. Unpaired t-tests and ANOVA’s were conducted where 
appropriate. A Fisher’s LSD post-hoc test was conducted following significant 
interactions in a two-way ANOVA. All statistics were performed using GraphPad Prism 
7 (San Diego, CA, USA). 
 
Results 		
Unique HepG2 cell growth response to palmitoylcarnitine compared to HT29 and HCT 
116 
HepG2, HT29, and HCT 116 cells were exposed to 0µM and 100µM 
palmitoylcarnitine (Figure 5.1A) for 24 and 48 hours. While HT29 and HCT 116 cells 
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displayed varying degrees of decreased relative cell survival (Figure 5.1B, p<0.05) 
following 24 and 48 hours of 100µM palmitoylcarnitine, in contrast, HepG2 cells 
displayed an ~8% increase in relative cell growth (Figure 5.1B, p<0.05). This response is 
notable considering HepG2 cells have a population doubling time of ~44 hours. These 
responses were related to increased mitochondrial respiration kinetics in HepG2 cells at 
24 hours (Figure 5.1C, p<0.05) vs decreased respiration in HT29 cells (Figure 5.1D, 
p<0.05). To gain insight into whether the increased respiration was linked to greater 
content of electron transport system proteins, we stimulated maximal electron flux by 
uncoupling the inner mitochondrial membrane with FCCP. Indeed, the greater respiration 
seen following palmitoylcarnitine in HepG2 cells demonstrates a greater capacity of the 
electron transport system (Figure 5.1E, p<0.05). Consistent with previous data, HT29 
cells displayed a decrease in FCCP-stimulated capacity (Figure 5.1F, p<0.05) likely 
signifying that HT29 cells were non-viable rather than a direct decrease in mitochondrial 
respiratory kinetics following palmitoylcarnitine.  
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Figure 5 1 Palmitoylcarnitine promotes selective growth in HepG2 cells compared to 
HT29, and HCT 116 cells and increases mitochondrial respiratory capacity in 
HepG2 cells. A Schematic showing palmitoylcarnitine bypassing CPT-1, whereby it 
enters the mitochondria and stimulates β-oxidation resulting ATP and reactive oxygen 
species (ROS) production. B Relative cell survival was measured in HepG2 (N=14), 
HT29 (N=3) and HCT 116 (N=3) cells following 24 and 48 hours of 100µM 
palmitoylcarnitine relative to 0µM palmitoylcarnitine at same time points. Data are 
reported as means ±SEM with  ‘*’ representing a significant decrease and ‘#’ 
representing a significant increase relative to 0µM palmitoylcarnitine of the same cell 
type within the same time point. P < 0.05. HepG2 and HT29 cells were incubated with 
0µM or 100µM palmitoylcarnitine for 24 hours and mitochondrial respiration was 
measured following C and D ADP, glutamate (G) and succinate (S)  (N=4) and E and F 
maximal uncoupled rate of respiration following FCCP as an index of electron transport 
chain content (N=4). Data are reported as means ±SEM with  ‘#’ representing a main 
effect for palmitoylcarnitine. P < 0.05. 
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Redox responses to palmitoylcarnitine in HepG2 cells 
Considering that fatty acids have been demonstrated to stimulate mitochondrial 
superoxide and H2O2 emission (12, 17), and excess H2O2 emission can lead to deleterious 
effects throughout the cell such as glutathione depletion and cell death (13), we then 
measured reduced (GSH) and oxidized (GSSG) glutathione following palmitoylcarnitine 
for 24 hours in HT29 and HepG2 cells. HT29 cells displayed signs of oxidative stress, as 
there was a palmitoylcarnitine-induced decrease in GSH (Figure 5.2A, p<0.05), an 
increase in GSSG (Figure 5.2B, p<0.05) and a decrease in the GSH/GSSG ratio (Figure 
5.2C, p<0.05). However, HepG2 cells showed an increase in both GSH (Figure 5.2D, 
p<0.05) and GSSG (Figure 5.2E, p<0.05) and no changes in GSH/GSSG (Figure 5.2F, 
p<0.05).  
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Figure 5 2 Redox stress following palmitoylcarnitine exposure: maintenance of 
overall redox conditions (GSH/GSSG) in HepG2 cells but not in HT29 cells. HepG2 
and HT29 cells were incubated with 0µM and 100µM palmitoylcarnitine for 24 hours A 
and D reduced glutathione (GSH), B and E oxidized glutathione (GSSH) C and F the 
ratio of reduced-to-oxidized glutathione (GSH/GSSG) was assessed (N=5). Data are 
reported as means ±SEM with ‘*’ representing a significant decrease and ‘#’ representing 
a significant increase with 100µM palmitoylcarnitine compared to 0µM. P < 0.05. 
 
In agreement with HepG2 cells displaying an increase in mitochondrial 
respiratory kinetics following palmitoylcarnitine, HepG2 cells displayed a decrease in 
intracellular lactate (Figure 5.3A, p<0.05). The decrease in lactate and increase in 
mitochondrial respiratory control suggests a shift from glycolysis to aerobic metabolism. 
However, despite these responses, there was a decrease in NAD(P)H following 
palmitoylcarnitine (Figure 5.3B, p<0.05).  
In HepG2 cells, H2O2 emission increased transiently by 10 minutes followed by a 
decrease at 24 hours (Figure 5.3C, p<0.05). This reversal was related to an increase in 
total glutathione in HepG2 cells contrasted to decreasing total glutathione in HT29 cells 
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(Figure 5.3D, p<0.05), suggesting a redox buffering mechanism may have been triggered 
by the initial H2O2 emission. To test this possibility, HepG2 cells were co-incubated with 
palmitoylcarnitine and the glutathione depleting agent buthionine sulfoximine (BSO). 
BSO prevented palmitoylcarnitine-induced growth (Figure 5.3E, p<0.05, Figure 5.3G), 
but did not sensitize HepG2 cells to decreasing cell survival as observed in HT29 and 
HCT 116 cells. We then determined whether the reversal in H2O2 emission was related to 
a 2nd mechanism of mitochondrial uncoupling. The UCP2 inhibitor genipin caused 
marked sensitization of HepG2 cells to palmitoylcarnitine resulting in a drastic decrease 
in cell survival (Figure 5.3E, p<0.05, Figure 5.3G), despite no change in UCP2 protein 
content in HepG2 cells (Figure 5.3F). Collectively, these findings support a model 
whereby palmitoylcarnitine stimulates acute increases in H2O2, which leads to both an 
increase in total glutathione and UCP2 activation to ultimately decrease H2O2 and protect 
HepG2 cells (Figure 5.3H).  
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Figure 5 3 Palmitoylcarnitine alters H2O2, glutathione and growth in HepG2 cells. A 
Intracellular lactate (N=5) and B NAD(p)H (N=9) was measured in HepG2 cells 
following 24 hours of 0µM or 100µM palmitoylcarnitine. C H2O2 was assessed following 
10 minutes and 24 hours of 0µM and 100µM palmitoylcarnitine (N=15). D Total 
glutathione was measured in HepG2 cells following 24 and 48 hours of 0µM or 100µM 
palmitoylcarnitine (N=5). E Relative cell survival was assessed in HepG2 cells following 
48 hours of 0µM or 100µM palmitoylcarnitine as well as concurrent incubated with 
50µM buthionine sufloximine or 100µM genipin (N=3). F HepG2 cells were incubated 
with 0µM and 100µM palmitoylcarnitine for 24 hours and uncoupling protein-2 (UCP2) 
protein content was determined (N=5). G Schematic depicting the selective inhibtion of 
UCP2 by genipin and the depletion of glutathione with buthionine sulfoximine (BSO). H 
Schematic of palmitoylcarnitine acutely triggering an increase in H2O2 emission, 
resulting in UCP2 activation and an increase in GSH, which in turn lowers H2O2 as well 
as stimulates an increase in growth. Data are reported as means ±SEM with  ‘*’ 
representing a significant decrease and ‘#’ representing a significant increase relative to 
0µM palmitoylcarnitine. P < 0.05.  
 
Discussion  	
Unlike HT29 and HCT 116 colorectal carcinoma cells, HepG2 HCC cells were 
resistant to palmitoylcarnitine-induced decreases in cell survival and demonstrated a 
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small increase in growth by 48 hours. This protection in HepG2 cells was associated with 
increased mitochondrial respiratory kinetics concurrent with decreased intracellular 
lactate content, suggesting a shift towards a greater reliance on OXPHOS. Furthermore, 
inhibition of the glutathione redox couple prevented palmitoylcarnitine-induced HepG2 
cell growth and UCP2 inhibition sensitized HepG2 cells to palmitoylcarnitine stress. 
These findings support a model that HepG2 cells invoke a cytoprotective response to 
palmitoylcarnitine that is associated with a mitochondrial and redox-based flexibility 
system (Figure 5.4).  
 
Figure 5 4 Proposed model of HepG2 cell adaptation to palmitoylcarnitine. The 
mitochondrial substrate, palmitoylcarnitine, stimulates an acute increase in H2O2. A 
compensatory increase in glutathione and activation of UCP2 eventually lead to lower 
H2O2 emission. These hormetic responses to palmitoylcarnitine result in an increase in 
glutathione redox buffering capacity. An increase in oxidative capacity also improves 
ATP synthesis. Collectively, the metabolic and redox flexibility of HepG2 cells results in 
improved proliferation in response to palmitoylcarnitine in contrast to the abrogations 
observed in HT29 and HCT 116 cells. 
 
Metabolic adaptations in HepG2 responses to palmitoylcarnitine 
A dynamic series of metabolic and redox adaptations occurred within 48hr of 
palmitoylcarnitine exposure. First, a transient increase in H2O2 emission by 10 minutes 
was noted. This suggests that the reducing equivalents (NADH, FADH2) generated by β-
UCP2
Initial response to palmitoylcarnitine Adaptive response to palmitoylcarnitine
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oxidation may have exceeded a relatively low rate of OXPHOS in HepG2 cells consistent 
with the concept of electron slip in situations of excess reducing equivalent supply (16). 
The stimulation of H2O2 emission by 10 minutes may have preceded the increase in 
glutathione content at 24 hours that coincided with the maintenance of cell survival, in 
conjunction with the UCP2 dependency observed at 48 hours. While evidence suggests 
that UCP2 may not be a direct uncoupler of membrane potential (16), inhibition of UCP2 
by genipin in HepG2 cells was previously shown to increase superoxide generation in 
response to palmitoylcarnitine in HepG2 cells (12), suggesting that UCP2 attenuates 
mitochondrial H2O2 emission in response to fatty acids (3). Collectively, the present 
findings suggest that the initial H2O2 emission at 10 minutes was related to activation of 
uncoupling via UCP2, although this latter point is speculative without measures of proton 
conductance (16) . 
 In support of the current proposed model of redox flexibility in HepG2 cells, in 
mice fed a high fat diet, inhibition of UCP2 by genipin was able to prevent high fat diet 
induced liver damage (21), suggesting that UCP2 may be involved in the pathogenesis 
and progression of liver damage towards HCC development. Likewise, Huang et al. (10) 
demonstrated that glutathione is a critical regulator in HepG2 cell growth whereby 
depletion of glutathione through BSO stagnated growth whereas increasing glutathione 
levels triggered increases in HepG2 proliferation. Collectively, these previous findings 
align with the present study and support the proposed model that early induction of H2O2 
by palmitoylcarnitine in HepG2 cells mediated cell survival through a UCP2-dependent 
attenuation of redox stress concurrent with increased glutathione content.  
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Another possible mechanism pertains to the increased mitochondrial respiratory 
capacity observed after palmitoylcarnitine treatment in HepG2 cells. 24 hours of 
palmitoylcarnitine increased ADP-stimulated mitochondrial respiration in conjunction 
with lower NAD(P)H content, which might suggest that NADH was oxidized to greater 
extents following this adaptive period. While NAD(P)H content on its own does not 
represent rate of generation or oxidation by the mitochondria, the greater respiratory 
kinetics following palmitoylcarnitine suggests the lower NAD(P)H was related to a 
greater rate of utilization. Indeed, lower lactate accumulation support this notion of a 
switch to mitochondrial OXPHOS following palmitoylcarnitine incubations. The lower 
NADH could, in theory, place less pressure on membrane potential-dependent superoxide 
generation, thereby explaining the lower H2O2 emission observed by 24 hours in addition 
to UCP2 induction discussed above. 
 
Perspectives and Conclusions 
The results in HepG2 cells suggest that fatty acid stress survival mechanisms 
through a dynamic relationship between oxidant generation and compensatory increases 
in glutathione redox buffering capacity. These observations may explain previous reports 
of HepG2 cell survival following direct exposure to fatty acids (19) and that glutathione 
is a critical regulator in not only promoting HepG2 survival but also driving the early 
induction of HepG2 cell growth (10). The present findings highlight how the interplay 
between metabolism and redox biology is not necessarily a predictable event of simple 
oxidative stress, but rather could manifest as a hormetic system that triggers an 
advantageous compensation promoting cancer cell growth. As such, this model could be 
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applied to determine how inherent metabolic and redox flexibility through H2O2 
emission, OXPHOS, UCP2 activity and glutathione dynamics could confer protection 
from fatty acid stress. 
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Abstract 	
Auranofin inhibits thioredoxin reductase, rendering the thioredoxin antioxidant system 
incapable of functioning, and has gained recent popularity as a potential antineoplastic 
therapy. However, it is likely that the coordinated inhibition of thioredoxin and 
glutathione, the main intracellular antioxidant, is required for potent anticancer effects. 
Serine and glycine (S&G) starvation has been demonstrated to elicit p53-/- glutathione 
depletion, whereas p53+/+ cells were less sensitive. Therefore, the purpose of this study 
was to determine whether thioredoxin inhibition with auranofin coupled with S&G 
starvation selectively abrogates p53-/- colorectal cancer proliferation. HCT 116 p53+/+ and 
p53-/- cells were incubated with or without auranofin and S&G. p53-/- cells were resistant 
to auranofin relative to p53+/+, however this was overcome by the coordinated starvation 
of S&G. N-acetylcysteine and exogenous glutathione were able to rescue both p53+/+ and 
p53-/-. Auranofin treatment resulted in a compensatory increase in glutathione in p53-/- 
cells, this compensatory increase was prevented when p53-/- cells were incubated with 
auranofin but without S&G. Nrf2 is a transcription factor responsible for increasing many 
antioxidant response genes. When Nrf2 was pre-activated prior to auranofin exposure, 
p53+/+ cells were dose-dependently rescued primarily when S&G were present, yet when 
Nrf2 was concurrently inhibited along with auranofin; p53-/- cells were sensitized to 
auranofin-induced decreasing cell survival. This data suggests that p53-/- are resistant to 
auranofin through a compensatory increase in glutathione and that S&G starvation 
renders p53-/- cells susceptible to auranofin. This demonstrates the potential for 
overriding p53-/- cell insensitivity to auranofin through coordinated glutathione depletion 
by S&G starvation. 
		 131	
Introduction 	
Despite the presence of oxygen, many cancers rely on non-mitochondrial 
glycolysis as their main source of ATP production, this is known as the Warburg effect 
[1]. These associated alterations in energy metabolism confer many cellular benefits 
resulting in a pro-growth environment [2]. The generation of reactive oxygen species 
(ROS), such as hydrogen peroxide (H2O2), is often associated as a byproduct of growth. 
As cancers are in a state of constant growth, they are reliant on antioxidant buffering 
systems, which utilize intracellular antioxidants, glutathione and thioredoxin, to combat 
elevations in H2O2 [3].  Both glutathione and thioredoxin have previously been implicated 
in conferring pro-growth advantages and chemoresistance in cancers. For example, 
relationships between both glutathione [4] and thioredoxin [5] systems and levels of 
cisplatin resistance have been established in a variety of cancers. Thioredoxin system 
proteins are often elevated in cancers [6], and the experimental generation of cisplatin-
resistant HT29 and St-4 cells resulted in an adaptive ~2.5-fold increase in thioredoxin in 
the cisplatin-resistant cell lines relative to their parental controls [7]. Similar to 
thioredoxin, glutathione is also often elevated in many cancers [8], and increased 
intratumoural glutathione levels at the time of diagnosis conferred with worse disease 
progression in colorectal carcinoma patients [9]. 
 Auranofin is a gold complex drug historically used to treat rheumatoid arthritis 
[10]. It has gained recent popularity as a cancer therapeutic as it functions through the 
inhibition of thioredoxin reductase [11], effectively inhibiting the thioredoxin system. 
However, glutathione compensation is a concern with thioredoxin inhibition as 
glutathione is the most abundant intracellular antioxidant, and is therefore implicated in 
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both ROS handling and cell fate [12]. Harris et al. [13] demonstrated that glutathione is a 
critical regulator for cancer initiation.  However, it appears that glutathione becomes less 
important in later stages of cancer progression due to the redundant action of thioredoxin. 
Coordinated inhibition of both glutathione (through buthionine sulfoximine – BSO) and 
thioredoxin (through auranofin) was able to display potent cancer cell death in 
spontaneous tumour forming mice [13]. However, systemic inhibition of both glutathione 
and thioredoxin may lead to off-target effects given the importance of redox buffering for 
healthy cell function. Furthermore, while BSO is a potent mechanistic glutathione-
depleting agent, it appears to have limited efficacy in humans, as intravenous human 
BSO administration failed to deplete glutathione levels to a significant degree [14]. 
Serine and glycine are two non-essential amino acids and are critical components 
in glutathione synthesis [15]. It has been previously demonstrated that serine and glycine 
starvation leads to a marked depletion of glutathione levels and eventual cell death, and 
this response was significantly heightened in HCT 116 p53-/- cells relative to HCT 116 
p53+/+ cells [15]. This is critical given that ~50% of human cancers display mutations in 
the TP53 gene, resulting in hyper-aggressive cancer growth and apoptotic and 
chemoresistance [16]. Preliminary data from our lab demonstrates that HCT 116 p53-/- 
cells relative to HCT 116 p53+/+ cells are significantly less sensitive to auranofin. Which 
is consistent with previous data demonstrating increased chemoresistance in p53-/- cells 
such that HCT 116 p53-/- cells were less sensitive to 5-FU and oxaliplatin relative to HCT 
116 p53+/+ cells [17]. As such, it is possible that targeted depletion of glutathione in p53-/- 
cancer cells by serine and glycine deprivation would uniquely sensitize these cells to 
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thioredoxin inhibition by auranofin, which is otherwise tolerated by non-cancerous p53+/+ 
cells. 
The purpose of this study was to first determine whether HCT 116 p53-/- cells are 
less sensitive to auranofin compared to HCT 116 p53+/+ cells, and secondly, to determine 
whether HCT 116 p53-/- cells could be sensitized to auranofin through coordinated 
glutathione depletion by serine and glycine starvation. While we were unable to 
recapitulate previous results that demonstrated increased sensitivity of HCT 116 p53-/- 
cells to serine and glycine starvation [15], we demonstrate that HCT 116 p53-/- cells are 
insensitive to auranofin-induced cell death at a concentration that is effective in HCT 116 
p53+/+ cells. Using serine and glycine deprivation, we show that this resistance in p53-/- is 
attributed to a compensatory increase in glutathione, resulting in heightened cell 
protection from H2O2. This heightened cell protection can be over-ridden by starvation of 
serine and glycine and exploited as a means of sensitizing these cells to auranofin-
induced cell death. 
 
Experimental procedures 		
Cell culture 
HCT 116 p53+/+ and HCT 116 p53-/- colon adenocarcinoma cells and HT29 colon 
adenocarcinoma cells were generously gifted from Dr. Samuel Benchimol (York 
University, Toronto, Canada). Cells were passaged in DMEM supplemented with 10% 
fetal bovine serum (Wisent Inc, Saint-Jean-Baptiste, QC, Canada) and 1% 
penicillin/streptomycin (Wisent Inc). For experimental conditions, cells were seeded in 
desired culture dishes in condition media similar to previously published [15] with serine 
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and glycine. Following up to 72 hours, cells were exposed to condition media with or 
without serine and glycine and 1µM auranofin (Tocris Bioscience, Bristol, UK). In 
addition to auranofin and serine and glycine manipulations, in separate experiments cells 
were also treated with N-acetyl cysteine (NAC), reduced glutathione (GSH), 3H-1,2-
dithiole-3-thione (D3T) and N-[4-[2,3-Dihydro-1-(2-methylbenzoyl)-1H-indol-5-yl]-5-
methyl-2-thiazolyl]-1,3-benzodioxole-5-acetamide (ML 385) (Sigma-Aldrich). 
 
Relative cell survival 
The crystal violet assay was used to determine relative cell survival [18]. Cells 
were treated for up to 72 hours in 96-well optical bottom black walled plates 
(ThermoFisher Scientific). Following treatment time, cells were fixed using 10% 
formalin (Sigma-Aldrich) for 10 minutes. Formalin was subsequently removed and 0.5% 
crystal violet (Sigma-Aldrich) solution in 25% MeOH was added for 10 minutes. 
Following crystal violet staining, wells were rinsed clean with water and dried overnight. 
Relative cell survival was visualized as crystal violet fluorescence conducted using the 
LiCor odyssey scanner (LiCor Biosciences, Lincoln, NE, USA) and fluorescent density 
analysis was conducted using LiCor software. 
 
Glutathione 
Glutathione was measured as previously published [19]. Both reduced (GSH) and 
oxidized (GSSG) glutathione were measured using a Shimadzu Nexera X2 UPLC system 
(Mandel Scientific Company inc. Guelph, Canada) and separation was achieved using a 
Zorbax C18 column (Agilent Technologies, Mississauga, ON, Canada). Following 
		 135	
experimental conditions for 24 and 48 hours, cells were washed with PBS and scraped in 
50mM TRIS based buffer (pH 8.0 with HCl) with 20mM boric acid (Sigma-Aldrich), 
2mM L-serine (Sigma-Aldrich), 20µM acivicin (Enzo Life Sciences, NY, USA) and 
5mM N-ethylmaleimide (Sigma-Aldrich). Cell suspension was used for GSH and GSSG 
determination as well as protein concentration was assessed with BCA (ThermoFisher 
Scientific) according to kit instructions. 
 
GSH 
This method was adapted from Giustriani et al. [20]. Following cell scraping, 
cells were deproteinated in 10µl trichloroacetic acid with 100µl cells in suspension. GSH 
samples were run under isocratic conditions using a 0.25% glacial acetic acid mobile 
phase with 6% acetonitrile at a flow rate of 1.05ml/min. GSH was detected using a 
modular UV-VIS detector (Shimadzu) detector at 265nm wavelength. 
 
GSSG 
This method was adapted from Kand’ar et al. [21]. Cells were deproteinated in 
equal parts 15% perchloric acid to sample volume. 100µl of deproteinated sample was 
added to 500µl of 0.5M NaOH. 37.5µl of 0.1% o-pthalymide in methanol was added and 
incubated for 15 minutes rocking in the dark creating a GS-OPA conjugate. Following 
incubation, samples were transferred to HPLC autosampler vials and ready for column 
separation. GSSG samples were run under isocratic conditions using a 25mM Na2HPO4 
in HPLC grade water with 15% methanol mobile phase at a flow rate of 0.5ml/min. 
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GSSG was excited at 350nm and emission was detected at 420nm using a HPLC/UHPLC 
fluorescence detector (Shimadzu). 
 
Mitochondrial bioenergetics assessment 
Cell preparation 
Cells were seeded in 10cm dishes for 24 hours. Cells were trypsin harvested, 
washed in PBS and re-suspended in mitochondrial respiration media (MIRO5, in mM): 
0.5 EGTA, 10 KH2PO4, 3 MgCl2·6 H2O, 60 K-lactobionate, 20 Hepes, 20 Taurine, 110 
sucrose and 1 mg/ml fatty acid free BSA (pH 7.1) supplemented with 20mM creatine. 
Cells were then permeabilized with 10ug/ml digitonin (Sigma-Aldrich, St. Louis, MO, 
USA) for 30 minutes rocking at room temperature. Cells were pelleted, and re-suspended 
in 105µl MIRO5, with 5µl subsequently removed to determine protein content, while the 
remaining 100µl was used for high-resolution respirometry. 
Cells suspended in mitochondrial respiration media (MIRO5) were loaded into the 
Oroboros Oxygraph-2k (Oroboros Instruments, Corp., Innsbruck, Austria) system. Total 
volume was 2mls, spinning at 750 rpm at 37oC. To determine ADP-stimulated 
respiration, 5mM pyruvate and 2mM malate were added as complex I substrates, 
followed by ADP titrations of 25µM, 500µM and 5mM ADP. Polarographic oxygen 
measurements were acquired in 2 s intervals with the rate of respiration derived from 40 
data points and expressed as pmol/s/mg protein.  
 
Western blotting 
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Cells were seeded in 6-well plates. Following experimental conditions, cells were 
washed with PBS then scraped into 68mM TRIS-HCl buffer containing 2% SDS, 10% 
glycerol, protease and phosphatase inhibitors (Sigma-Aldrich), on ice and subsequently 
boiled for 10 minutes. Cells were then vortexed and centrifuged at 10,000RPM for 10 
minutes. Supernatent was collected and stored in -80oC until further analysis. Hybridoma 
generated PAb 421 p53 antibody was provided by Dr. Samuel Benchimol. Cleaved Parp 
and p-p53ser46 antibody cocktail (p53 mediated apoptosis WB cocktail, Abcam 
ab140360), 4-hydroxynoneonal (4-HNE, Abcam ab ab46545), glutathione reductase 
antibody (SAB4200182, Sigma-Aldrich), were used. 
 
Statistics 
Data is reported as mean ± SEM. Significance is reported as p<0.05 for all 
measures. Each ‘N’ signifies an individual experiment, with each experiment conducted 
in triplicate where appropriate. For the comparison of only two groups, unpaired t-tests 
were used. For the comparison of more than two groups, ANOVA’s were performed. 
Following significance of a two-way ANOVA, a Fisher’s LSD post-hoc was performed 
on appropriate groups. All statistics were performed using GraphPad Prism 7 (San Diego, 
CA, USA). 
 
Results 		
p53 knockout results in decreased complex I capacity, decreased steady-state H2O2 and 
increased glutathione 
		 138	
In order to determine baseline metabolic phenotypic alterations, HCT 116 p53+/+ 
and p53-/- cells (Figure 6.1A) were subject to examination of mitochondrial oxygen 
consumption, glutathione and steady-state H2O2 emission. Consistent with previous data 
demonstrating that HCT 116 p53-/- cells displayed decreased O2 consumption relative to 
HCT 115 p53+/+ cells [22], HCT 116 p53+/+ cells displayed increased complex I-
supported mitochondrial respiration compared to HCT 116 p53-/- cells (p<0.05, Figure 
6.1B), as well as greater steady-state H2O2 levels in HCT 116 p53+/+ cells relative to HCT 
116 p53-/- cells (p<0.05, Figure 6.1C). Despite the apparent decrease in oxidative reliance 
in HCT 116 p53-/- cells, HCT 116 p53-/- cells displayed higher intracellular total 
glutathione levels (p<0.05, Figure 6.1D). These data suggests that HCT 116 p53-/- cells 
display an altered metabolic phenotype resulting in increased basal glutathione levels. 
 
Figure 6 1 HCT 116 p53+/+ cells display greater oxidative characteristics despite 
lower glutathione relative to HCT 116 p53-/- cells. A HCT 116 p53+/+ and p53-/- cells 
were assessed for p53 protein content. B ADP supported mitochondrial respiration was 
measured in HCT 116 p53+/+ and p53-/- cells (N=4-8). Data are reported as means ±SEM 
with ‘#’ representing a main effect for p53 status. P<0.05. C H2O2 emission (N=14) and 
D total glutathione (N=8-10) was assessed in HCT 116 p53+/+ and p53-/- cells. Data are 
reported as means ±SEM with ‘*’ representing a significant difference between groups. 
P<0.05. 
 
 
p53+/+ p53-/-
50 kDa - 
0
50
100
150
200
JO
2 
(p
m
ol
⋅se
c-
1 ⋅
m
g-
1 
pr
ot
ei
n) HCT 116 p53+/+
HCT 116 p53-/-
P/M 25µM
 ADP
500µM
 ADP
5000µM
 ADP
#
0
10
20
30
40
50
To
ta
l G
lu
ta
th
io
ne
 (t
G
S,
 µ
m
ol
/g
 p
ro
te
in
)
HCT 116 
p53+/+
HCT 116 
p53-/-
*
0.00
0.01
0.02
0.03
0.04
H
2O
2 
(µ
m
ol
/g
 p
ro
te
in
)
*
HCT 116 
p53+/+
HCT 116 
p53-/-
A
B C D
		 139	
HCT 116 p53-/- cells are insensitive to auranofin-induced cell death, yet the 
coordinated starvation of serine and glycine overcomes this insensitivity 
As reported previously, in the presence of serine and glycine, cancer cells 
typically rely on anaerobic pathways of glycolysis for ATP production (Figure 6.2A). 
With the removal of serine and glycine, glycolytic intermediates are re-directed towards 
serine biosynthesis and a subsequent increase in mitochondrial activity is required in 
order to maintain ATP levels for cell viability. This metabolic redirection results in 
potential increases in H2O2, allowing for further decreases in glutathione levels associated 
with serine and glycine starvation (Figure 6.2B) [15].  
 
Figure 6 2 Auranofin-induced thioredoxin inhibition coupled with glutathione 
depletion through serine and glycine starvation renders the cell sensitive to 
oxidative stress. A Typical cancer cell metabolism functions through glycolytic ATP 
production despite the presence of oxygen, while reduced glutathione (GSH) is 
synthesized from serine and glycine. B In the absence of serine and glycine, glycolytic 
intermediates are shunted towards de novo serine production, resulting in increased 
mitochondrial activity. While, serine and glycine starvation renders the cell incapable of 
producing new glutathione, coupled with auranofin renders the cell vulnerable to 
oxidative stress. 
 
HCT 116 p53+/+ and p53-/- cells were incubated in conditioned media with or without 
serine, glycine and auranofin for up to 72 hours (Figure 6.3A and 6.3B). Relative to 
A B
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complete conditioned media, both cell lines displayed a moderate slowing of growth in 
the absence of serine and glycine (p<0.05), and HCT 116 p53+/+ cells had significantly 
decreased cell survival with auranofin regardless of serine and glycine status within the 
media (p<0.05). Alternatively, HCT 116 p53-/- cells were insensitive to auranofin alone 
as these cells still grew relative to earlier time points, yet auranofin combined with serine 
and glycine starvation resulted in a significant decline in cell growth and resulted in 
decreased cell survival relative to earlier time points (p<0.05). Cell survival of HCT 116 
p53+/+ and p53-/- cells with or without auranofin and serine and glycine was mimicked 
using a trypan blue exclusion assay to determine cell viability (p<0.05, Figure 6.3C and 
6.3D). Furthermore, HCT 116 p53+/+ cells demonstrated an increase in phospho-p53ser46 
content (Figure 6.3E), suggesting a likely activation of p53-mediated apoptotic signaling 
[23]. 
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Figure 6 3 Combined serine and glycine starvation sensitizes HCT 116 p53-/- cells to 
auranofin. A and B Relative cell survival of HCT 116 p53+/+ and p53-/- cells incubated 
for 24 (N=9), 48 (N=9) and 72 hours (N=3) with or without auranofin (AUR) and serine 
and glycine (SG) Data are reported as means ±SEM with ‘φ’ representing a main effect 
for time, ‘*’ representing a main effect for condition media and ‘$’ representing an 
interaction. P<0.05. C and D Trypan blue exclusion was measured in HCT 116 p53+/+ 
and p53-/- cells following 24 hours of treatment (N=4). Data are reported as means ±SEM 
with ‘#’ representing a main effect for auranofin, ‘$’ representing a significant difference 
between all groups yet not different from each other, ‘*’ representing a significant 
difference between all groups. P<0.05. E The phosphorylation of p53 at serine residue 46 
was determined following 24 hours of treatment in HCT 116 p53+/+ and HCT 116 p53-/- 
cells. 
 
As auranofin coupled with serine and glycine starvation was theorized to elicit 
antineoplastic effects through increasing cellular susceptibility to oxidative stress, cell 
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survival was measured in HCT 116 p53+/+ and p53-/- cells incubated with auranofin and 
starved of serine and glycine in the presence and absence of exogenous antioxidants N-
acetylcysteine (NAC, Figure 6.4A and 6.4B) and reduced glutathione (GSH, Figure 6.4C 
and 6.4D) for up to 48 hours. Both NAC and exogenous GSH were able to rescue HCT 
116 p53+/+ and p53-/- cells from auranofin coupled with serine and glycine starvation 
(p<0.05). This suggests that combined auranofin and serine and glycine starvation 
function through a ROS dependent pathway to elicit deleterious effects.  
Nuclear factor erythroid-derived 2-like 2 protein (Nrf2) is a redox sensitive 
transcriptional regulator of glutathione synthesis as well as other antioxidant genes. In 
order to determine the role of Nrf2 during auranofin and serine and glycine starvation, 
Nrf2 was pre-activated with D3T in HCT 116 p53+/+ cells 24 hours prior to experimental 
conditions (Figure 6.4E and 6.4F). Nrf2 pre-activation dose-dependently elicited 
protective effects against auranofin, yet was less efficacious when auranofin was coupled 
with serine and glycine starvation (p<0.05). Furthermore, Nrf2 inhibition by ML 385 in 
HCT 116 p53-/- cells sensitized these cells to auranofin despite serine and glycine status 
(p<0.05, Figure 6.4G and 6.4H). It is therefore possible that HCT 116 p53+/+ cells are 
sensitive to auranofin as they undergo oxidative stress caused by auranofin resulting in 
p53-mediated cell death, while HCT 116 p53-/- cells are insensitive to auranofin as 
without p53, they likely engage Nrf2 and increase antioxidant defence mechanisms, such 
as glutathione, resulting in a compensatory cell protection against thioredoxin inhibition.  
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Figure 6 4 Altering cell survival through manipulating antioxidant related 
pathways. Relative cell survival was measured in HCT 116 p53+/+ and p53-/- cells 
following incubation with or without auranofin (AUR) and serine and glycine (SG) as 
well as A and B N-acetylcysteine (NAC, N=6-9) and C and D exogenous reduced 
glutathione (GSH, N=6). Data are reported as means ±SEM, ‘*’ representing a significant 
difference relative to +SG without auranofin, ‘#’ representing a significant difference 
relative to –SG + auranofin. P<0.05. E and F D3T stimulated Nrf2 activation (N=3) and 
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G and H ML 385 stimulated Nrf2 inhibition (N=3). Data are reported as means ±SEM, 
‘*’ representing a significant increase relative to 0µM D3T or ML 385, ‘#’ representing a 
significant difference between +SG and –SG of the same Nrf2 manipulating condition. 
P<0.05. 
 
Serine and glycine starvation resulted in elevated H2O2 emission regardless of p53 
status, yet coupled with auranofin resulted in variable responses in glutathione 
Serine and glycine starvation resulted in an increase in H2O2 emission regardless 
of p53 status (p<0.05, Figure 6.5A). In conjunction with cell survival, HCT 116 p53+/+ 
cells demonstrate decreased total glutathione levels with auranofin (p<0.05, Figure 6.5B 
and 6.5C). While HCT 116 p53-/- cells respond to auranofin through increased 
glutathione, auranofin combined with serine and glycine starvation prevented this 
compensatory increase, resulting in a significant decrease in total glutathione relative to 
untreated cells (p<0.05, Figure 6.5D and 6.5E).  
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Figure 6 5 Serine and glycine starvation results in increased H2O2 emission and 
altered glutathione responses between HCT 116 p53+/+ and p53-/- cells. A H2O2 
emission (N=9) and B – E total glutathione (N=4-5) was measured in HCT 116 p53+/+ 
and p53-/- cells following incubation with or without auranofin (AUR) and serine and 
glycine (SG). Data are reported as means ±SEM, ‘*’ representing a significant difference 
between adjacent groups, ‘#’ representing a significant difference relative to +SG without 
auranofin. P<0.05. 
 
In response to auranofin, HCT 116 p53+/+ cells display decreased reduced (GSH, Figure 
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116 p53-/- cells, however, display a compensatory increase in GSH (Figure 6.6C and 
6.6D) and GSSG (Figure 6.6G and 6.6H), and coupled with serine and glycine starvation, 
GSH and GSSG responses differ. Auranofin coupled with serine and glycine starvation 
results in a near abolishment of GSH in HCT 116 p53-/- cells (p<0.05). While there is a 
decrease in GSSG, GSSG levels remain elevated over control, suggesting that HCT 116 
p53-/- cells are unable to produce new GSH, yet elevated levels of GSSG remain high. 
 
Figure 6 6 Auranofin induces a compensatory increase in glutathione in HCT 116 
p53-/- cells but not HCT 116 p53+/+ cells. A – D reduced glutathione (GSH) E – H 
oxidized glutathione (GSSG) and I – L GSH/GSSG ratio was measured in HCT 116 
p53+/+ (N=4) and p53-/- cells (N=5) following incubation with or without auranofin 
(AUR) and serine and glycine (SG). Data are reported as means ±SEM, ‘*’ representing a 
significant difference within DMSO or auranofin conditions, ‘#’ representing a 
significant difference relative to +SG without auranofin. P<0.05. 
 
HT29 p53mutant colorectal carcinoma cells display insensitivity towards auranofin, yet 
are sensitized through combined serine and glycine starvation  
 In order to further validate the role of p53 in determining cell fate when exposed 
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of serine and glycine, HT29 cells, which have mutated p53 (p53mutant), were exposed to 
auranofin with and without serine and glycine. Similar to HCT 116 p53-/- cells, cell 
survival was marginally influenced by auranofin or serine and glycine starvation alone, 
however in combination, resulted in a significant decrease in cell survival (p<0.05, 
Figure 6.7A). This decrease in cell survival was rescued by NAC and exogenous GSH 
(p<0.05, Figure 6.7B). Similarly, auranofin induced a compensatory increase in 
glutathione, which was negated when auranofin was incubated without serine and 
glycine, in which glutathione levels were undetectable (p<0.05, Figure 6.7C and 6.7D). 
In conjunction with a compensatory increase in total glutathione levels, glutathione 
reductase was increased following auranofin treatment (p<0.05, Figure 6.7F), which is 
indicative of Nrf2 activation in response to auranofin as glutathione reductase is a 
downstream target of Nrf2. Furthermore, 4-HNE (Figure 6.7G) and cleaved PARP 
(Figure 6.7H) protein content were solely increased in HT29 cells when exposed to 
auranofin coupled with serine and glycine starvation (p<0.05). 
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Figure 6 7 HT29 p53mutant cell insensitivity to auranofin is overcome by coordinated 
serine and glycine starvation. HT29 p53mutant cells were treated with or without 
auranofin (AUR) and serine and glycine (SG) and A relative cell survival (N=3-6). Data 
are reported as means ±SEM with ‘φ’ representing a main effect for time, ‘*’ 
representing a main effect for condition media and ‘$’ representing an interaction. 
P<0.05. In addition, cell survival was also measured B with NAC and exogenous GSH 
(N=3-6). Data are reported as means ±SEM, ‘*’ representing a significant difference 
relative to  +SG without auranofin, ‘#’ representing a significant difference relative to –
SG + auranofin. As well as C and D total glutathione (N=3), E trypan blue exclusion 
(N=4), protein content of F glutathione reductase (N=4), G 4-HNE (N=4) and H cleaved 
PARP (N=5). Data are reported as means ±SEM, with ‘#’ representing a main effect for 
auranofin and ‘*’ representing a significant difference relative to all groups. P<0.05. 
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Discussion 	
Auranofin caused marked decreases in cell survival in HCT 116 p53+/+ cells, 
however HCT 116 p53-/- cells and p53mutant HT29 cells were insensitive. To combat the 
inhibition on thioredoxin, HCT 116 p53-/- cells and HT29 cells were able to increase 
glutathione levels, likely through Nrf2 mediated pathways. Resistance to auranofin was 
overcome when HCT 116 p53-/- cells and HT29 cells were coordinately incubated 
without serine and glycine, preventing the increase in glutathione resulting in significant 
decreases in cell survival. The loss in cell survival appears to be driven primarily by 
exposure to H2O2 given that the antioxidants NAC and GSH were able to protect all cells 
from auranofin regardless of serine and glycine. The pre-incubation of HCT 116 p53+/+ 
cells with the Nrf2 activator, D3T, was able to dose dependently protect HCT 116 p53+/+ 
cells from auranofin. However, this was primarily observed in cells with serine and 
glycine, as the starvation of serine and glycine likely prevented Nrf2-induced increases in 
glutathione synthesis, therefore preventing the protective role of Nrf2 during auranofin-
induced stress. The concurrent inhibition of Nrf2 along with auranofin sensitized HCT 
116 p53-/- cells to decreasing cell survival, regardless of serine and glycine. These results 
suggest that auranofin is able to influence cells in a p53 dependent manner, and this is 
likely related to whether a cell enters p53-mediated apoptotic signaling or whether a cell 
is able to increase glutathione levels likely through the activation of Nrf2, resulting in 
cyto-protection to auranofin. 
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Synergistic thioredoxin inhibition and glutathione depletion result in cell death 
through ROS mediated pathway 
Auranofin coupled with the starvation of serine and glycine resulted in a marked 
decrease in cell survival in all cells. This decrease in cell survival was rescued both by 
the antioxidant NAC and with exogenous GSH. This suggests that H2O2 is a primary 
stressor upon the cells when exposed to these conditions. Given that cancers typically 
rely on non-mitochondrial glycolysis as their main source of ATP production, another 
possible mechanism of decreasing cell survival would be through an inability of cancer 
cells to produce sufficient levels of mitochondrial-derived ATP. This however does not 
seem to be the case as NAC and GSH effectively restored cell survival, likely pointing to 
H2O2, not a lack of ATP, as the primary driver of decreasing cell survival. While it is 
possible that excess H2O2 can inhibit ATP production through the alteration of 
mitochondrial electron complexes, this data would suggest that H2O2 rather than 
metabolic redirection is the primary influencing factor mediating the deleterious effects 
of auranofin and serine and glycine starvation on cell survival.  
The powerful efficacy in combined thioredoxin and glutathione inhibition has 
been previously demonstrated. Harris et al. [13] eloquently demonstrated that the 
combined inhibition of thioredoxin and glutathione resulted in antineoplastic properties, 
suggesting redundant functions of both systems. Interestingly, in a panel of over 100 non-
small cell lung cancer (NSCLC) cell lines, the anticancer properties of auranofin were 
significantly greater in cell lines with lower or compromised glutathione pathways [24]. 
One possible avenue for potential therapies could be the use of intracellular glutathione 
as a potential biomarker to predict cell sensitivity to auranofin. However, in an attempt to 
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determine a cancer specific approach to glutathione depletion, Maddocks et al. [15] 
demonstrated that HCT 116 p53-/- cells were particularly sensitive to serine and glycine 
starvation, and that this sensitivity was due to the inability of p53-/- cells to produce 
glutathione when starved of serine and glycine. Current work was unable to recapitulate 
their findings directly, whereby HCT 116 p53-/- cells were not overly sensitive to serine 
and glycine starvation alone. While currently still unknown, it is possible that the 
dialyzed FBS used in this study contained trace levels of serine and glycine preventing 
the full starvation these non-essential amino acids. Therefore, increasing the consumption 
of serine and glycine through a compensatory increase in glutathione, as triggered by 
auranofin, may provide a combined approach to glutathione depletion. 
 
The cyto-protective effects of Nrf2 against auranofin require serine and glycine 
Nrf2 activity is commonly promoted through oncogenic signaling resulting in 
enhanced protection from oxidative stress for cancer cells [25]. The pre-activation of 
Nrf2 was able to dose-dependently protect HCT 116 p53+/+ cells from auranofin. This 
cyto-protective effect was significantly blunted when cells were concurrently starved of 
serine and glycine. As it is likely that Nrf2 elicited protective effects against auranofin 
through a compensatory increase in glutathione, concurrent auranofin and serine and 
glycine starvation would prevent substrate availability for de novo glutathione synthesis. 
As many cancers display increased Nrf2 activity, serine and glycine starvation may 
indeed prevent increased Nrf2 chemoresistance [26]. Hayes and McMahon [27] 
determined that roughly 15% of lung cancer patients sampled had mutations which 
prevented Keap1 associated Nrf2 degradation, potentially allowing for an increase in 
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nuclear accumulation of Nrf2. Interestingly, certain mutant variants of p53 have been 
demonstrated to increase nuclear accumulation of Nrf2 as well, resulting in an increase in 
Nrf2 activity [28]. Given that Nrf2 activity promotes the expression of both thioredoxin 
and glutathione related genes, the up-regulation of the thioredoxin system has been 
previously demonstrated in several cancers [29, 30] whereby higher thioredoxin levels 
have been positively correlated with higher levels of aggression in cancers [29]. This has 
also been demonstrated with glutathione, where increased levels of glutathione are 
associated with more aggressive tumour growth [9]. Therefore, the combined inhibition 
of both systems appears to be critical in order to prevent redundant up-regulation of the 
opposing system. The concurrent inhibition of Nrf2 with auranofin was able to dose 
dependently sensitize HCT 116 p53-/- cells to auranofin, regardless of serine and glycine 
status. This suggests that Nrf2 regulates the ability of HCT 116 p53-/- cells to increase 
glutathione as a protective mechanism; therefore, whether the required precursors of 
glutathione are present or not is of lesser importance given that the stimulus to increase 
glutathione upstream was inhibited. 	
 
Perspectives and conclusions 
Collectively, this data demonstrates that HCT 116 p53-/- cells are insensitive to 
auranofin at a dose that HCT 116 p53+/+ cells are sensitive. This resistance is attributed to 
a compensatory increase in glutathione, and the prevention of this increase through 
combined starvation of serine and glycine renders HCT 116 p53-/- cells sensitive to 
auranofin-induced cell death. Previous literature has demonstrated the combined effects 
of glutathione and thioredoxin inhibition as a potent antineoplastic therapy [13, 24], 
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however the possibility exists that cancers may dissipate ROS production by lowering 
mitochondrial H2O2 production [31]. Therefore, combining thioredoxin inhibition with 
serine and glycine starvation represents a strategy that creates redox stress through 
combined attenuation of thioredoxin and glutathione and increased mitochondrial H2O2 
emission. While it is possible that the elevated H2O2 emission is solely in response to the 
coordinated decreasing glutathione, previous literature would suggest that serine and 
glycine starvation results in an increase in mitochondrial respiratory activity through 
increasing TCA cycle intermediates, thereby increasing mitochondrial H2O2 in 
coordination with decreasing glutathione levels. However, it remains to be determined 
whether normal non-cancerous cells can tolerate this potential therapy. These findings 
demonstrate a possible p53-/- targeted, cancer-specific therapy, for circumventing p53-/- 
cell induced chemoresistance towards auranofin-induced cell death. Combining auranofin 
with serine and glycine starvation may prove to be an efficacious anticancer therapy.  
  
		 154	
 
Author contributions 
P.C.T. and C.G.R.P. designed the study. P.C.T., A.C.D., B.P., M.C.H., and L.D. 
conducted experiments and analyzed data. All authors interpreted the findings. P.C.T. and 
C.G.R.P. wrote the manuscript. All authors approved the manuscript. 
 
Conflict of interest 
The authors declare that they have no conflicts of interest with the contents of this article. 
 
Funding 
Funding was provided to C.G.R.P. by the National Science and Engineering 
Research Council (#436138-2013), with infrastructure supported by Canada Foundation 
for Innovation, the James. H. Cummings foundation and the Ontario Research Fund. 
P.C.T and M.C.H were both supported by a NSERC CGS-PhD scholarship. 
 
 
 
 
  
		 155	
References 
 
1. Warburg, O., The metabolism of carcinoma cells. The Journal of Cancer 
Research, 1925. 9(1): p. 148-163. 
2. Liberti, M.V. and J.W. Locasale, The Warburg Effect: How Does it Benefit 
Cancer Cells? Trends Biochem Sci, 2016. 41(3): p. 211-8. 
3. Trachootham, D., J. Alexandre, and P. Huang, Targeting cancer cells by ROS-
mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov, 
2009. 8(7): p. 579-91. 
4. Fujimori, S., et al., The subunits of glutamate cysteine ligase enhance cisplatin 
resistance in human non-small cell lung cancer xenografts in vivo. Int J Oncol, 
2004. 25(2): p. 413-8. 
5. Yamada, M., et al., Increased expression of thioredoxin/adult T-cell leukemia-
derived factor in cisplatin-resistant human cancer cell lines. Clin Cancer Res, 
1996. 2(2): p. 427-32. 
6. Jia, J.J., et al., The role of thioredoxin system in cancer: strategy for cancer 
therapy. Cancer Chemother Pharmacol, 2019. 
7. Kim, S.J., et al., High thioredoxin expression is associated with resistance to 
docetaxel in primary breast cancer. Clin Cancer Res, 2005. 11(23): p. 8425-30. 
8. Gamcsik, M.P., et al., Glutathione levels in human tumors. Biomarkers, 2012. 
17(8): p. 671-91. 
9. Barranco, S.C., et al., Relationship between colorectal cancer glutathione levels 
and patient survival: early results. Dis Colon Rectum, 2000. 43(8): p. 1133-40. 
10. Finkelstein, A.E., et al., Auranofin. New oral gold compound for treatment of 
rheumatoid arthritis. Ann Rheum Dis, 1976. 35(3): p. 251-7. 
11. Roder, C. and M.J. Thomson, Auranofin: repurposing an old drug for a golden 
new age. Drugs R D, 2015. 15(1): p. 13-20. 
12. Balendiran, G.K., R. Dabur, and D. Fraser, The role of glutathione in cancer. Cell 
Biochem Funct, 2004. 22(6): p. 343-52. 
13. Harris, I.S., et al., Glutathione and thioredoxin antioxidant pathways synergize to 
drive cancer initiation and progression. Cancer Cell, 2015. 27(2): p. 211-22. 
14. Bailey, H.H., et al., Phase I clinical trial of intravenous L-buthionine sulfoximine 
and melphalan: an attempt at modulation of glutathione. J Clin Oncol, 1994. 
12(1): p. 194-205. 
15. Maddocks, O.D., et al., Serine starvation induces stress and p53-dependent 
metabolic remodelling in cancer cells. Nature, 2013. 493(7433): p. 542-6. 
16. Hientz, K., et al., The role of p53 in cancer drug resistance and targeted 
chemotherapy. Oncotarget, 2017. 8(5): p. 8921-8946. 
17. Boyer, J., et al., Characterization of p53 wild-type and null isogenic colorectal 
cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin 
Cancer Res, 2004. 10(6): p. 2158-67. 
18. Feoktistova, M., P. Geserick, and M. Leverkus, Crystal Violet Assay for 
Determining Viability of Cultured Cells. Cold Spring Harb Protoc, 2016. 2016(4): 
p. pdb prot087379. 
		 156	
19. Mandel, E.R., et al., The superoxide dismutase mimetic tempol does not alleviate 
glucocorticoid-mediated rarefaction of rat skeletal muscle capillaries. Physiol 
Rep, 2017. 5(10). 
20. Giustarini, D., et al., Analysis of GSH and GSSG after derivatization with N-
ethylmaleimide. Nat Protoc, 2013. 8(9): p. 1660-9. 
21. Kand'ar, R., et al., Determination of reduced and oxidized glutathione in 
biological samples using liquid chromatography with fluorimetric detection. J 
Pharm Biomed Anal, 2007. 43(4): p. 1382-7. 
22. Matoba, S., et al., p53 regulates mitochondrial respiration. Science, 2006. 
312(5780): p. 1650-3. 
23. Mayo, L.D., et al., Phosphorylation of human p53 at serine 46 determines 
promoter selection and whether apoptosis is attenuated or amplified. J Biol 
Chem, 2005. 280(28): p. 25953-9. 
24. Yan, X., et al., Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic 
Lethality in Lung Cancers with Compromised Glutathione Homeostasis. Cancer 
Res, 2019. 79(1): p. 125-132. 
25. DeNicola, G.M., et al., Oncogene-induced Nrf2 transcription promotes ROS 
detoxification and tumorigenesis. Nature, 2011. 475(7354): p. 106-9. 
26. Huang, Y., et al., The complexity of the Nrf2 pathway: beyond the antioxidant 
response. J Nutr Biochem, 2015. 26(12): p. 1401-13. 
27. Hayes, J.D. and M. McMahon, NRF2 and KEAP1 mutations: permanent 
activation of an adaptive response in cancer. Trends Biochem Sci, 2009. 34(4): p. 
176-88. 
28. Lisek, K., et al., Mutant p53 tunes the NRF2-dependent antioxidant response to 
support survival of cancer cells. Oncotarget, 2018. 9(29): p. 20508-20523. 
29. Lincoln, D.T., et al., Thioredoxin and thioredoxin reductase expression in thyroid 
cancer depends on tumour aggressiveness. Anticancer Res, 2010. 30(3): p. 767-
75. 
30. Berggren, M., et al., Thioredoxin and thioredoxin reductase gene expression in 
human tumors and cell lines, and the effects of serum stimulation and hypoxia. 
Anticancer Res, 1996. 16(6B): p. 3459-66. 
31. Derdak, Z., et al., The mitochondrial uncoupling protein-2 promotes 
chemoresistance in cancer cells. Cancer Res, 2008. 68(8): p. 2813-9. 	
 
 	  
		 157	
Chapter 7 Summary of findings 
 
7.1 General findings and future directions 	
Cancer is a disease of uncontrollable cell proliferation brought on by selective 
mutations conferring a pro-growth phenotype leading to drastic cell expansion despite 
restraints on growth [1]. With the current practices of cancer prognosis and therapies, 
roughly 1 in 5 people will die as a result of cancer [2]. In order to sustain and promote 
cell division, apoptotic resistance and migration, cancers have evolved altered metabolic 
pathways resulting in sustained ATP production and the production of many biosynthetic 
molecules required for growth. These alterations in cancer metabolism were first 
observed almost 100 years ago [3, 4], and forced manipulations of cancer metabolism 
may lead to promising cancer-targeted therapies. An anthropomorphic view of cancer 
cells suggests that cancers have become ‘addicted’ to their metabolic phenotype, and that 
altering their metabolism may be too costly and result in either stagnation of cancer cell 
growth or death [5]. The classic understanding of cancer bioenergetics state that most 
cancers rely primarily on glycolysis ending in lactate production as their primary source 
of ATP production, despite the presence of oxygen, in a process coined ‘aerobic 
glycolysis’. Forced oxidation of pyruvate, rather than lactate production, has 
demonstrated the potential benefit of mitochondrial activation in lung and tongue cancers 
[6] among others.  
In response to palmitoylcarnitine, mitochondria produce the reactive oxygen 
species (ROS) superoxide (O2●-)[7] and subsequent hydrogen peroxide (H2O2) formation 
during oxidative phosphorylation [8], therefore the role of both ROS generation and ROS 
handling is crucial in dictating cell fate. H2O2, in itself is hormetic in nature, whereby low 
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levels of H2O2 can function to increase cell proliferative rates, yet high levels of H2O2 can 
result in deleterious cellular fates. Glutathione is the main intracellular antioxidant, and 
functions through the direct electron donation in the reduction of H2O2 resulting in H2O 
formation. It is the most abundant non-protein thiol present in all mammalian tissues in 
concentrations between 1-10mM, with the highest concentrations being noted in the liver 
[9]. However, glutathione has many critical functions beyond an antioxidant, such as 
promoting cell growth [10] through nuclear recruitment [11, 12], acting as a substrate for 
protein post-translational modifications [13], xenobiotic functions [14] and as a critical 
cysteine reservoir in the cell [15]. Consequently, in response to palmitoylcarnitine, 
cellular glutathione levels seemingly dictated cell survival. In HT29 cells, 
palmitoylcarnitine incubations resulted in reduced cell survival, increased H2O2 and 
decreased glutathione. By contrast, CCD 841 cells were insensitive to palmitoylcarnitine 
despite an increase in H2O2 as they were able to maintain glutathione levels. HepG2 cells 
displayed a decrease in H2O2 with an increase in glutathione, as this increase in 
glutathione appears to have promoted growth. Furthermore, combined inhibition of both 
glutathione (through serine and glycine starvation) and thioredoxin (through auranofin 
incubations), the other main intracellular antioxidant, overcame HCT 116 p53-/- 
insensitivity to auranofin resulting in decreasing cell survival. Given the potential 
heightened reliance on glutathione and thioredoxin in cancers (as discussed in chapter 2), 
endogenous antioxidants serve as novel potential therapeutic targets for future 
antineoplastic treatments. 
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Palmitoylcarnitine elicits various responses in cell fate dictated, in part, by cellular 
glutathione responses 	
This thesis in part sought to determine the response of glutathione to increased 
mitochondrial activity through forced provision of a mitochondrial substrate, and whether 
manipulating glutathione could alter cancer cell survival. The findings of this thesis 
identify glutathione as a critical regulator in determining cell fate during cell exposure to 
the mitochondrial substrate, palmitoylcarnitine. Such that there was a relationship 
between cell survival and the change in total glutathione following 100µM 
palmitoylcarnitine across CCD 841, MCF7, HT29 and HepG2 cells (Figure 7.1).  
Figure 7 1 The change of glutathione in response to palmitoylcarnitine relates to the 
change in cell survival in response to palmitoylcarnitine. Linear regressions were 
performed in HT29, MCF7, CCD 841 and Hepg2 cells following 24 and 48 hours of 
100µM palmitoylcarnitine comparing the change in glutathione in cells to the change in 
cell survival in cells. Data are reported as means ±SEM. P<0.05. 
 
Following both 24 and 48 hours of 100µM palmitoylcarnitine, the response of total 
glutathione mirrored that of cell survival, as larger decreases in total glutathione levels 
corresponded to larger decreases in cell survival. In an attempt to explain the role of 
glutathione during palmitoylcarnitine-induced H2O2 emission, glutathione was depleted 
using buthionine sulfoxomine (BSO) concurrently with palmitoylcarnitine exposure. 
Interestingly, not all cells were sensitized to the deleterious effects of palmitoylcarnitine 
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in the absence of glutathione. There was a relationship observed between 
palmitoylcarnitine-induced H2O2 emission and the response of cells to BSO concurrent 
with palmitoylcarnitine, where only the cells that produced an increase in H2O2 emission 
following palmitoylcarnitine were influenced by glutathione depletion (Figure 7.2).  
 
Figure 7 2 The change H2O2 emission in response to palmitoylcarnitine relates to the 
change in cell survival in response to palmitoylcarnitine concurrent with glutathione 
depletion by BSO. Linear regressions were performed in HT29, MCF7, CCD 841 and 
Hepg2 cells following 24 and 48 hours of 100µM palmitoylcarnitine with BSO 
comparing the change in H2O2 emission in cells to the change in cell survival in cells. 
Data are reported as means ±SEM. P<0.05. 
 
This demonstrates the importance of glutathione as a buffering agent to combat changes 
in H2O2 emission. With regards to the role of glutathione in promoting cell growth, it 
appears that an increase in palmitoylcarnitine-stimulated glutathione levels preceded 
HepG2 cell growth given that HepG2 cells had increased glutathione levels at 24 hours 
(and continued on to 48 hours), yet observable HepG2 cell growth occurred at 48 hours 
(Figure 7.1). In an attempt to explain the apparent lack of response of MCF7 cells to 
palmitoylcarnitine, it is possible that any MCF7 cell adaptation may occur past 48 hours. 
As redox biology is highly dynamic in nature, yet methodological sampling is temporal, 
early sampling times of 24 hours and 48 hours may not have been long enough to capture 
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any noticeable MCF7 adaptation. Interestingly, it has been previously demonstrated that 
low levels of chronic exogenous H2O2 can stimulate MCF7 cell growth despite an acute 
decrease in cell survival [16]. Furthermore, exogenous incubations of H9c2 cells with 
H2O2 for 24 hours resulted in an almost doubling of glutathione levels leading to 
enhanced cyto-protection against a further H2O2 challenge, however concurrent treatment 
with BSO rendered H9c2 cells susceptible to the latter H2O2 challenge [17]. While there 
were no observed statistical increases in glutathione, or alterations in H2O2 emission in 
MCF7 cells in response to palmitoylcarnitine, it is possible that further incubation times 
and more frequent methodological sampling could have resulted in observable adaptive 
responses to a fatty-acid stress.  
Many current chemotherapies function through increasing intracellular ROS 
emission [18], yet following therapy, cells that survive are typically more resilient to 
ROS-induced cell death. It is theorized that cancers typically display heightened levels of 
basal ROS emission, and that successful chemotherapy treatment is aimed at pushing 
cancer cells passed the precipice of ROS handling resulting in ROS-induced death. 
However, (as previously discussed in section: 2.5.2.2 Glutathione in chemoresistance), 
glutathione is a key contributor to chemoresistance in many cancers, and elevating 
glutathione is a critical mechanism for a cell to decrease intracellular ROS levels. 
Chemotherapies such as arsenic trioxide for leukemia treatment is a potent complex I-II 
inhibitor resulting in drastic increases in mitochondrial ROS production [19, 20], and 
many compounds in the anthracycline family, such as doxorubicin [18], or platinum-
based compounds such as cisplatin [21], target the mitochondria to stimulate 
mitochondrial derived ROS resulting in cell death. A current methodological limitation in 
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cancer therapies is the inability to directly assess ROS levels in vivo during treatment. 
Sampling tumours during various stages of chemotherapy administration to measure 
glutathione levels may serve as a proxy to determine the efficacy of treatment on raising 
ROS to a deleterious level within a cell. One could argue that measuring intracellular 
glutathione, rather than ROS, may prove more beneficial, as CCD 841 cells demonstrated 
a significant increase in palmitoylcarnitine-induced H2O2, yet maintained glutathione 
levels, while HT29 cells increased H2O2 emission, palmitoylcarnitine resulted in a drastic 
decrease in glutathione levels as well as intracellular oxidation through decreasing the 
GSH/GSSG ratio. Therefore, determining the response of glutathione in cancer cells to a 
variety of chemotherapies may serve to expand the current understanding of whether 
some cancers will be susceptible to certain therapies over others.  
Determining the glutathione response to a mitochondrial challenge may be 
beneficial in designing targeted anticancer therapies. Future work should examine 
expanded cell lines and the role of other mitochondrial activators, such as nicotinamide 
riboside (NR), a vitamin B3 analogue and a precursor to NAD+ production that has been 
demonstrated to increase mitochondrial oxidative capacity through increasing the 
NAD+/NADH ratio [22]. While NR has been demonstrated to improve mitochondrial 
function in a variety of murine pathologies such as advanced aging and Duchenne 
muscular dystrophy [23], Alzheimer’s disease [24] and respiratory chain deficient 
mitochondrial myopathy [25], little work has been conducted on examining the role of 
NR supplementation towards mitochondrial activation therapies in cancers. Furthermore, 
there was a relationship between mitochondrial oxidative capacity and susceptibility 
towards palmitoylcarnitine (Figure 7.3) that warrants further exploration.  
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Figure 7 3 Mitochondrial respiratory capacity relates to the susceptibility of cells to 
palmitoylcarnitine-induced changes in cell survival. A linear regression was 
performed in HT29, MCF7, CCD 841 and Hepg2 cells following 24 hours of 100µM 
palmitoylcarnitine exposure comparing the mitochondrial respiratory capacity to the 
change in cell survival following palmitoylcarnitine in cells. 5mM ADP stimulated 
respiration was supported by 5mM pyruvate and 2mM malate. Data are reported as 
means ±SEM. P<0.05. 
 
As such, it would be interesting to determine whether mitochondrial depletion through 
ethidium bromide-induced mitochondrial depletion [26] or increasing mitochondrial 
capacity through PGC-1α [27], TFAM [28] or frataxin [29] overexpression could alter 
sensitivity towards mitochondrial-targeted therapies. With the hypothesis being that 
lowering mitochondrial capacity would sensitize the cell to mitochondrial activation 
(rendering the cell insensitive to mitochondrial inhibition) whereas increasing 
mitochondrial capacity would sensitize the cell to mitochondrial inhibition (rendering the 
cell resistant to mitochondrial activation). To further expand on this concept, an 
additional study should be conducted to determine the mitochondrial capacity in many 
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different cancer cells and determine whether mitochondrial capacity can indeed predict 
sensitivity to either mitochondrial activation or mitochondrial inhibition. Cancers with 
low mitochondrial capacity would perhaps be successfully targeted with mitochondrial 
activating therapies, while cancers with high mitochondrial capacity would perhaps be 
successfully targeted with mitochondrial inhibition therapies. Depending on these results, 
mitochondrial capacity could serve as a biomarker to guide directed therapies based on 
where cancers fall on a ‘mitochondrial continuum’. 
 
Dual glutathione and thioredoxin inhibition is required for potent antineoplastic 
function 	
Given that glutathione and thioredoxin increase in coordination of 
chemoresistance, Chapter 6 was designed in such a way that would result in increased 
mitochondrial ROS production while concurrently depleting glutathione and inhibiting 
thioredoxin. Through experimentation of the effects of BSO and auranofin on MCF7, 
HepG2 and HT29 cells, low doses of both BSO and auranofin individually had little 
influence over cell survival, however, in combination, BSO and auranofin resulted in 
drastic decreases in cell survival in all three cell lines (Figure 7.4). 
 
Figure 7 4 The combined effects of auranofin and buthionine sulfoxomine (BSO) 
result in decreasing cell survival in cancer cells. Relative cell survival was assessed in 
HT29, MCF7 and HepG2 cells with or without 1µM auranofin and 50µM BSO (N=6). ‘*’ 
represents a significant difference between all other conditions. Data are reported as 
means ±SEM. P<0.05. 
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These findings are in conjunction with the findings of Harris et al. [30] who noted that 
glutathione depletion through BSO was enough to prevent tumour formation in a mouse 
model of spontaneous cancer development, but once the tumour was established, both 
glutathione and thioredoxin inhibition (through combined BSO and auranofin) were 
required to elicit antineoplastic properties. However, (as previously discussed in Chapter 
2, section 2.5.4.1.1 Buthionine sulfoximine (BSO)), the efficacy of BSO for in vivo 
glutathione depletion has been met with varied results, such that 28 patients with various 
cancers received 30 minutes of BSO infusions every 12 hours for up to 2 weeks, and 
despite a relatively safe profile, BSO infusion was unable to deplete intracellular 
glutathione levels below a threshold of ~30% compared to baseline [31]. However, 
glutathione depletion through BSO in conjunction with other compounds that stimulate 
mitochondrial ROS, such as arsenic trioxide, have demonstrated potent anticancer effects 
[32]. Additionally, the combination of BSO and auranofin likely do not stimulate an 
increase in mitochondrial ROS emission, therefore, it is possible that a cancer could adapt 
to such a therapy through decreasing mitochondrial ROS emission (through increases in 
UCP2 activity for example), rather than increasing ROS buffering compounds. 
Interestingly, Maddocks et al. [33] demonstrated that serine and glycine starvation 
resulted in glutathione depletion, with a preferential effect being observed in HCT 116 
p53-/- cells. This is critical given that ~50% of human cancers display mutations in the 
TP53 gene [34], therefore serine and glycine starvation is an attractive model to induce 
glutathione depletion as it potentially preferentially targets cells without normal 
functioning p53. Typically, PKM2 is allosterically activated by serine levels [35], and 
during serine and glycine starvation, loss of PKM2 activity results in glycolytic 
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redirection towards de novo serine synthesis. While they did not measure H2O2 directly, 
Maddocks and colleagues [33] demonstrated that serine and glycine starvation resulted in 
an increase in TCA cycle intermediates suggesting an increase in mitochondrial 
activation for ATP production, and this current work serves to add to this literature as 
serine and glycine starvation resulted in an increase in H2O2 in both HCT 116 p53+/+ and 
p53-/- cells. 
Given that serine and glycine starvation has been demonstrated to deplete 
intracellular glutathione levels concurrent with an increase in mitochondrial activity, the 
purpose of Chapter 6 was to examine the combined effects of serine and glycine 
starvation in combination with auranofin. Interestingly, there were no differences in the 
responses of serine and glycine starvation alone in HCT 116 p53+/+ and p53-/- cells, unlike 
previously published data, which demonstrated increased sensitivity to serine and glycine 
starvation in HCT 116 p53-/- cells [33]. While difficult to explain, it is possible that there 
were trace levels of serine and glycine in the dialyzed FBS. If this is the case, this may be 
more representative of the whole body response to serine and glycine starvation, as 
tissues such as muscle are able to synthesize and release amino acids into circulation. 
Indeed, serine and glycine starvation resulted in a decrease in serum amino acids in mice; 
however, starvation did not result in the complete abolishment of serine and glycine from 
the serum [36]. While serine and glycine starvation yielded favorable anticancer results in 
vitro, when expanded to a murine model, serine and glycine starvation resulted in a 
modest slowing of cancer cell growth, however not a stagnation of growth [33, 36]. 
Therefore, an adjunct therapy appears to be required to increase the rate of cellular serine 
and glycine consumption and subsequent glutathione depletion.  
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While there is no direct evidence that auranofin caused an increase in serine and 
glycine consumption, auranofin resulted in a compensatory increase in glutathione levels 
in HCT 116 p53-/- and HT29 cells, suggesting that HCT 116 p53-/- and HT29 cells 
consumed greater levels of serine and glycine required to synthesize de novo glutathione. 
Furthermore, HCT 116 p53+/+ cells were sensitive to low concentrations of auranofin, 
however both HCT 116 p53-/- cells and HT29 cells were resistant at similar 
concentrations. This is consistent with the notion that p53 mutations can confer 
chemoresistance [34]. It appears that auranofin induced p53-dependent cell death in HCT 
116 p53+/+ cells, however HCT 116 p53-/- and HT29 cells were insensitive the deleterious 
influence of auranofin resulting in the activation of Nrf2 leading to a compensatory 
increase in glutathione and cell survival. These interpretations are based on the findings 
that auranofin stimulated an increase in p-p53ser46, which has been previously 
demonstrated to amplify p53-dependent apoptosis [37]. Nrf2 manipulation was able to 
alter cell fate following serine and glycine starvation coupled with auranofin. Concurrent 
forced activation of Nrf2 was able to dose-dependently rescue HCT 116 p53+/+ cells from 
auranofin preferentially when serine and glycine were present suggesting the importance 
of glutathione synthesis in conferring cyto-protection during auranofin exposure, while 
Nrf2 inhibition was able to dose dependently sensitize HCT 116 p53-/- cells to auranofin 
regardless of serine and glycine status. Interestingly, auranofin combined with serine and 
glycine starvation prevented the compensatory increase of glutathione in all cells 
resulting in decreasing cell survival, induction of cell death markers and an increase in 
trypan blue positive cells.  
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While both auranofin administration and serine and glycine starvation have been 
independently proven to be safe to mammals, the safety of auranofin coupled with serine 
and glycine starvation has yet to be proven. Therefore, future work should examine the 
effects of auranofin combined with serine and glycine starvation in vivo. This is of 
particular importance for two mains reasons: 1) Previous work in cell culture has 
demonstrated that serine and glycine starvation alone elicits potent antineoplastic effects, 
however the strength of these findings did not translate to in vivo testing, therefore while 
these results demonstrate potent anticancer effects in in vitro conditions, in vivo 
experimentation is required to further elucidate the efficacy of auranofin and serine and 
glycine starvation; 2) Unlike previous work examining the response of cells to 
palmitoylcarnitine, where both transformed and non-transformed cells were exposed to 
palmitoylcarnitine, normal cells were unable to grow in conditions required to test the 
effects auranofin coupled with serine and glycine starvation. This was due to the inability 
of non-transformed CCD 841 cells to grow in media with dialyzed FBS. Therefore, while 
previous literature highlights the increased sensitivity of cancers to antioxidant depletion, 
there is a possibility that auranofin combined with serine and glycine starvation may 
result in deleterious effects in all cells, rather than cancer-specific effects.  
 
7.2 Limitations 	
While careful consideration was performed during the design of the experiments, 
there are limitations to the experimental designs that limit the interpretation of the data. 
Chapter 4 attempted to re-produce the findings observed by Wenzel et al. [7], where it 
was demonstrated that palmitoylcarnitine in conjunction with free carnitine selectively 
		 169	
killed HT29 cells, but not normal NCOL-1 cells. The conditions designed by Wenzel et 
al. [7] were mimicked both for palmitoylcarnitine concentrations, as well as the addition 
of free carnitine. Wenzel and colleagues [7] demonstrated that HT29 cells have low 
levels of intracellular free carnitine required for palmitoylcarnitine entry into the 
mitochondria (see figure 2.7), therefore due to consistency across conditions, as well as 
uncertainty as to free carnitine levels across other cell lines, a strength of Chapter’s 4 and 
5 was that all conditions contained free carnitine. The cancer specific effects of 
palmitoylcarnitine were repeated in HT29 cells, however instead of normal NCOL-1 cells 
as was used previously, CCD 841 primary colon epithelial cells were used, as NCOL-1 
cells may not be a suitable comparative cell line. In a response to criticism from their 
previous work, Wenzel and Daniel [38] addressed the possible cell line contamination of 
NCOL-1 cells with the cancerous LoVo cells. They addressed that NCOL-1 cells display 
distinct differences from LoVo and HT29 cells, however they could not distinctly 
identify NCOL-1 cells as non-transformed cells, rather “preneoplastic” cells. Therefore, 
CCD 841 primary colon epithelial cells were used as they are more commonly applied in 
the literature, and are readily available for purchase through the ATCC. While attention 
was made to closely mimic the study of Wenzel and colleagues [7], direct interpretations 
may be tempered, as not all cell lines were consistent between studies. 
With regards to both Chapter 4 and 5, Wenzel et al. [7] used only 
palmitoylcarnitine as their mitochondrial substrate. While other papers have examined 
the effects of palmitoylcarnitine in prostate cancers and normal prostate cells, the role of 
exploring other mitochondrial substrates is warranted. One limitation of using 
palmitoylcarnitine as an exogenous substrate is that it is unknown whether 
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palmitoylcarnitine enters the cell, as endogenous palmitoylcarnitine is made solely within 
the cell. Previous work has demonstrated that exogenous palmitoylcarnitine incubations 
resulted in increased intracellular palmitoylcarnitine in neuroblastoma NB-2a cells [39], 
and has previously been demonstrated to cause an adaptive increase in oxidative capacity 
in mouse embryonic fibroblasts [40]. Current work demonstrated that palmitoylcarnitine 
resulted in an adaptive increase in mitochondrial respiratory capacity in HepG2 cells in 
Chapter 5. However, there is no direct evidence that proves whether palmitoylcarnitine 
results in a direct increase in oxidative phosphorylation. Therefore, while it is possible 
that palmitoylcarnitine directly enters the cell as it increases intracellular 
palmitoylcarnitine levels and results in adaptive increases in mitochondrial capacity, it is 
unknown whether these adaptations are of a direct result of palmitoylcarnitine entering 
the cell, or downstream adaptations. 
Previous preliminary work was done using other fat sources other than 
palmitoylcarnitine, such as intralipid, an emulsified fat mixture, and conjugated linoleic 
acid/oleic acid, however these resulted in minimal effects, even in the mM dosage. HT29 
and MCF7 cells were incubated in these alternative fat sources resulting in minimal 
changes in cell survival, H2O2 emission or caspase 3/7 activation. Therefore, CPT-1 
inhibition likely accounts for limitations in using fat as a viable therapy, and suggests in 
part why a high fat diet would not be beneficial to cancer patients. Rather, 
palmitoylcarnitine administration would be likely as an infused compound aimed to elicit 
anticancer properties. Further limitations associated with Chapter 4 are that there were 
only a select number of cell lines, and the efficacy of palmitoylcarnitine was examined 
only in in vitro settings. Furthermore, interpretation of the data was limited as the 
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exogenous antioxidant N-acetylcysteine (NAC) failed to elicit a strong rescuing effect in 
HT29 cells following palmitoylcarnitine, only a modest protective effect (Figure A.1). 
While the possibility exists that glutathione depletion and decreasing cell survival 
associated with palmitoylcarnitine is occurring through non-ROS mediated mechanisms, 
it cannot be excluded that glutathione depletion is perhaps occurring through ROS 
mediated mechanisms. However, when comparing the effect of NAC between Chapter 4 
and Chapter 6, it is possible that the varied ability of NAC to protect the cells depends on 
the degree of H2O2 emission that occurred in the respective treatments. Specifically, in 
Chapter 6, serine and glycine deprivation increased H2O2 emission in HCT 116 p53+/+ 
and p53-/- cells by ~120%; by contrast palmitoylcarnitine stimulated H2O2 emission in 
HT29 cells between ~140% - 715%. Another possibility may relate to the amount of 
NAC taken up by cells. Both studies employed a co-incubation approach whereby NAC 
was applied concurrently with either palmitoylcarnitine or serine and glycine deprivation. 
This approach may not have permitted enough time for maximal cysteine uptake as 
compared to pre-treatment approaches. If cysteine uptake was sub-maximal with the co-
treatment approach, this may explain why NAC was more effective with the relatively 
lower rates of H2O2 emission seen in Chapter 6 than Chapter 4. It should be noted that 
while developing the NAC protocol, a dose-response curve was conducted in CCD 841, 
HT29, MCF7 and HepG2 cells (Figure A.1) establishing a tolerable range of NAC 
concentrations in each cell line to avoid cytotoxicity. As such, it is unlikely that these 
cancer cells could tolerate higher concentrations of NAC compared to the 3mM used in 
Chapters 4 and 6. In this light, an alternative pre-treatment approach with NAC could be 
warranted to rescue HT29 cells from palmitoylcarnitine similar to what was seen with 
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serine and glycine deprivation. While testing the early effects of palmitoylcarnitine in 
Chapters 4 and 5 is a strength in determining acute responses to an oxidative challenge, it 
is also possible that longer exposure to palmitoylcarnitine and NAC may have resulted in 
a more robust protective effect of NAC in HT29 cells to palmitoylcarnitine 
In Chapter 6, one main limitation of the data was that there were no differences 
between HCT 116 p53+/+ and p53-/- with reference to serine and glycine starvation as 
previously published by Maddocks et al. [33]. While speculative, residual levels of serine 
and glycine found in dialyzed FBS perhaps explain this observation. However, given that 
there were no measures of serine and glycine in the dialyzed FBS, this remains unknown. 
Furthermore, there were limited comparisons as only HCT 116 and HT29 colorectal 
carcinoma cells were used; therefore examination in other cell lines is warranted. 
Certainly, further examination into non-transformed cells to determine whether normal 
cells tolerate serine and glycine starvation coupled with auranofin is of critical 
importance.  
 
7.3 Conclusions  	
The findings from this thesis highlight the potential of mitochondrial and 
antioxidant targeting for future cancer therapies. While palmitoylcarnitine, and 
potentially other mitochondrial substrates and sources of mitochondrial activation, may 
indeed prove to be efficacious as an anticancer therapy, caution must be taken as 
palmitoylcarnitine resulted in a decrease in HT29 and HCT 116 cell survival; however it 
resulted in an increase in growth in HepG2 cells.  The findings provide a foundation to 
explore the degree to which glutathione serves as a biomarker to predict cancer cell fate 
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in response to palmitoylcarnitine. If a therapy results in lower intratumoural glutathione, 
perhaps that is suggestive of a cancer which is sensitive to that given therapy. 
Furthermore, the development that serine and glycine starvation sensitize p53-null cells 
to auranofin offers a potential nutritional/pharmaceutical combination approach. While it 
remains to be determined whether this is tolerated in vivo, auranofin coupled with serine 
and glycine starvation may be a promising therapeutic option for combating cancer. 
Therefore, understanding the underlying mechanisms associated with cancer 
bioenergetics and redox buffering may be fruitful in the development of future cancer-
targeted therapies aimed at manipulating the highly dynamic relationship between cancer 
metabolism and redox biology. 
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Appendix A – Additional figures 	
 
 
 
Figure A 1 N-acetylcysteine (NAC) provides marginal protection in HT29 cells 
against palmitoylcarnitine. A Relative cell survival was assessed in CCD 81, HT29, 
MCF7 and HepG2 cells were treated with increasing levels of NAC for 24 hours. B and 
C Relative cell survival was assessed in HT29 cells treated with palmitoylcarnitine and 
NAC for 24 and 48 hours. Data are reported as Data are reported as means ±SEM. ‘*’ 
represents a significant difference from 0µM palmitoylcarnitine, ‘#’ represents a 
significant difference between the same palmitoylcarnitine concentration at the same time 
point. P<0.05. 		  
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Appendix B – Full western blot images 		
	
Figure B 1 Total western blot images of UCP2 protein represented in Chapter 5. 
Left panels Images of UCP2 protein and right panels total protein stains of adjacent 
western blots as performed using Amido black. 		
UCP2-
UCP2-
0µM 100µM 0µM 100µM 0µM 100µM 0µM 100µM 0µM 100µM 0µM 100µM
Palmitoylcarnitine Palmitoylcarnitine
HepG2 cells
		 179	
	
Figure B 2 Total western blot images of p-p53ser46 in HCT 116 cells. Left panel 
Images of p-p53ser46 protein and right panels total protein stains of adjacent western blots 
as performed using Amido black. 		  
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Figure B 3 Total western blot images of glutathione reductase (GR) in HT29 cells. 
Left panel Images of glutathione reductase (GR) protein and right panels total protein 
stains of adjacent western blots as performed using Amido black. 	  
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Figure B 4 Total western blot images of 4HNE in HT29 cells. Left panel Images of 
4HNE protein and right panels total protein stains of adjacent western blots as 
performed using Amido black. 	  
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Appendix C – Outlined experimental methods 
 
A.1 Cell lines: 
 
Cell line Origin (and ATCC reference) Growth media 
HT29 Human colon adenocarcinoma 
https://atcc.org/Products/All/HTB-
38.aspx 
DMEM 
10% FBS 
1% P/S 
MCF7 Human breast adenocarcinoma  
https://www.atcc.org/products/all/HTB-
22.aspx 
AMEM 
10% FBS 
1% P/S 
CCD 841 Human colon normal epithelial 
https://www.atcc.org/Products/All/CRL-
1790.aspx#generalinformation 
EMEM 
10% FBS 
1% P/S 
HepG2 Human liver hepatocellular 
carcinoma 
https://www.atcc.org/products/all/HB-
8065.aspx 
EMEM 
10% FBS 
1% P/S 
HCT 116 Human colon adenocarcinoma 
https://www.atcc.org/products/all/CCL-
247.aspx 
DMEM 
10% FBS 
1% P/S 
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A.2 Crystal violet for relative cell survival 
 
Purpose: 
Crystal violet stain is used to determine cell number in fixed adherent cells.  
 
Make up before: 
To make crystal violet staining solution: 
 
- 0.5% (w/v) crystal violet powder (Sigma-Aldrich) in 25% MeOH in RO water 
 
Procedure: 
- Plate cells at a desired density in black-walled optical bottom 96-well cell culture 
plates (ThermoFisher) 
- Following treatment for set time, remove media and fix cells with 10% formalin 
(Sigma-Aldrich) 
o Replace media volume with same volume of formalin (100µl media 
aspirated off and replaced with 100µl 10% formalin) 
- Following 10 minutes, aspirate off formalin and add in 50µl crystal violet staining 
solution for 10 minutes 
- Dump out stain and carefully rinse clean with water 
- Allow to dry inverted in fume hood (good air circulation) 
- To analyze, scan plates using Odyssey LiCor scanner and analyze using internal 
software to establish fluorescent density 
  
		 184	
A.3 Digested in-well protein assay 
 
Purpose: 
Either as a crude stand alone measure of cell number, or to normalize data from live-cell 
assays (such as H2O2 and XTT) 
 
Make up before: 
Make sure we have BCA kit reagents (ThermoFisher) and RIPA buffer (Sigma-Aldrich) 
- To make up BCA-RIPA solution, make up BCA reagent according to kit 
instructions with final volume including 10% RIPA buffer 
 
Procedure: 
- Carefully aspirate off media as to not dislodge any adhered cells 
- Using a multi-channel pipette, fill up each well entirely with PBS to make sure no 
residual media is left in the well 
- Carefully aspirate off PBS and add 200µl BCA-RIPA solution to each well 
- Incubate at 37oC for 30 minutes 
- Remove from incubator and carefully wipe off any precipitated moisture on the 
bottom of the plate 
- Place plate on rocker while setting up plate reader 
- Using the VICTOR3 1420 Multilabel Counter plate reader (PerkinElmer), read 
plate using BCA setting 
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A.4 Live-cell H2O2 emission 
 
Purpose: 
Real time H2O2 emission as either static or kinetic read in live adhered cells. Ensure that 
whatever variable you are adding to the media does not interfere with AmplexRed signal 
(does not alter background signal) 
 
Make up before: 
Make stocks of AmplexUltraRED (ThermoFisher) and horseradish peroxidase (HRP, 
Sigma-Aldrich) 
- AmplexRed at 5mM in DMSO 
- HRP at 10 units/ml in ddH2O 
- Make up working solution 
o In condition media, make up working solution of AR+HRP in media 
o Add in 0.02µl of each AR+HRP per well 
§ Figure out how many wells you need, make up solution such that 
you are adding in 10µl of working solution per well and adjust 
math accordingly 
§ Working solution = (Final volume: Number of wells x 10µl) – 
(0.02µl AR x final volume) – (0.02µl HRP x final volume) 
• Final volume equation dictates how much media to add to 
bring up to final volume. Always make up more than you 
need. Example (96-wells, therefore, make up 1ml) 
o Working solution = (1000µl) – (0.22 x 1000) – 
(0.22 x 1000) 
o Therefore: Media added = 960µl, AR and HRP at 
20µl each 
 
Procedure 
- Following desired incubation time with desired compound (example, if you are 
doing a 24 hour incubation time with a drug, after the 24 hours is complete) 
- Quickly add in 10µl of working solution into each well and then protect from light 
- Using BioTek Citation plate reader, read plate at 568ex/581em 
o If doing kinetic read, make sure plate reader is at 37oC at 5% CO2 
- Make signal relative to an H2O2 standard curve 
- Following read, determine well protein concentration using protocol A.3 
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A.5 High-resolution respirometry 
 
Purpose: 
To determine site specific mitochondrial oxygen consumption 
 
Make up before: 
- Thaw MiRo buffer 
- Air phase chambers using MiRo, leave stoppers out as to minimize volume loss 
from liquid adhered to the stoppers 
- 1mg/ml digitonin in water 
- Make up protein assay tubes (45µl RIPA buffer) 
 
Procedure: 
- Plate cells in 10cm cell culture dish 
- Following desired treatment or plating time, trypsin harvest cells, pellet, wash in 
PBS, pellet and re-suspend 1ml MiRo containing 10µl digitonin solution 
- Let cells rock for 30 minutes at room temperature 
o To validate whether the cells are permeable, take out 10µl of cells at 
desired times and view cells under microscope with trypan blue. If the cell 
membrane is permeable, cells will take up trypan blue 
- Following 30 minutes and successful permeabilization, pellet cells and re-suspend 
in 110µl of MiRo 
- Take out 5µl of cell suspension and add to protein assay tubes and freeze for later 
protein determiniation 
- Add 100µl of cell suspension to the chamber and add stopper 
- Follow respiration protocol as so desired 
- Reference Hughes and or Ramos theses for detailed O2K protocol  
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A.6 Intracellular lactate determination 
 
Purpose: 
Intracellular lactate determination can be an index of glycolytic flux or pyruvate 
redirection. Avoid touching anything with bare skin as perspiration has high levels of 
lactate in it, wear clean gloves at all times. If your gloves touch your skin, change your 
gloves. Move fairly quickly as to avoid lactate degradation until acidification step.  
 
Make up before: 
 
Lactate assay buffer: 
- 1M Glycine 
- 500mM Hydrazine sulfate 
- 5mM EDTA disodium salt 
- pH to 9.5 with NaOH 
 
NAD (make fresh) 
- 25mM NAD in lactate assay buffer 
 
Perchloric acid (PCA) 
- 0.5M PCA in ddH2O 
 
Potassium Bicarbonate (KHCO3) 
- 2.2M KHCO3 in ddH2O 
 
Protein tubes 
- In order to normalize data, make up protein tubes containing 45µl of RIPA buffer 
per sample 
 
Make sure you have lactate hydrogenase (LDH, Sigma-Aldrich, heart isoform) 
 
 
Procedure: 
- Plate cells in desired dishes (depending on cell type, this can range from 24-well 
plate up to a 10cm dish in my experience) 
- Do the following quickly:  
o Following cell treatment, wash cells with PBS 
o Trypsin harvest cells, wash in PBS, pellet 
o Carefully aspirate off PBS and re-suspend pellet in 100µl PBS 
§ Take out 5µl and add to protein tube (keeping note that this is from 
a 100µl sample. Sample volume can be adjusted depending on cell 
confluence and cell type). 
§ Freeze protein tube for protein analysis at a later time 
o Following 5µl removal, bring up volume of remaining 99.5µl up to 1ml, 
and pellet again 
o Carefully aspirate off PBS and add in 150µl of 0.5M PCA 
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§ Transfer total volume into a 1.5ml eppindorf tube 
§ Vortex thoroughly 
§ Freeze thaw 3X 
- Sample is now stable following de-proteination by PCA 
- Spin at 4oC at 7,000 RPM for 5 minutes 
- Collect supernatant and transfer to new tube 
- On ice, add 120µl of sample to 36µl KHCO3 
o It is the ratio that is important, so if you have less than 120µl, adjust 
accordingly 
- This will bubble up and a precipitate will form, vortex thoroughly several times 
and open and close the lid to dissipate pressure 
- Spin at 4oC at 7,000 RPM for 5 minutes 
- Collect supernatant and transfer to new tube 
o This is now the final sample 
- Per reaction: 
o 20µl sample + 20µl NAD + 2µl LDH + 258µl lactate buffer 
o Load sample in triplicate onto a 96-well plate 
§ I make up 1ml per sample and load 300µl per well 
• 66.66µl sample + 66.66µl NAD + 6.66µl LDH + 860.02µl 
lactate buffer 
o Incubate at 37oC until reaction stops (~1hr, cell line depending. Whatever 
time point you decide, be consistent throughout) 
o Read on plate reader at 340nm 
o Use Beer’s law to determine lactate concentration and normalize to protein 
values 
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A.7 Glutathione 
 
Purpose: 
To determine redox state and total content of intracellular glutathione levels 
 
Make up before: 
 Buffer:	- TRIS-BSA: homogenization buffer with Trizma Base + Boric 
Acid/Serine/Acivicin to inhibit γ-glutamyltranspeptidase from metabolizing 
GSH/GSSG.   
o 200mL HPLC grade water 
o 50mM Trizma Base: 1.212g -- (MW=121.14g) 
o 20mM Boric Acid: 0.248g – (MW=61.83g) 
o 2mM L-serine: 0.042g – (MW=105.69g) 
o 20uM Acivicin: (MW=178.57) 
o Acivicin inhibits y-glutamyltranspeptidase, a protein bound to the cell 
membrane which catabolizes glutathione upon contact 
o pH to 8 with HCL - DAY OF: 
o Add 25ul 0.2M NEM for every 1ml TRIS-BSA fresh day of use (some 
suggest NEM is light sensitive, freeze sensitive, not sure if this is true 
or not, but adding it same day allows for to decide whether you would 
want to or not add NEM, only time you wouldn’t add NEM is if you 
wanted to measure total glutathione) 
§ NEM irreversibly binds to GSH creating a GS-NEM conjugate 
and inhibits glutathione reductase preventing the auto-
oxidation GSH to GSSG 
Making Mobile phase solvents 
- GSH mobile phase 
o Solvent A: 0.25% Glacial Acetic Acid in HPLC grade water 
§ 2.5mL glacial acetic acid into 997.5mL water 
• Or 1.25ml glacial acetic acid into 498.75mL water 
§ pH to 3.1 by adding in a couple drops of 2M NaOH to bring pH up 
or glacial acetic acid to bring pH down 
§ Prepare fresh every day 
o Solvent B: 100% Acetonitrile 
- GSSG mobile phase 
- Solvent A: 25mM Na2HPO4 in HPLC grade water 
o Make 425ml 
§ pH to 6.0 using phosphoric acid 
o Add 75ml MeOH to get final 15% methanol mobile phase 
 
Sample preparation: 
- Make up 6 tubes per sample: 
o Tube1 for homogenate/lysis 
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o Tube2 for protein assay 
§ 5ul homogenate into 45ul buffer/RIPA buffer for cells 
§ Poke hole in top of tube 
o Tube3 with TCA 
§ 7ul TCA into tube 
o Tube4 PCA 
§ 70ul PCA into tube 
o Tube5 labeled GSH 
§ Poke hole in top of tube 
o Tube6 labeled GSSG 
§ 500ul 0.5M NaOH 
 
Procedure:  
 
- For muscle: 
o Homogenize tissue in TRIS-BSAN at a 1mg-10ul ratio, leave on ice until 
all samples are done (I usually do about 10 samples at a time, do samples 
in random order). 
§ Try and get at least 145ul final volume, otherwise need to adjust 
volumes of TCA and PCA, not a big deal, but adds time 
o Spin samples at 800g for 10 minutes at 4 degrees 
o Add supernatant to tube 1 
- For Cells: 
o Wash cells in PBS-NEM (PBS with 0.5mM NEM – 25ul 0.2M NEM into 
10ml PBS) 
o Trypsinize cells, re-suspend in media-NEM (2mM NEM in media) 
o spin at ~1000g for 5 minutes at 4oC 
o Wash cells with PBS-NEM 
o spin at ~1000g for 5 minutes at 4oC 
o aspirate off PBS-NEM carefully, re-suspend in ~155ul TRIS-BSAN 
o Add to tube 1 
- Now have cells or muscle homogenate in tube 1 
- Take from tube 1: 
o 5ul tube 1 -> tube 2  (protein tube) 
§ Freeze in liquid nitrogen 
o 70ul tube 1 -> tube 3 (TCA tube, for GSH) 
§ Put onto rocker 
o 70ul tube 1 -> tube 4 (PCA tube, for GSSG) 
§ Put onto rocker 
o Vortex tubes 3 and 4 
- Spin TCA and PCA tubes at 20,000g for 5minutes at 4oC 
- Carefully take tubes out of centrifuge, be careful not to dislodge pellet 
- From tube 3: Take off supernatant, and transfer to tube 5 (GSH tube) 
- From tube 4: take 100ul of tube 4 ->  tube 6 (GSSG tube) 
- Freeze 
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Determine protein from samples using tube 2 (protein tube) 
 
GSH determination (UV) 
- GSH flow rate at 1.25 ml/min on old Agilent system (new Shimadzu HPLC down 
to 1.05ml/min) 
- Sample detected using VWD (UV detector) detector (on HPLC stack) at 265nm 
- 94% Mobile phase A, 6% acetonitrile 
o Protocol name on HPLC is TurnbullGSH 
- Take GSH tube, transfer total volume into HPLC vial. 
- Have machine insert 10ul of sample into machine 
o GSH elutes as two peaks right before NEM spike 
§ Two peaks: it is because the configuration of GSH (3 amino acids) 
can be built in two ways depending on the specific amino acid 
configuration, I always use 2nd peak because 1st peak is sometimes 
influenced by other compounds depending on the tissue being 
analyzed 
- GSH Standard 
o Every day, run a 4 point standard  
o 250uM GSH, 62.5uM GSH, 31.25uM GSH, 15.6uM GSH 
o Step 1: Make 50mM GSH in TRIS-BSAN 
o Step 2: Dilute 50mM GSH -> 5mM GSH in TRIS-BSAN 
o Step 3: Dilute 5mM GSH -> 0.5mM GSH in TRIS-BSAN 
o Step 4: Do serial dilutions from 0.5mM (500uM GSH) 
§ 500uM GSH -> 250uM GSH -> 125uM GSH -> 62.5uM GSH -> 
31.25uM GSH -> 15.6uM GSH 
o Take 70ul of 250uM GSH, 62.5uM GSH, 31.25uM GSH, 15.6uM GSH 
tubes, and transfer to new tubes with 7ul TCA 
o Transfer GSH-TCA tube to HPLC vial, ready to load 
GSSG determination (fluorescent)  
- Excitation/Emission 350/420nm 
- Flow rate at 0.5 ml/min 
- Sample elutes as a single peak 
- Injection volume: 50ul 
- Protocol is set up as TurnbullGSSG 
- Take tube 6 out of freezer 
- When thawed, add in 37.5ul of 0.1% OPA (our fluorophore, which is stored in -
20oC freezer) 
- Incubate samples in the dark for at least 15 minutes 
- After incubation, transfer to HPLC vial, ready for run.  
- GSSG Standard 
o Every day, run a 4 point standard  
o 10uM GSH, 2.5uM GSH, 1.25uM GSH, 0.625uM GSH 
o Step 1: Make up 20mM GSSG in TRIS-BSAN 
o Step 2: Dilute 20mM GSSG -> 2mM GSSG in TRIS-BSAN 
o Step 3: Dilute 2mM GSSG -> 0.2mM GSSG in TRIS-BSAN 
o Step 4: Dilute 0.2mM GSSG -> 20uM GSSG in TRIS-BSAN 
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o Step 5: Do serial dilutions starting from 20uM GSSG 
§ 20uM GSSG -> 10uM GSSG -> 5uM GSSG -> 2.5uM GSSG -> 
1.25uM GSSG -> 0.625uM GSSG.  
o Step 6: Take 70ul of GSSG standard and mix with 70ul PCA 
o Take 100uL from GSSG standards and transfer to new tube with 500ul 
0.5M NaOH 
o Add in 37.5ul of 0.1% OPA-MeOH (our fluorophore, which is stored in -
20oC freezer) 
o Incubate standards in the dark for at least 15 minutes 
o After incubation, transfer to HPLC vial, ready for run.  
 
 
 
Day of checklist: 
- Make up TRIS-BSAN 
o Thaw 0.2M NEM stock from freezer, add 25ul NEM per 1ml TRIS-BSA 
- Make up mobile phase 
- Make up standard curve 
- For GSH: 
o Transfer tubes into HPLC Vials 
- For GSSG: 
o Incubate with OPA for 15 minutes before transfer tubes to HPLC vials 
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A.8 XTT for NAD(P)H determination 
 
Purpose: 
XTT is a tetrazolium salt that once reduced turns into a soluble formazan dye (it dissolves 
when reduced and turns red/orange). It is used as a proxy assay to determine intracellular 
NADH/NADPH (NAD(P)H) levels.  
 
Make up before: 
Make up XTT solution and phenazine methosulfate (PMS) solution 
- XTT: 1mg/ml in condition media (this can be pre-made and frozen into stocks) 
- PMS: 3mg/ml PMS powder into PBS (this can be pre-make and frozen into 
stocks) 
- Both are potentially light sensitive 
- To create detection solution: right before you are about to start, add 2.5µl/ml PMS 
solution to XTT solution 
o Make sure you are constantly mixing this solution as you are loading into 
plates, XTT does not fully dissolve until reduced 
 
Procedure: 
- Following desired incubation time with desired compound (example, if you are 
doing a 24 hour incubation time with a drug, after the 24 hours is complete) 
- Add 50µl detection solution into each well (bringing up the volume of each well 
to 150µl) 
- Incubate plate for ~2-4 hours (depending on strength of signal, longer time greater 
signal strength. Whatever you do, be consistent throughout study) 
- Measure absorbance using VICTOR3 1420 Multilabel Counter plate reader 
(PerkinElmer) read at 450nm 
- Normalize signal to protein content using protocol A.3 
 
  
		 194	
A.9 Caspase -3, -8 and -9 activity assays 
 
Purpose: 
Caspase activity is indicative of apoptotic mediate cell death. Caspase-3 is considered a 
final effector caspase and can act upon the entire cell; it is cleaved by various earlier 
caspases such as caspase-8 and -9. Caspase-8 is considered an external stimulus initiated 
caspase, whereas caspase-9 is triggered by mitochondrial mechanisms. 
 
Make up before: 
 
Homogenisation buffer: 500 ml  
  
Chemical  Concentration  Amount added  
HEPES  20mM  2.38g  
NaCl  10mM  0.29g  
MgCl  1.5mM  0.152g  
DTT  1mM  0.077g  
Glycerol  20%  100mL  
Triton  0.1%  0.5mL  
pH 7.4  
  
Incubation buffer: 100 ml  
  
Chemical  Molecular Weight  Concentration  Amount added  
HEPES  283.3  100 mM  2.38g  
Sucrose    10%  10g  
DTT  154.25  1 mM  0.015g  
pH 7.5  
  
Fluorescent substrates for Caspase activities:  
  
Caspase-3: AC-DEVD-AMC (Enzo - ALX-260-031-M001)  
1mg into 1.48 mL DMSO for 1mM Stock  
  
Caspase-3 Inhibitor: AC-DEVD-CHO (Enzo - ALX-260-030-M001)  
1mg into 2mL DMSO for 1mM Stock  
  
Caspase-8: AC-IETD-AMC (Enzo - ALX-260-042-M001)  
1mg into 1.48 mL DMSO for 1mM Stock  
  
Caspase-8 Inhibitor: AC-IETD-CHO (Enzo - ALX-260-043-M001)  
1mg into 2mL DMSO for 1mM Stock  
  
Caspase-9: AC-LEHD-AMC (Enzo - ALX-260-080-M001)  
1mg into 1.45 mL DMSO for 1mM Stock ** Different MW from 3 and 8  
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Caspase 9 Inhibitor: AC-LEHD-CHO (Enzo - ALX-260-079-M001)  
1mg into 1.86mL DMSO for 1mM Stock  
  
** Aliquot Substrates into 100µl, Aliquot inhibitors into 10µl. Store in black tubes at -
20oC  
 
Procedure: 
 
Preparation of cellular fraction:  
- Scrape cells into 150µl of lysis Buffer  
- Sonicate 3x3 seconds with a break in between rounds of sonication  
- Freeze all fractions at -80ºC  
  
Protein determination:  
- Protein determination is done with the Bradford method using a reducing agent 
compatible kit.  
- Put a micro plate on ice (a layer of aluminium foil between plate and ice)  
  
Caspase Activity:  
  
- Dilute 1mM stock of each substrate substrate into 100µM using incubation buffer  
o make up total volume needed for all samples plus 20µl extra  
- Add 40ug of protein from S2 into the wells  
o total of 6 wells for each sample 
- Add x µl of diluted substrate (110- amount added for 30µg protein) for Caspase-3 
to 2 wells  
o Repeat step 3 using Caspase-8 and Caspase-9 substrate 
- Add 3µl of Caspase-3 inhibitor to 1 of 6 wells  
- Repeat step 5 for Caspase 8 and 9 inhibitor  
- Read every 2 minutes for 1 hour  
 
** Do not need to run inhibitor for every sample, just use as a check  
 
Fluorometer measurements:  
  
Prepare the fluorometer settings before adding standards, muscle extracts and substrates 
into the micro plates.  
Temperatur 37ºC; Excitation filter 360 nm; Emission filter 460 nm  
Gain 80 % of max value  
Read every 2 min for 1 hour  
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A.10 Trypan blue exclusion 
 
Purpose: 
To determine cell viability. As cells die, they lose integrity of outer membrane, allowing 
for non-membrane permeable dyes to penetrate. Tryan blue is a membrane impermeable 
dye, therefore, if the cell takes up trypan blue, it must have a permeable outer membrane.  
 
Make up before: 
Make up an eppindorf tube containing the desired amount of trypan blue (this ratio is 
important as it will dictate total number of cells). If cell number is high, a 10X to 20X 
dilution with trypan blue may be necessary (20µl cell suspension into 180µl trypan blue) 
 
Procedure: 
- Trypsin treat cells with 1ml of trypsin and place in incubator until cells dislodge 
- Neutralize trypsin with 2ml of media (bringing total volume to 3ml) 
- Remove cell suspension and place in a 15ml falcon tube 
- Take out desired amount (from example before, 20µl) and place into trypan blue 
tube 
- Count trypan blue-cell suspension mixture for both trypan blue negative (alive) 
and trypan blue positive (dead) cells 
- Calculate total number of cells using standard hemocytometer practice and 
determine % alive and dead cells.  
 
 
 
